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Human Serum Albumin (HSA) is a plasma protein of great significance with an ability to bind 
numerous endogenous and exogenous ligands, having a single polypeptide chain of 585 amino 
acids constructed in three domains of relatively equal size. Although HSA's existence has been 
known for many years, its characterisation and ability to bind ligands still remain enigmatic. Only 
in 1992 was the crystal structure of HSA reported (Carter and Ho, 1992). Effective 
crystallisation and the determination of meaningful crystallographic data and structure had 
proven difficult. The 1992 report concerned HSA crystals grown using zero gravity conditions. 
 
The objective of this project is the characterisation of recombinant and native HSA using Ultra-
violet (UV) & circular dichroism spectroscopy (CD) and involved HSA conformational changes, 
which altered the ability to bind or off-load ligands. Changing environment, together with the use 
of characteristic "marker ligands," influences binding to provide a handle that can be utilised and 
monitored. This enables the assignment of binding sites and the study of perturbating conditions. 
 
Changing conditions such as pH, temperature, ionic strength and solvents in the presence and 
absence of ligands were employed to extract further information on this elusive protein. 
Fragments of recombinant HSA were also used (namely domain I and domain I + II) under 
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The ubiquitous nature of human serum albumin (HSA), sometimes referred to as albumin, has 
ensured that it is a much studied protein, and its reluctance to relinquish all its structural 
characteristics has tantalised the curiosity of scientist for many years. However, persistency has 
paid off with a plethora of information resulting in the first crystal structures of albumin being 
determined by Carter in 1989, and more recently by scientists such as Curry et al 1998, Carter et 
al 1999, Sugio et al 1999, Bhattacharya et al 2000 and Yang et al 2007. There has been an 
explosion in the crystallographic information available on HSA and slowly its structural 
information is being revealed. Albumin, once thought to be a scavenger with no specific binding 
function other than to “mop up” and transport excess ligands is now thought to be responsible 
primarily for the transport of unesterified fatty acids (FA) together with the ability and capacity to 
bind numerous drugs and metabolites (covered in more detail later) (Curry et al, 1998). FA is an 
essential component in the body and is used in membrane lipids, hormones as well as being an 
important source of metabolic energy. Albumin aids in the transport of FA which have a low 
solubility and are stored as triglycerols in the body’s adipose tissue (Bhattacharya et al 2000). 
There is between 0.1 – 2 moles of FA bound to albumin through hydrophobic interactions which 
although bound tightly is in rapid exchange with the solution (a more detailed account to follow). 
Albumin’s high ability to bind, transport and off-load FA makes it an ideal facilitator for the 
transport of FA (Muravskya et al, 2004). As many as twelve FA binding sites have been detected 
on HSA, the number of sites found are determined by the chain length of the FA with a certain 
degree of unspecificity shown by albumin as to arrangement of binding sites. An asymmetrical 
distribution of FA sites is observed. 
 
HSA is a plasma protein with an in vivo concentration of approximately 50mg/ml and a 
molecular weight of 66500D, whose existence together with haemoglobin and fibrin were 
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recognised as far back as 1916 (Peters, T. Jr., 1996). Many attempts have been made to isolate 
and characterise serum albumin, however, it was the medical applications in World War II that 
prompted the biggest achievements in albumin purification. The sequence and structural 
similarities between bovine serum albumin (BSA) and human serum albumin (HSA) prompted 
the use of bovine serum albumin in place of human. The huge demands on albumin during the 
war together with the availability of bovine albumin made it an ideal substitute for human serum 
albumin. Unfortunately, small differences between the two plasma proteins were sufficient to 
produce deleterious effects in some patients, and proved fatal in others (Peters, T. Jr., 1996). The 
use of BSA in humans was terminated. Cohn and co-workers, during the 1940's, purified BSA 
from cold alcohol, producing a flocculent white precipitate. The protocol revolutionised albumin 
purification with the removal of alcohol by evaporation at low temperature, thus removing the 
need for salt to precipitate (salting-out) the protein. This method had the benefit of suppressing 
bacterial growth in the absence of salt (Cohn et. al., 1941). 
 
Albumin, being the major blood plasma transport protein binds numerous different endogenous 
and exogenous compounds that would be toxic in the unbound state but rendered non-toxic by 
virtue of its bound state (Olsen et al, 2004), a mode of action that has enabled albumin to act as 
an extracellular antioxidant (Kragh-Hansen, 1990, and Halliwell, 1988). Albumin’s high 
concentration is responsible for buffering the blood to pH 7.4 and maintaining 80% of the bodies 
colloidal osmotic pressure, 30% due to the presence of HSA itself and the other 50% due to the 
presence of cations like sodium and potassium associated with the negative surfaces of albumin 
(Tavirani et al, 2006). HSA is the most abundant secreted protein found, and belongs to a class of 
proteins which share the same multigene deriving from 190 amino acids (aa) (others include α-
fetoprotein and the vitamin D-binding protein) (Peters, T. Jr., 1985, and Kraig-Hansen, 1990). 
The gene for albumin is located on chromosome 4 that is 16,951 nucleotides long from the 
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putative “cap” site to the first poly (a) addition site. It is split into 15 exons which are distributed 
throughout the three domains that are the result of triplication of a “single primordial domain” 
(Wikipedia, 2007). 
 
Albumin is found in all secretions, including concentrations of between 0.1 - 0.5mg/ml in the 
gastrointestinal track. Trace amounts have also been detected in sweat and tears, with about 30mg 
excreted in urine per day (Rosenoer, 1977). As one of several transport proteins found in the 
body, albumin is unlike the other proteins that show great specificity binding only one or two 
ligands. HSA will bind numerous ligands reversibly with high affinity, particularly those with 
limited solubility in blood that include long chain fatty acids (LCFA) and bilirubin (Blaur et. al., 
1978). HSA can also transport ligands such as haematin, thyroxin and some steroids whose 
specific transport proteins are saturated (Seery, et. al., 1977) It is said that more than 70% of 
drugs can be transported by albumin (Kratochwil et al., 2002). Clean albumin appears white, but 
bound ligands such as bilirubin induces a yellow colour with an intensity dependent upon the 
amount of the ligand bound. 
 
HSA, compared to other proteins of similar molecular weights has proven to be atypical; this may 
explain some of the diversities of the protein. The content of tryptophan is unusually low, one in 
human and two in bovine, the average found in proteins generally is around seven. The 
hydrophobic amino acids, Methionine (6 residues), glycine (12 residues) and isoluecine (8 
residues) are also atypically low (Peters, T. Jr., 1996) for proteins with MW ~ 65000. 
Conversely, the numbers of cystine, leucine and ionic residues like glutamic acid and lysine are 
unusually high giving a large number of ionisable residues, estimated to be around 185 charges 
per molecule of HSA at pH7. Since there are more negative charges present (i.e. more acidic 
residues), HSA has a high negative charge. At pH7 the charge number lies between -12 and -17 
which facilitates the solubility of the protein. Albumin is the most acidic plasma protein found in 
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the body, essentially not glycosylated, it is one of a few proteins to have little to no association 
with carbohydrates. Only 1% of glucose is bound to albumin in the average person. The inability 
of albumin to bind carbohydrates is thought to be associated with the lack of the sequence: 
Asn - X - Ser / Thr 
where X is any amino acid other than proline that inhibits the functionality of this site; the low 
presence of carbohydrates is an ideal marker for the quality control of HSA purity (Hughes, W. 
L., 1954). The purity of HSA is based on having a carbohydrate concentration of less than 0.05%; 
the integrity of HSA is determined by electrophoresis which shows albumin to be essentially a 
single species.  
 
In the body there exists in equilibrium two pools of albumin, vascular and extra-vascular pools of 
140g and 180g respectively, with the vascular pool being the more important metabolically. The 
heterogeneous nature of the extra-vascular pool exhibits exchanges of varying rates. Exchanges 
between, for example, the lymph and metabolically active organs are fast, whilst exchanges with 
muscles and skin are slow. The vascular pool circulates around the body once every minute only 
spending between 1-2 seconds exchanging transported substances with cells. Albumin is replaced 
at a rate of 14g/day and has a half-life of between 19-20 days (Blaur et. al., 1975). The synthesis 
of albumin is primarily affected by nutrition, but is also influenced by osmotic pressure, state of 
health and hormones such as thyroxin, cortisone, insulin and growth hormones. Hormonal 
influence can stimulate synthesis by up to 30%, but this effect causes an automatic increase in the 
rate of catabolism by the same amount keeping the relative overall concentration the same  
(Roseneor et. al., 1977). 
 
Small amounts of HSA are present in infants under the age of two. However, studies have shown 
albumin production increases dramatically during the last month of gestation, reaching levels of 
up to 40mg/ml. Specific to infants is a protein called α-fetaoprotein (AFP) which is similar to 
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HSA but contains 5 extra residues (590 as opposed to 585) giving a molecular weight of 68950D 
(as opposed to 66500), and belongs to the same group derived from the same multigene (Peters. 
T. Jr, 1992). AFP contains five more residues in the region of 1-10 in loop 1, and has very similar 
physical properties to HSA, sharing a similar size, shape and ability to bind numerous ligands. 
But unlike HSA, AFP has a weaker ability to bind long chain fatty acids (LCFA), having only 
three binding sites as opposed to albumin that has been reported as having up to ten. AFP has 32 
cysteines compared to HSA's 35, 30 of which show similar sequence alignment to HSA ( Peters 
T. Jr 1996). The disulphide forming loop six in HSA is missing in AFP, and there is a half 
cystine at position 18 which will not form a free thiol. One significant difference between AFP 
and HSA is that AFP has an n-glycosylated site in subdomain IIA that enables it to bind 4% of 
carbohydrates (Krusius et al, 1982). There is only a 39% sequence homology between the two. 
Both AFP and HSA are synthesised in the liver, but many questions remain unanswered about the 
mechanism. The biosynthesis of HSA is thought to occur in the hepatocytes in the liver, and is 
secreted into the hepatic plasma where it enters the circulatory system (Glaumann, H., 1970, 
Peters et al, 1971). The initiation of synthesis is triggered by a hydrophobic 'signal peptide', 18 
residues long (Figure1). Transcribed mRNA affixes itself to cytoplasmic ribosomes where 
synthesis takes place. The signal peptide guides the nascent 'preproalbumin into the cytoplasmic 
secretary canals where cleavage leads to 'proalbumin' (Blaur et al. 1975), where molecular 
folding occurs. The proalbumin is cleaved further with the loss of a basic amino-terminal 
hexapeptide just before secretion from the hepatocytes, cleaving (Arg-Gly-Val-Phe-Arg-Arg) 
sequence in most mammals. Not much is known about the propeptide, but it is thought to be 
responsible for the correct alignment of the Cys prior to S-S formation, and is also believed to be 
responsible for protecting the nascent protein against enzymatic cleavage. Chaperonins are 
thought to bind to the partially folded protein, protecting it and completing the folding process 
(Ellis et. al. 1991). 
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              mRNA → Ribosomes → Rough Endoplasmic reticulum ────┐ 
Exocytotis ← Golgi complex ← Smooth Endoplasmic reticulum   ←┘ 
 
Figure 1.  Schematic Representation of the Synthetic Route of HSA 
 
The liver is the primary site found for albumin production, and the synthetic cycle takes on 
average 25mins to complete. However, albumin is not secreted immediately on synthesis but is 
retained for 20-30mins prior to secretion., HSA is not stored but synthesised as and when 
required. Unlike its metabolism, the catabolism of HSA is vague. Neither the mechanism nor the 
site of catabolism are known. During its 27day journey around the body, albumin picks up many 
small ligands that stick to the molecule. Structural damage also occurs with 'nicks' and tears 
appearing. The rate of degradation is proportionally linked to the rate of synthesis, ensuring the 
overall concentration remains constant. The manner in which albumin molecules are selected is 
not fully understood, but it is believed that criteria such as oxidation, additions and S-S 
interchanges play an important part in the selection process. HSA is broken down into its 
constituents and released into the body for further peptide formation. 14g/day of albumin is 
replaced, of which 5% of the body’s nitrogen is supplied by albumin in this way. Degradation is 
thought to occur in the cytosol where most of the peptidases are concentrated. 
 
This thesis endeavours to provide a closer understanding of the characteristics, behaviour and 
binding capabilities of HSA, to reduce some of the ambiguity surrounding the protein and to 
postulate further advances on the road to discover our most illustrious protein. A lot of work as 
been carried out in recent years that has brought us ever closer to unlocking albumin’s illusive 
structural characteristics, but with any reluctant protein, albumin still remains as complex as ever 
showing diverse characteristics when cocktails of ligands are considered. There is still a lot of 






































Chapter 1:  Structure and Properties of Human Serum Albumin (HSA) 
1.1  Introduction 
 
Albumin is one of a few specialised proteins that exhibit non-specific polyligand binding 
phenomena; its veracity to bind numerous ligands with great affinity is unprecedented as 
no other protein in the body binds with such indiscrimination (Zunszain et al, 2003). The 
ability of albumin to bind stems from an unusual distribution of amino acids together with 
conformational abilities strongly influenced by environment (Rosenoer, 1977). The 
conformation of albumin is pH dependent (Peters, T. Jr., 1996); observed pH induced 
changes are reversible in the range of pH 2 – pH 12, with the formation of five defined 
structural states that will be discussed later (Basir et al, 2007). The conformational 
characterisation of albumin has been fraught with difficulties. Although a much studied 
protein, the structure of HSA in part has challenged scientists, made difficult by its 
relatively large size, which has made the determination of qualitive data by conventional 
means difficult (Fanall et al, 2007).  
 
One contentious area in the structural elucidation of albumin has been the number, 
availability and location of binding sites, be they pockets or tunnels. This has caused much 
debate. He and Carter were the first to have initial success in not only managing to obtain 
decent crystals that yielded measurable X-ray diffractions, but also obtaining meaningful 
diffraction patterns from them, enabling the elucidation of secondary and more importantly 
tertiary structure. The determination of the X-ray structure (Carter, 1989) has provided a 
greater understanding of the size and shape of albumin and its binding sites. However, the 
routine determination of the albumin structure remained difficult; NMR is restricted as the 





1.2.  Amino Acid content and Primary Structure of Albumin 
 
HSA is a negatively charged, unglycosylated single polypeptide of 585 amino acids     
(MW ≅ 66,500D), with an in vivo concentration of approximately 50mg/ml (Peters, 1985) 
and is responsible for approximately 80% of the colloidal osmotic pressure in the body 
(Carter, 1994). Although albumin is unglycosylated, nature allows for approximately 10% 
formation by non-enzymatic glycosylation involving the ∈-amino group of lysine 525  
(Shaklai et al, 1984). This site specific glycosylation results in a change in the 
conformation that affects the way in which some ligands bind to glycosylated albumin, 
with the result of reduced binding of some ligands such as fatty acids. However, haemin 
binding remains unaffected. This effect has implications when looking at albumin from 
diabetic patients, who as a whole have detectable levels of glycosylated albumin.  
 
The molecular structure of albumin divides into three domains that can all be further sub-
divided generating six subdomains. The complete amino acid (aa) sequence of HSA was 
determined by Meloun (Meloun et al., 1975) and is shown in Figure 1.1.,    complementing 
the work of J. R. Brown on his sequence determination of bovine serum albumin (Brown, 
1975). The comparison of bovine and human albumin shows great similarities. However, 
the differences are significant to make the use of bovine albumin in humans non-
compatible. Table 1.1 shows the distribution of amino acids within human albumin in 
comparison to BSA. There are great similarities between the two in terms of both structure 
and sequences, giving 76% sequence homology (Peters, 1985 and Carter et al, 1993). As 
an alternative to native human serum albumin, the production of the recombinant product 
is now in development and the initial results look promising.  
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     Missing disulphide bond that is present in the other domains 
Loop       ↕          
Number                 ┌─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ─   ┐ 
  1   Human -  DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCD      __________________ 
      Bovine – DTHKSEIAHRFKDLGEEHFKGLVLIAFSQYLQQCPFDEHVKLVNELTEFAKTCVADESHAGCE        
           -         -         -         -         -  └──────┘        ↑ 
             ┌────────────┐      │ 
2 KSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRL   │ 
KSLHTLFGDELCKVASLRETYGDMADCCEKEQPERNECFLSHKDDSPDLPKL   │ 
              -         -         └────────-┘        -          Domain 1 
                  100    │ 
   ┌─────────────────────────────────────┐        │ 
 3    VRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKAS     │ 
   KPDPNTLCDEFKADEKKFWGKYLYEIARRHPYFYAPELLY ANKYNGVFQECCQAEDKGACLLPKIETMREKVLTS     │ 
      -         -         -         -         -       └─-─────┘ -         -       ↓ 
   ┌─────────────────────────────────────┐       ________________ 
  4    SAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDR 
  SARQRLRCASIQKFGERALKAWSVARLSQKFPKAEFVEVTKLVTDLTKVHKECCHGDLLECADDR       ↑ 
         -         -         -         -         -    └──────┘          │ 
        200              │ 
            ┌──────────┐       │ 
  5             ADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAAD   │ 
           ADLAKYICDNQDTISSKLKECCDKPLLEKSHCIAEVEKDAIPEDLPPLTAD   │ 
             -         -       └────────┘            -              Domain 2 
             300       │ 
         ┌─────────────────────────────────────┐        │ 
  6    FVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNL     │ 
  FAEDKDVCKNYQEAKDAFLGSFLYEYSRRHPEYAVSVLLRLAKEYEAYLEECCAKDDPHACYTSVFDKLKHLVDEPQNL     │ 
   -         -         -         -         -         └──────┘-         -            ↓ 
        ┌──────────────────────────────────────┐       __________________ 
  7      IKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSV 
    IKQNCDQFEKLGEYGFQNALIVRYTRKVPQVSTPTLVEVSRSLGKVGTRCCTKPESERMPCTEDYLSL      ↑ 
      -         -         -         -         -      └────────┘ -           │ 
     400             │ 
             ┌───────────────┐      │ 
  8          VLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAET   │ 
        ILNRLCVLHEKTPVSEKVTKCCTESLVNRRPCFSALTPDETYVPKAFDEKL      Domain 3 
            -         -     └──────────┘  -         -         │ 
                  500    │ 
   ┌────────────────────────────────────────────┐        │ 
  9    FTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL     (585)   │ 
  FTFHADICTLPDTEKQIKKQTALVELLKHKPKATEEQLKTVMENFVAFVDKCCAADDKEACFAVEGPKLVVSTQTALA     (582)   ↓ 
     -         -         -         -         -       └──────┘  -         -         __________________ 
 
─ Indicates successive 10th residue      Each domain comprises of 1 long, 1 short and 1 long loop 
└─┘ Disulphide Bonds 
Figure 1.1.  Amino Acid Composition of Human and Bovine Serum albumin.  (Rosenoer, 1977) 
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Amino Acid Human Bovine HSA/BSA 
& 
Single Letter Code 














Aspartic Acid     (D) 36 6.2 40 6.9 0.9 
Asparagine         (N) 17 2.9 14 2.4 1.2 
Threonine           (T) 28 4.8 34 5.8 0.8 
Serine                  (S) 24 4.1 28 4.8 0.9 
Glutamic Acid    (E) 62 10.6 59 1.1 1.1 
Glutamine          (Q) 20 3.4 20 3.4 1.0 
Proline                 (P) 24 4.1 28 4.8 0.9 
Glycine               (G) 12 2.1 16 2.7 0.8 
Alanine               (A) 62 10.6 46 7.8 1.3 
Valine                  (V) 41 7.0 36 6.2 1.1 
Cysteine              (C) 35 6.0 35 6.0 1 
Methionine        (M) 6 1.0 4 0.7 1.5 
Isoleucine             (I) 8 1.4 14 2.4 0.6 
Leucine               (L) 61 10.4 61 10.5 1 
Tyrosine              (Y) 18 3.1 20 3.4 0.9 
Phenylalanine     (F) 31 5.3 27 4.6 1.1 
Lysine                 (K) 59 10.1 59 10.1 1.0 
Histidine             (H) 16 2.7 17 2.9 0.9 
Tryptophan       (W) 1 0.2 2 0.3 0.5 
Arginine              (R) 24 4.1 23 3.9 1.0 
Total 585 100.1 583 99.7  
 
Table 1.1  Comparison between the amino acid content of human and bovine HSA. 
(U. Kragh-Hansen, Danish Medical Bulletin, 37, 1990, 57 – 88) 
 
The amino acids in albumin form nine loops arranged into a distinctive pattern. Each domain 
contains three loops arranged with one long, one short and one long loop. The arrangements 
of the loops in relation to the nomenclature of the domains are as follows; 
 
Loop 1 – 2 4 – 5 7 – 8 
Domain IA 2A 3A 
 
 
   
Loop 3 6 9 
Domain IB 2B 3B 
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Although the domains show some structural similarities with some degree of sequence 
conservation, there is only between 18-25% sequence homology at best (Table 1.2). The 
differences in sequence are sufficient to show differences in the domain activity especially 
where binding is considered. 
 
Domain I Versus Domain II 25% Identical 
Domain II Versus Domain III 20% Identical 
Domain I Versus Domain III 18% Identical 
Table 1.2.   Comparison of Identical Residues in each Domain. 
 
Protein folding is an intricate and complicated process that yields a biologically active 
product. This is further complicated if the protein contains domains that are able to fold 
independently and interact with one another (Wetlaufer, 1981). The X-ray crystal structure of 
intact albumin has shown how HSA divides into three homologous domains. With that in 
mind, Dockal and coworkers have determined the crystal structure of the individual domains 
of albumin by means of cloning and expression (Dockal et al, 1999). Conventional methods 
to separate the domains using chemical cleaving or proteolytic techniques have shown to 
produce defective domains; the reagent used dictates the cleavage products. Often the 
fractions generated by such methods are non-representative of the domains in the intact 
protein, and result in “unimpaired structural integrity,” which in turn can lead to a debilitation 
in domain functionality. The cloning and expression of HSA creating fractions of domain I   
(1 - 197), domain II (198 – 385) and domain III (386 – 585), with partial overlapping of some 
regions of the domains, creates fractions with intact domains cleaved at natural boundaries. 
The ability to produce stable intermediates and determine their conformation has aided in 
elucidating the tertiary structure and function of the whole protein. Figure 1.2. shows 
consistency in both the secondary and tertiary structures of the three domains of albumin. 
Unlike the sequence homology, the secondary and tertiary structural homology shows very 
close agreement, but contains subtle differences sufficient to affect the functionality of the 






Figure 1.2.  X-ray Crystal Structure of the recombinant domains of HSA. 
( Carter et al, J. Biol Chem, Vol 274, Iss 41, 29303 – 29310, 1999) 
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Human albumin contains only one tryptophan at position 214 found in the long loop 4, (BSA 
has two), lower levels than that found for most proteins of similar size that would more 
typically contain seven tryptophans (Kraigh-Hansen, 1989). The number of methionines, 
glycines and isoleucines are also atypically low, 6, 12 and 8 respectively, with a high 
abundance of cystines, leucines and ionic amino acids like glutamic acid and lysine that 
produce a high charge on albumin facilitating its solubility in aqueous solutions. A pH 7 there 
are potentially 185 charges/molecule (Peters, 1985). The high abundance of acidic residues 
compared to basic residues gives HSA a net charge of 12- at pH7, making it a very acidic 
plasma protein.  
 
Albumin contains 35 cysteine (cys) (17 cystine) residues, of which 34 pair to form a distinct 
disulphide bridge pattern (Foster et al, 1977 and Carter, 1992). The disulphide pattern makes 
the albumin molecule both flexible and resistant to extreme conditions, by ensuring a cys-cys 
trans peptide bond that prevents adjacent cysteines from forming disulphide bridges with each 
other. The disulphide bridges fix the spatial orientation of the helices and constrain the protein 
domain structure ( Blaur et al., 1978.). In domain I is an omission at position 34 of one of the 
disulphide bonds, leaving a free cys often partially blocked by covalently bound ligands. In 
domain I, there are also two cys residues “missing” that should be found at positions 8 and 54 
( refer to Figure 1.3) and may account for the lack of binding ability in this domain when 







Missing Cys at position 8   Missing Cys residue at position 54 
       ↑            ↑ 
       │        Cys-34        │ 
       │        ↑        │ 
       │       │        │ 
       │        │        │ 
  Successive 10th Residue     SH       S↓   S 
      1 ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼  74 
 
       S  SS     S 
          75 ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼ 112 
 
          S      SS    S 
             123  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼  197 
 
                S       SS   S 
           198  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼  262 
              ◄▬▬▬► 
         S      S   S   S    
          263  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼  313 
 
        S       SS  S    
           314  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼  389 
 
       S            SS        S 
          390  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼458 
 
       S   SS      S 
        459  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼511 
 
             ┌─────────┐ 
               S           SS  S 
         512  ┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼┼ 
              └───────────────────────────────────────────┘ 
 
S  Cys Residue  ◄▬▬▬► Cys-Cys Separation  └──┘ Disulphide Bond 
 
Figure 1.3.  Diagrammatic Representation of the Disulphide Pattern in HSA forming 9 loops. 
( Rosenoer, 1977) 
Another structural difference can be located within domain II with the separation of the 
cysteine pairing that is not adjacent but separated by three residues (Figure 1.3). Since domain 
III binds preferentially first with respect to that of domain II, a contributing factor may result 
from the cysteine separation found within domain II, or at least this factor may contribute to 
the possible lower disulphide constraint that may exist within that binding pocket (Peters, 
1985). There are no disulphide bonds formed between adjacent cysteine residues (Foster, 
1977). The formation of cys-trans peptide bonds together with a 100° rotation between 
adjacent cys-cys groups ensures non-compatibility with the adjacent SH groups. 
 
HSA contains 18 tyrosine and 31 phenylalanines, which together with the single tryptophan 
make up the aromatic residues responsible for the observed UV and CD spectrum. There is a 
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large population of tyrosines distributed within loops 3 and 6. Loop 3, a short length of 24 
residues contains 7 tyrosines (Peters, 1996). Traditionally, the absorption of a protein at 
280nm is ascribable to tryptophan (ε280 = 5540). However, the combined contributions of 18 
tyrosines will be significant (Tyr residue, ε280 = 1480); disulphides ε280 = 134 will also make a 
small contribution (Peters, 1985). Although there is a high concentration of phenylalanine 
compared to the other aromatic residues, its ε280 = 0 offers no contribution in terms of 
absorption. Absorption in the far UV (i.e. below 240nm) is dominated by the peptide bond 
(Rosenheck & Doty, 1961). 
1.3.  Secondary, Tertiary and Quaternary Structure of Albumin 
 
Initial secondary structure calculations, based on several techniques including circular 
dichroism (CD) spectroscopy, found HSA to contain 44-48% α-helix, 16% β-sheet with the 
remainder as irregular structure (36-40%). The early consensus on the quaternary structure of 
HSA was that albumin was ellipsoidal, with dimensions of 140Å along the x-axis and 40Å 
along the y-axis (Figure 1.4); the results were based on many techniques including 
hydrodynamic studies (Hughes, 1954, and Squire et al, 1966). At pH 3.6, the ellipsoid 
consists of three spheres of diameters 38Å, 53Å and 38Å (Broomfield et al, 1966), which 
represent the three domains. The separation of the spheres is affected by pH; at pH 2.2 the 
separation was found to be as much as 34Å. 
 
Figure 1.4.  Model of HSA based on its Physical Properties. 
( Rosenoer, 1977) 
  The broken circles represents the domains, I, II and III, within the 
  polypeptide, the horizontal red bars represent the 17 disulphide bridges. 
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Within each domain there are six helices, three in each subdomain, X, Y and Z which run 
anti-parallel to one another and are held in place by the extensive disulphide bridging (with 
the exception of domain I that has only one connecting disulphide bond). The concept of a 
"trough-like" structure or "well" was forwarded as illustrated in Figure 1.5.b. The subdomains 
are held together by strands of polypeptide chains called hinge regions, separating subdomain 
A & B from subdomain C (Figure 1.5.). A polarity separation exists within the protein with 
all the hydrophobic residues located inside or between the helices and the hydrophilic 




































Interdomain Connections Disulphide Bond
 
Figure 1.5.a.  Schematic representation of HSA showing the helices, subdomains and domains. 
( Rosenoer, 1977) 
 




The arrangement of the helical bundles in the sundomains (depicted as X, Y and Z as shown 
in Figure 15.a.) was first highlighted by Brown when determining the sequence of albumin in 
1975, and further supported by Meloun and coworkers soon after, as shown in Figure 15.b. Of 
the nine loops, eight  form a double loop due to the arrangement of the Cys-Cys repeating 
sequence of eight of the 17 pairs, only the first loop does not form the pairing and this is most 
likely due to the missing Cys at position 8. 
 
 
Figure 1.5.b.  Schematic representation of one of HSA’s subdomain, showing the 
trough like arrangement of the helical bundles. 
( Rosenoer, 1977) 
 
Two possible approaches to the ways in which the adjacent Cys-Cys pairing could bond have 
been determined, these are shown in Figure 1.5.c. Of the two possibilities, by common 
consensus, the arrangement shown in Figure 1.5.c.(II) is the more likely. The arrangement 
that includes the adjacent Cys is the most likely configuration as it introduces an extra residue 
into the loop. This arrangement also has the effect of reducing the possibilities of any steric 
contributions that could exist on the exclusion of the Cys when considering the smaller loop 
of each pairing, limiting possible rotations that could be created with the α-carbon bonds 
between adjacent Cys-Cys residues. 
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Cys Cys Cys Cys
(I) (II)  
Figure 1.5.c.  Schematic representation of two possible  
                           arrangements of disulphide pairing. 
 
1.4  X-Ray Crystal Structure of Human Serum Albumin 
 
Determining the X-ray crystal structure of HSA has proven over the years to be problematic, 
with the production of inferior crystals, too small to study and incredibly soft, possibly due to 
the high water content of around 55%. The crystal shape, size and consistency varied 
dramatically resulting in conflicting information. In 1989, the first crystal structure 
determination was reported (Carter et al., 1989) with crystals that gave meaningful 
diffraction patterns that were both detected and analysed. The new crystals were difficult to 
grow, growing with continuous solvent channels running throughout. The solvent content of 
the crystals was 78% and although the crystals showed weak scattering of X-rays, diffraction 
patterns in the recombinant form of human serum albumin (rHSA) was measured at a 
resolution of 2.8Å. rHSA crystals were grown from polyethylene glycol (PEG) at neutral pH 
and recrystallized under a microgravity environment. The real advances in structural 
determination of albumin came in 1992 (Carter et al., 1992) that showed the cigar shaped 
structure that was previously accepted as the standard shape was in fact inaccurate, at least 
where the crystal structure was concerned at physiological conditions. He and Carter found 
HSA to be heart shaped, similar to that of an equilateral triangle, with sides of around 80Å 
and a depth of around 30Å. The work carried out by He and Carter has prompted enormous 
advances in the structural analysis of albumin (Carter et al, 1994; Curry et al, 1998; Sugio et 
al, 1999, Bhattacharya et al., 2000, Qin et al, 2007). Figure 1.6 shows the extent of the 
information with the high resolution X-ray crystal structure of HSA compatible with that 
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determined by He and Carter, and shows how domain I is situated perpendicularly to domain 
II forming a T-shaped configuration. Conversely, there is a 45° angle between domain II and 
domain III forming a Y-shaped configuration. It is this arrangement of the domains that gives 
albumin its characteristic heart shaped structure, with very little interaction between domain I 
and domain III. It should be noted that the recombinant form of albumin exhibits the same 
structural conformation as the native form based upon the X-ray crystal structure with an 
r.m.s deviation of 0.24Å for all Cα atoms (Sugio et al, 1999).  
 
Crystallographic studies show HSA to contain 67% α-helix, distributed in 28 helical bundles. 
Earlier predictions by Pearson (Pearson, 1990) found HSA to contain 19% β-sheet. Recent 
studies have shown HSA to contain 23% extended chain conformation with the remainder, 
~10% existing as turns. In accordance with earlier findings, He and Carter found the evidence 
of three domains, domain I, II and III (starting from the N-terminal), and each domain was 




Figure 1.6.   X-ray Crystal Structure of HSA first reported by He and Carter in 1992. 
( Sugio et al, Protein Engineering, Vol 12, No 6, 439 – 444, 1999) 
 
Diagram is colour coded to show the subdomains, domain IA is coloured yellow, IB is in 
green, IIA is in red, IIB is in magenta, IIIA is in blue and IIIB is in cyan (Sugio et al, 1999). 
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The structural arrangement of each domain was identical regardless of the primary sequence 
and composed of ten helices labelled h1-h10 (Figure 1.7.). The subdomains, A and B share a 
common motif with helices h1, h2, h3 and h4 in subdomain A identical to those of h7, h8, h9, 
and h10 in subdomain B with two exceptions. Firstly, the disulphide bridge joining h1 and h3 
in subdomain 1A does not exist. Secondly, subdomain A contains two additional short helices 
running anti-parallel to one another, helices h5 and h6. These are linked together by a pair of 
disulphide bridges forming a small double loop that ensures the continuity of the helices 
throughout subdomain A, and contributes to a network of four interhelical disulphide bridges 
(refer to Figure 1.7.). Subdomain B is complementary to that of subdomain A for helices 
found, but it also contains the N- terminal portion of the extended polypeptide chain that links 






Figure 1.7.i.  Ribbon diagram of domain II, (disulphides are shown in red). 
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This disulphide
























Figure 1.7.ii.  Representation of Domain II, showing the 10 helices as 
determined by X-ray crystal structure. 
(Carter et al, Nature, Vol 358, 209 – 215, 1992) 
 
Linkages joining the subdomains IA-IB, IIA-IIB and IIIA-IIIB are referred to as interdomain 
connections or hinge regions, and exist as extended polypeptide chains found between 
residues Lys 106 to Glu 119, Glu 292 to Val 315 and Glu 492 to Ala 511 in domains I, II and 
III respectively. There are exceptions, the structural conformation of the interdomain 
connection between IB and IIB are helical, extending from the C-terminal portion of the 
helices to the N-terminal portion of IIA and IIIA respectively. Subdomains IIA and IIIA are 
also helical, (helices: h10(I) - h1(II) and h10(II) - h1(III)), and the longest helix is found 
between subdomain IB-IIA, extending over 31 residues. The charge distribution across the 
domains is uneven, -9, -8 and +2 for domains I, II and III respectively in human HSA. In view 
of the uneven charge distribution, the acid/base distribution seems less problematic. There 
does not seem to be any significant patterns of acid versus base distribution throughout 
albumin except in one area on the surface of domain I that is basic in nature (Carter, 1994). 
Conversely, there seems to be distinct areas of uncharged amino acids, thought to be 
associated with long chain fatty acid (LCFA) interactions. The X-ray structure confirms 
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Brown's predictions (Brown, 1975) on the arrangement of the 35 cysteine residues with a 
unique arrangement of disulphide pairing, 16 of the 17 cystines present forming disulphide 
linkages. The disulphide linkages are found to be predominantly gauche-gauche-gauche as 
predicted by Raman spectroscopic studies, with a typical Cβ1-S1-S2-Cβ2 torsion angle 
clustered around ±80°( Aoki et al, 1973), and are located between helical segments in most 
cases. The unique network of disulphide pairing gives HSA its exceptional abilities not seen 
in other proteins, with the disulphides well protected and relatively inaccessible to solvents. 
The disulphide bridges are arrangement within albumin as follows: 
 
Domain I Domain II Domain III 
 200 – 246 392 - 438 
53 – 62 245 – 253 437 - 448 
75 – 91 265 – 279 461 – 477 
90 – 101 278 – 289 476 - 487 
124 – 169 316 – 361 514 – 559 
168 – 177 360 – 369 558 - 567 
 
The free cysteine residue, Cys34 is located between the helices of IA-h2 and IA-h3.  In 
practice, between 30 – 40%  Cys34 residues in albumin are oxidised by residues of cysteine 
or glutathione contained within other regions of the molecule to form an intermolecular 
disulphide linkage (Peters, 1985). Cys-34 is located on the surface of the albumin molecule. 
However, its Sγ is directed towards the interior of the molecule and is surrounded by the side 
chains of Pro 35, His 39, Val 77 and Tyr 84. This arrangement of the residues stops the 
sulfhydryl group within the molecule from coupling with another external cysteine residue 
from neighbouring molecules. Blocking the free thiol, Cys-34, adds to the stability of the 
protein, preventing mixed disulphide formation and dimerization (Peters, 1985). Cys-34, has 
an unusually low pKSH (pKSH = 5), compared to cysteine and glutathione (pKSH = 8.5 and 





1.5.  Properties of Human Serum Albumin 
 
The chemical nature of HSA ensures a high buffering capacity resisting small changes in pH. 
When dissolved in water, HSA attains a neutral pH between pH 6.5 - 7.0. However, changing  
pH results in conformational changes that are both distinctive and indicative of that pH and 
result in protein unfolding with the possible cleavage of some of the disulphides, all of which 
are reversible once physiological conditions are re-established (Figure 1.8). Five transitions 
(or forms) have been defined when the pH is changed: the N-form (normal), F-form (fast),   
E-form (extended), B-form (basic) and the A-form (aged), as shown in Table 1.3. Each form 
has an associated change in structural conformation in the protein resulting in tertiary and 
quaternary changes. Along with the structural changes are physical changes. Lowering the pH 
to below pH3.5 causes a dramatic increase in viscosity together with an increase in 
hydrodynamic volume. There is also an increase in electrostatic repulsion with the moving 
apart of disulphide loops. Intermediate transitions have also been detected, for example at 
pH4, with smaller changes in intrinsic viscosity resulting in other physical changes that are 
not as dramatic (Luetscher, 1939). The effect of pH changes are considered important as it 
allows conformational changes to aid the loading and off-loading properties of the protein. A 


















Figure 1.8.  Structural representation of HSA showing its pH dependence. 








State pH Physical Characteristics 
N-Form Neutral 5-7 
Natural form, heart shaped 
 
 
F-Form Fast ~4.0 
Viscosity starts to increase, partial unfolding of 
domain III, loss in contact between domain III and 
domain II due to loss in hydrophobic contact 
 
 
E-Form Extended <3.0 
Increase in viscosity, loss in helical content, 
decrease in solubility 
 
 
B-Form Basic ~8.0 
Loss of helical content, increase affinity for small 









Table 1.3.  Conformational Changes of HSA with respect to pH. 





A decrease in pH promotes the sequential unfolding of the albumin molecule that originates 
from the N-terminal, with domain III unfolding first, followed by domain II and concluding 






Seperation of  domains,
as much as 34A
Fully extended molecule with the
loss of α helix. Exposure of tyr and
Trp and protonation of remaining COOH.
Loss in interdomain helix between h10(I) - h1(II)
and h10(II) - h1(III).
Dramatic increase 
in viscosity
Increase in tyr  exposure, up
to 50% giveing 11 residues that
are exposed. 16% loss in helix
N-F' = Opening of hydrophobic regions
F-F' = Exposure of hydrophobic residues
Expansion in size forming 2 halves,
Domain I + IIA and IIB + III
30% Tyr accessable,
therefore 6 residues 
are exposed, hidden 
in a hydrophillic 
crevice. Only 
affected by small 
pertabants such as 
ethyleneglycal
pH 2.0 pH 3.0 pH 3.5 pH 4.0 - 4.5
Table 1.4  Schematic Representation of the Physical Properies and Chemical Changes in Albumin in responce to pH.
pH 7.0
Large population of tyr
in loops 3, a short loop
containing 7 tyr & loop 6
Rest of the Tyr are 
hidden in the 
hydrophobic crevises
Discrete transitions characterised 
by unusually low pK of imidizole
group
Increase in size
Exposure of Tyr, Ser,
Arg, Ile, Phe & Pro,
N-terminal end more 
affected
Sub IIA most affected,
increase binding of warfarin
Sub IIIA not affected
Slight changes in Dom I,
approx 5 His protination
and Cys 34 affected. Could
affect other sites triggering
release
Sulfhdryl important as N-B transition catalysed by 
free, which becomes unhindered instead of restricted













and may cause 
cleavage
Sulfhdryl group located in crevice which opens
during N-B transition. Sulfhyry group moves 
from being restricted to an unhindered environment
N-B Transition gives







At extremes in pH causes





Large pertabants such as
sucrose can now interect
Trp moves to a more
hydrophobic environment
Unfolding of Domain III
7-8 Cl- bound/molecule,
plus Na+ & K+ binding
22 Cl- bound/molecule,
little Na+ & K+ binding




1.5.i.  Fast -form Transition of Albumin (F-form) 
 
The formation of the F-form within the pH range pH4 to pH4.5 involves transitions 
involving at least three cooperative steps (Leonard, 1961), with some intramolecular 
dissociation of the subdomains with possible secondary structural rearrangements. 20% 
more tyrosyl residues become accessible to environmental perturbations, increasing the 
existing 30% normally found at pH7 to 50%. Binding affinities are affected similarly in the 
F-form showing a reduction that can be correlated with the increase in viscosity observed. 
Foster and co-workers (Foster et al, 1957) believed the N-F transition occurs in two stages 
involving an intermediate F' state that can be represented by N → F' → F.  Associated with 
this transition is the loss in percentage α-helical content reflected in the cooperative forms, 
the N-F' transition shows a reduction in helix from 51% to 44% and the F' - F transition 
presents a further reduction from 44% to 35% resulting in a total loss of 16 % of helical 
content (Leonard, 1961), as shown in Table 1.4. The N-F' transition is thought to be the 
opening of first the hydrophilic regions with the F'-F transition reflecting the exposure of 
the hydrophobic residues.  Towards pH4, there is an expansion in size with the HSA 
molecule becoming more extended, more asymmetric with more of the molecule becoming 
accessible to the solvent. Carter and He suggested that during this transition, HSA 
separates into two halves, defined by domain I + IIA and domain IIB + III, (refer to Figure 
1.8). 
 
A pH change from pH7 to pH3 sees the neutralization of approximately 40 COOH side 
chains with a collective pKa = 3.7. Glutamic residues normally show a pKa = 4.1, aspartic 
residues typically give pKa~3. It has been possible to isolate the F-form by gel 
electrophorisis (Foster et al, 1957) at a pH between pH3 – pH4. Foster found that there 
was a certain amount of insolubility associated with this state, the F-form has a solubility 
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<<1µ/ml in 3M KCl as opposed to the N-B form (neutral-base form) which is totally 
soluble. In the F-form, HSA becomes more extended and more asymmetric, attributed to 
the changes in the ionisation status of the COOH groups and the accessibility of three of 
the five tyrosine side chains. A blue shift in the UV absorption is observed. Changes in 
helicity have also been inferred at 333nm by fluorescence excitation studies of HSA 
tryptophan (Foster et al, 1957). 
 
1.5.ii.  Extended-form Transition of Albumin (E-Form) 
 
Below pH 3.0, HSA undergoes further quaternary structural changes due to the further loss 
of α-helix conformation; a fully extended structure prevails. There is a dramatic increase in 
solution viscosity and turbidity increases. Fluorescence studies have shown an increase in 
the exposure of the tyrosine and tryptophan residues. All the remaining carboxyl residues 
have become protonated (Leonard, 1961). Like the F-form, formation of the E-form is 
completely reversible. The loss in secondary structural conformation is thought to be due 
to the loss of structure in the interdomain helices between h10(I) - h1(II) and h10(II) - 
h1(III) (Peters, 1996). 
 
1.5.iii.  Base-form Transition of Albumin (B-Form) 
 
At pH≥9.0 (alkaline conditions), HSA undergoes another transition that is more subtle than 
the lower pH changes but nevertheless of physiological importance (Dockal et al, 2000). 
There is evidence suggesting that this transition occurs in discrete steps with a loss in 
helical content (Hart et al., 1986). This transition is characterised by the unusually low pKa 
value of the imidazole groups. There is an expansion in size of the HSA molecule with the 
exposure of buried residues, especially Tys, Ser, Arg, Ile, Phe and Pro. The amino-terminal 
end of the molecule is most affected. Structural changes affecting subdomain IIA (Site I) 
are evident with increased binding for warfarin detected, but with no significant observable 
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effects seen in subdomain IIIA (Site II). Small structural contributions are observed in 
domain I. NMR studies have confirmed some of the histidines (~5) become protonated, 
and Cys-34 is also affected (Zurawski, 1974). Although domain I does not contain any 
major binding sites, changes in conformation could be a factor in triggering the release of 
bound ligands from HSA bound drugs at their target sites. The N-B transition is catalysed 
by the presence of the free sufhydryl residue and is inhibited when the sufhydryl residue is 
blocked (Stroupe et al., 1973); in this form, an increase binding of calcium ions is 
detected. 
 
1.5.iv.  Aged-form Transition of Albumin (A-Form) 
 
The A-form exists at pH≥10 and like the B-form is reliant on the sufhydryl residue. Its 
formation involves two cooperative states, the neutral-base transition (N-B form) and the 
base-aged form (B-A-form) with the release of protons. There is an expansion of the 
protein molecule with the major changes occurring within domain I and II through 
disulphide bond interchange. High pH affects the chemical stability of the S-S bond 
making them unstable with possible bond breakage. 
 
1.5.v.  Additional Aspects of Serum Albumin Structure 
 
There are several transitions associated with the different forms of HSA, which involve 
unfolded intermediates that are detected as the protein undergoes internal reorganisation. 
Albumin responds differentially to chemical perturbations in the N-form and the F-form. 
The effect of adding salts like potassium chloride (KCl) results in the N-form requiring 
high concentrations before precipitation occurs. Conversely the F-form can be ''salted'' out 
in 3M KCl, this is possibly due to the exposure of hydrophobic regions that are normally 
buried within the protein in the N-form. The ability of albumin to bind at low pH is also 
compromised with the F-form showing reduced binding ability when compared to the N-
form, this could be perceived as facilitating off-loading at an interface with target tissues. 
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The forms are the conformational structures that are attained after the transitions are 
completed. The N-F transition is thought to involve the unfolding of domain III (Geisow et 
al., 1977). Considering the fragments of albumin, no changes have been observed in either 
domain I or domain II. When albumin is in the N-form there are six tyrosyl residues 
exposed, when the pH is reduced to below pH4.5 (F-form) the amount of perturbed 
tyrosyls increase by a further five. In the N-form the tyrosyls are hidden in a hydrophilic 
crevice and can only be affected by small pertubants such as ethyleneglycol, sufficiently 
small enough to penetrate the crevice (Herskovitz et al., 1962); Tryptophan is also affected 
by reduced pH as it moves from an aqueous environment to a more hydrophobic one in the 
F-form. The extended structure of the F-form will allow larger purtubants such as sucrose 
to interact. 
 
The charge distribution across albumin is uneven at pH7 with a charge of -6 at the apex, -9 
at the base, -14 on the left and –1 on the right (Peters, 1996). The net charge on the 
albumin (-15) is also affected by changing pH. Bound salts are also affected; on average 
HSA has 7-8 chlorides (Cl-) bound / molecule. Decreasing the pH increases the amount of 
bound Cl- ions to 11 (Cl-) bound / molecule at pH5.2 and 22 (Cl-) bound / molecule at 
pH4.2 (Figge et al., 1991). Conversely, monovalent cations such as Na+ and K+ only bind 











































CHAPTER 2:  Ligand Binding to Human Serum Albumin 
2.1.  Introduction 
HSA can bind numerous ligands with high affinity. However, there is still ambiguity 
surrounding the actual number of binding sites that may be present within the protein. As 
many as nine sites for long chain fatty acids (LCFA)) has been reported, (Kragh-Hansen, 
1990). The challenge to determine just how many sites albumin has will always be 
influence by the environment in which the albumin molecule finds itself in at the time of 
binding, the degree of saturation of the ligand in question and/or the influences of other 
ligands that may bind at the same time and may add to the cocktail.  
 
Frequently there is a “connection” or linkage between the ability to bind at different sites. 
Linkage can be defined as the effect of binding ligands in relation to one another that can 
show positive or negative facilitation (Wyman & Gill, 2000). Linkage can also characterise 
or affect the way in which binding is attained. Linkage effects may be exhibited in the 
form of chemical linkage, physical ligand linkage, polysteric linkage and/or polyphasic 
linkage. When considering chemical linkages two principle possibilities exist, homotrophic 
chemical linkage where the ligand site in question binds the same ligands, or heterotrophic 
chemical linkage where the site binds different ligands. It is also possible to have a 
situation where the two different ligands interact with the protein and competitively bind 
simultaneously with respect to each other, this is referred to as identical linkage. A 
negative facilitation will inhibit binding; conversely, a positive facilitation gives rise to 
enhance binding.  
 
Physicochemical considerations can also influence the ability of the protein to bind 
ligands. Factors such as temperature and pressure (Peyrin et al, 1999) can influence and 
affect binding, giving binding curves that will be dictated by and reflect those changes. 




protein. Polyphasic linkages involve more than one phase. An example of this is 
demonstrated by aqueous sickle-cell haemoglobin binding gaseous oxygen. In both 
polysteric and polyphasic processes solvent effects are also a major consideration. 
 
2.2.  Structural Effects and Functionality 
 
A prerequisite to understanding binding is to understand the structure of the 
macromolecule under investigation. However, macromolecules that have similar amino 
sequence can show diverse variations in terms of binding ability and molecular shape. 
Often binding will invoke a conformation change in the macromolecule either at a local 
level or on a more global scale (see later for a more detailed account of the binding of 
myristate to HSA) which may in turn affect the functionality of the remaining binding 
sites, this can be referred to as an allosteric mechanism. A macromolecule can be seen as a 
“molecular transducer” that will, under certain circumstances, respond to, and can be 
considered to be effectively controlled by the modulating effects of the ligand in question. 
A binding ligand will control the macromolecular shape and response to subsequent 
ligands (Wyman & Gill, 2000).  
 
When considering the locations within a macromolecule that are responsible for the 
attachment of ligands, the terms binding sites and binding regions have been used in the 
literature. The two are clearly different and do not necessarily refer to the same position on 
HSA (refer to Table 2.2). The binding of most ligands is reversible. Association constants 
(Kass or Ka) for ligands binding to albumin are usually quoted as being of the order of 104 
to 106M-1. Ligand binding can cause conformational changes in both the protein and the 
ligand as the ligand binds (Peters, 1985). This may be to preserve the characteristics and 
functionality of both the protein and the ligand, or it may be a feedback mechanism to 
prevent further binding or offloading of the ligand or other ligands that may be in the  





2.3.  Location of Binding Sites on Serum Albumin 
 
The recent developments in the determination of the crystal structure of HSA have enabled 
the study of albumin in more depth with a distinction and discrimination between binding 
sites. Importantly, FAs are shown to be important in maintaining the binding functionality 
of the protein. The use of myristate in the formation of the crystal has enabled better 
crystal formation that gives rise to better diffraction of the X-rays. Myristate seems to 
stabilise the crystal structure which would concur with the fact that HSA is the main 
vehicle for carrying FAs (Curry et al, 2006). The presence of myristate has enabled the 
dramatic increase in data determination, obtained from crystallographic studies of HSA 
drug binding. The binding of drugs causes several effects, resulting in altering distribution, 
lowering the rate of clearance and increasing the half-life of the drug in the blood. 
 
2.3.i. Metal ion and anion binding 
 
The main metal binding site for ligands such as copper (Cu2+), nickel (Ni2+), zinc (Zn2+), 
gold (Au+) and silver (Ag+) is located at the N-terminal of subdomain IA involving the 
first three amino residues, Asp-Ala-His, with histidine at position 3 playing a pivotal role 
(Sadler et al., 1994). A second metal binding site involving the free sulfhydryl residue, 
Cys-34, has also been found. 
 
Chloride (Cl-) ions can affect the binding abilities of some ligands; its Kass in plasma is 
low (Kass=720M-1). There are between 7-8 Cl- ions bound to HSA at pH7.4 attracted to 
residue pairs such as Lys-Lys and Arg-Arg (detected by NMR) (Honoré et al, 1988). 
Albumin contains 9 such pairs, 5 are located in subdomain IIIA at positions 413, 444, 484, 
524 and 573. All are found in the helical stretch of the protein. Cl- is attracted to the C-
terminus and is known to reduce the binding of warfarin, Trp and octanoic acid, (Honoré et 




to make sure that the protein is as pure as possible so that influences such as Cl- do not 
interfere with the binding ability of the ligand under investigation. All samples are dialysed 
and freeze dried to ensure purity and stored in sealed containers in the refrigerator. Ionic 
effects from sodium chloride, sodium sulphate and sodium acetate were investigated for 
their effects on the structural and binding abilities of albumin, the results of which can be 
found in Chapter 4 of this thesis. 
 
2.3.ii.  Ligand (Drug) Binding 
 
The binding mechanisms of ligands are specific, invoking the interaction of different 
residues within albumin depending on the ligand in question, even though, in the majority 
of binding situations, the same locations are involved (IIA and IIIA). Reversible 
conformational changes occur as well as allosteric effects that remain as long as the ligand 
is bound. Albumin is an important determinant of the pharmacokinetic behaviour of many 
drugs. For example, albumin limits the free drug found in the plasma to between 1-10% 
depending on the drug. It is the free drug that is active in blood (Peters, 1996). Thus the 
drug concentration is controlled by albumin if albumin is the binding receptor in the 
circulation. The limiting factor of drug binding is the binding affinity to the protein. 
Although binding of ligands to albumin may be considered desirable for ligands of low 
solubility, thus preventing aggregation of the ligand, a strong affinity to albumin would 
mean that a higher dosage, in the case of drugs, would have to be used to obtain the 
effective free dosage in the blood (Curry et al, 2005). The binding of drugs is never simple 
in vivo as the drug has to compete with endogenous metabolites producing a cocktail. It is 
worth noting that in excess of 90% of drugs bind to HSA. In this way, HSA acts as a depot 
for ligands (Yan-Jun Hu et al, 2005). There also seems to be some degree of overlap of 
binding sites between the major drug binding sites and other ligands, especially when the 




is so great that some drugs become sequestered by HSA, leaving very low levels of 
therapeutic drug for active distribution (Curry et al, 2001).  
 
Subdomain IA, located in domain I, is not renowned for its binding abilities, as very few 
binding locations exist.  There is the possibility of a binding pocket located within the 
stretch of polypeptide that includes Cys-62, the first disulphide, located in a nonhelical 
stretch. However, the lack of disulphides in this location allows the helical stretch h3 to 
increase its packing angle with h4 (Figure 1.7. in Chapter 1.) effectively eliminating a 
pocket (Carter et al., 1994) and may explain the effective inability of ligands to bind 
within this region. There was speculation about a long chain fatty acid (LCFA) binding site 
allocated within subdomain IB; this has now been verified (see later).  
 
Two principal ligand (drug) binding sites on albumin have been observed for major ligand 
binding located within domains II & III. The first is often referred to as the Sudlow Site I. 
Sudlow characterised the site located in subdomain IIA that binds hydrophobic (Sudlow et 
al., 1976), bulky, heterocyclic molecules with a centrally located negative charge (e.g. 
warfarin) (Fanali et al, 2007). The second site, referred to as the Sudlow Site II, is found in 
subdomain IIIA and binds aromatic carboxylic acids with a negative charged at one end of 
the molecule (e.g. diazepam and ibuprofen). Table 2.1. and Figure 2.1. & 2.2. shows the 
possible ligands and their binding sites within albumin. The distribution of amino acids 
that line both binding site cavities are similar with an asymmetrical distribution of 
hydrophobic residues lining one half of the surface, and either basic or positively charged 
residues on the other. Subdomain IIIA is the most active or dominant binding site, an 
elongated "sock-shaped" cavity with mostly hydrophobic residues at the foot, hydrophilic 
residues located along the leg (Carter et al., 1994) and solvent accessibility at the opening. 
















(He & Carter) 
I 1 Long - chain fatty acid 
ions 
390 - 450 Primary binding site is between 
377 - 582. Several sites exist 
specifically for 1°,2° & 3°FA.  
IIIA 
II 2 Diazepam 
0ctanoate 





306 - 386 Positively charged amino acids, 
probably lysine residue are part 
of this binding region. as is 
histidine. The HSA tertiary 
structure is also important for 
this site. 
IIIA 
380 - 450 
III 3 Bilirubin 
Several dyes (Phenol 
Red) 
Iopanoate 
182 - 283 Large number of basic amino 
acids, lysine - 240, arginine  and  
 histidine ,and possibly 
tyrosine. 
IIA 
 4 Cu2+ 
Ni2+ 
1 - 3 + The three  amino terminal 
residues, Asp-Ala-His, His-3 is 
essential. 
IA 
  5 Haemin 124 - 298 This binding site is close to 
region 3. Several expts. have 
shown a separate and distinct 
binding site, and that the C-
terminal part of albumin is 
important for the spatial 
conformation of the haemin 
binding site. 
 






124 - 298 Lys - 199 important where 
acetylation occurs, acetyl group 
transferred by the aspirin. 




V  Warfarin 124 - 298 Lys 199 may be important, Trp- 
214 residue is essential. 
IIA 
Table 2.1.  Representation of the binding regions in HSA. 





Figure 2.1.  Location of binding sites on HSA. 
(U. Kragh-Hansen, Danish Medical Bulletin, 37, 1990, 57 – 88) 
 
2.4.  Site Specific Marker Ligands 
 
The ability of HSA to bind numerous ligands has made it a topic of study for many years. 
Inevitably, binding site locations on albumin with specific ligands have been discovered 
and used as markers for that specific binding site, (Figure 2.1. and Table 2.2.). Markers can 
be used as a valuable aid to locate, track and mark possible sites for ligands whose 
characteristics are not fully known or understood. The markers are diverse and their 
binding has been specifically located on albumin. Examples of some markers used in 
investigations in this thesis (refer to Table 2.1.) have been chosen to represent the 
diversities exhibited by albumin binding, as well as the distribution and susceptibility of 
binding pockets in the molecule. Figure 2.2. gives a more realistic view of how the marker 
ligands are distributed throughout the albumin molecule and the special orientation of the 
molecules relative to each other, as well as the close proximity of the fatty acids in relation  






Figure 2.2.  Tertiary and quaternary structure of HSA showing binding locations. 
(Curry et. al, Journal of Mol Biol, vol 353, issue 1, 2005, page 38 – 52) 
 
The ligands are shown as space-filling representation with oxygen shown in red, all 
others atoms are the FA (myristic acid). Endogenous ligands of haemin and thyroxin, 
and drugs are colour coded dark grey, light grey and orange respectively.  
 
Some markers exhibit more than one binding site as in the case of salicylic acid, although 
they may prefer a dominant site at lower ligand concentration. Such marker ligands can be 
used to determine which site on albumin an unknown ligand might occupy if used in a 
cocktail with a marker ligand of known binding site location. This, however, is not as 
simplistic as stated as other effects need to be considered such as competition effects, 
feedback effects whether positive or negative and environmental effects such as pH and 
solvents. 
Drugs Dyes Ions Fatty Acid 
Warfarin (War)  IIA Phenol Red (PR)  IIA Sodium Chloride 
 
Multiple occupancy 
Octanoic Acid (FA) 
IIA & IIIA + Multiple 
occupancy including 
unknown sites 
Diazepam (Daiz)  IIIA Bromophenol Blue (BPB)  IIA Sodium Sulphate  
Salicylic Acid (SA)  IIA & 
IIIA 
Bromocresol Green (BCG)  IIA Sodium Acetate  
5-Iodosalicylic Acid (5ISA)   
IIA & IIIA 
   
3,5-Diiodosalicylic Acid (DIS) 
 IIA & IIIA 
   




2.5  Mechanisms of Binding to Human Serum Albumin 
 
There is an inordinate number of bindings sites recorded for medium chain fatty acids 
(MCFA) and LCFA but quite where they may be located is yet to be exactly determined. 
What is known is that the chain length of the fatty acid (FA) is imperative to the 
determination of the numbers of binding sites found, the longer the chain length the more 
binding sites that have been detected. 
 
2.5.i.  The Effects of Myristate Binding to Albumin  
 
FA binding is one of the most important interactions of HSA in the body as it is the only 
way FAs are transported around the body. The effects of myristate (Myr) binding has 
already been stated previously. Myr is a medium chain fatty acid (MCFA). However, what 
has not been clarified is the total number and location of binding sites myrisate has on 
HSA. However, there seems to be agreement that there are at least 5 long chain fatty acid 
(LCFA) sites on albumin (Figure 2.3), 3 strong or primary sites and 2 weak or secondary 
sites giving rise to an asymmetric distribution of the FA on albumin.  
 
Figure 2.3  Schematic representation of 5 Myristate molecules bound to HSA. 
(Curry et al, Nature Structural Biology, 5, 827 – 835, 1998) 
 
 Domains I, II & III are represented in colours magenta, green and blue respectively. 
Subdomains A & B are the dark and light shades respectively in each domain. 




FA binding sites are characterised by being hydrophobic pockets with positively charged 
residues (Arg, Lys) or polar side chains (Ser, Tyr) at the entrance to the pocket. Where 
possible, H-bonding occurs to the FA carboxyl group holding the FA more strongly than 
just hydrocarbon chain interactions. Numbering the binding sites of FA is arbitrary and 
bears no significance to the magnitude of the binding affinities. The FA binding sites are 
shown for each domain in Figure 2.4 and Table 2.3.; all were determined by X-ray 
crystallography (Muravskya et al, 2004). 
 
         
 
Figure 2.4.  Schematic representation of the individual domains of albumin showing 
Myristate binding. 
(Curry et al, Nature Structural Biology, 5, 827 – 835, 1998) 
The colour coding is as described in Figure 2.3. for the domains, subdomains & 
Myr, with 2 molecules of Myr in domain I, 1 molecule in domain II and 3 




Myristate Location on HSA Affinity 
Myr 1 Located in subdomain IB Low 
Myr 5 Located in subdomain IIIB High 
Myr 2 Located in the interface between subdomain IA & IIA High 
Myr 3 Located in subdomain IIIA with contributions from IIB 
that anchors the carboxylate 
Low 
Myr 4 Located in subdomain IIIA High 
 




These five sites are the main FA binding sites to albumin, but there are four further 
putative FA sites that have not yet been shown in the X-ray crystal structure of Figure 2.4. 
A 6th possible site is located between subdomains IIA & IIB with interaction with Arg 209 
from IIA and H-bonding to Asp 324 & Glu 354 in IIB; this binding site is located close to 
IIB. Little is known about the 7th site other than it appears to be a low affinity site located 
entirely within the binding pocket of site IIA. The binding of FA induces a rotation of the 
domains (Curry et al, 1998). Domain II remains essentially the same, however, domain I & 
domain III  move (Figure 2.5). Conformational changes result from FA binding, resulting 
in the rotation of domains I & III with respect to domain II, said to be driven by FA 
binding in the junction between subdomains IA & IIA (Curry et al, 2006). 
 
Figure 2.5. Schematic representation of the conformational changes 
 resulting in Myr binding. 
(Curry et al, Nature Structural Biology, 5, 827 – 835, 1998) 
 
The colour coding for albumin domains with bound Myr is the same as described in Figure 
2.3. HSA only is colour coded grey with dark and light grey representing subdomains A & B 
respectively. The coloured helices indicate how much the albumin conformation changes 
when Myr binds, and the arrows show the direction that both domain I & III move with 
respect to domain II. The Cα of HSA with and without Myr are superimposed at domain II 
as this is the only domain that does not change. 
 
Although the binding of myristate exposes the asymmetrical properties of the domains, 
similarities in domain IB & IIIB exist with the myristate binding site existing within these 




approximately 1.7Å that runs perpendicular to the axes of helices h9 & h10. Differences 
are also observed in the way Myr 1 & Myr 5 are bound within subdomains IB & IIIB 
respectively in that the Myr molecules are inverted with respect to each other within these 
subdomains (refer to Figure 2.4.). No binding sites for Myristate has been determined in 
subdomain IIB, as although this tunnel exists it is highly restricted at its centre by aromatic 
residues, namely Phe 309, Phe 330 and Tyr 353.  There also exists a possible block at one 
end of tunnel IIB where the carboxylate residue of the FA would dock and bind (Carter et 
al, 1992). The interaction of myristate occurs in two stages. Firstly there is an ionic 
interaction of the FA carboxyl group with the albumin surface. The second stage is the 
carbon chain (C-chain) attraction of the FA to the interior of the protein globule that results 
in the dissociation of the carboxyl group (Muravskya et al, 2004). It is inevitable that 
albumin undergoes conformational changes with each addition of Myristate.  
 
2.5.ii.  Chain Length Dependence of Fatty Acid Binding to Albumin  
 
There is a relationship between the number of binding sites on albumin and the chain 
length of the FA, with an increase detected in primary association to high affinity binding 
FA sites associated with increase in chain lengths that are not linear (Kragh-Hansen et al, 
2006). FAs such as octanoate, decanoate, laurate and myristate are all examples of 
MCFAs. The principal site of octanoate and decanoate is a single site in domain III. 
Laurate binds to IIIA & IIIB and myristate binds to IB & IIIB. The primary binding sites 
were found to be affected by amino acid mutation in other regions of the protein. Of the 
MCFAs studied, only the X-ray crystal structure of the octanoate remains unknown 
(Bhattacharya et al, 2000). Site IIA is the site for shorter chain FAs like octanoate and 
decanoate. It should be noted that MCFAs constitutes only a small fraction of the FAs 
found in blood. For the longer chain FAs up to five principal high affinity binding sites 
have been detected. LCFA are known to control the binding of ligands to HSA, by 




et al, 2006). In vivo, FAs are stored as triacylgycerols in the adipose tissue, released into 
the circulation with transportation by albumin. The solubility of FA in the body unassisted 
is <1µM.  HSA will carry normally concentrations of FA between 0.1 – 2M/mol of HSA 
(Frederickson  et al, 1958). However, there are some occasions, such as after exercise or 
adrenergic stimulation, or extreme fasting, or in patients with diabetes, liver or 
cardiovascular decease when this concentration can increase to as much as 6M/mol of 
HSA. Not all FAs produce inhibitive or deleterious effects on the binding of other ligands 
to albumin. Indeed, the presence of FA (3M/mol of FA:HSA) has been shown to increase 
the binding of warfarin to albumin, bringing about as much as a 3 fold increase in the 
binding constant. Higher concentrations of FA produce competition between the FA 
molecules and warfarin, resulting in reduced binding of the drug (Chuang et al, 2006).  
 
Octanoate binds to the indole and benzodiazepine binding region of albumin located within 
subdomain IIIA. The presence of this FA now produces deleterious effects on the binding 
of benzodiazepines, prohibiting its binding (Kragh-Hansen et al, 1991), thus supporting 
the view that the distribution of FA is heterogeneous, non-specific, can be shared or 
overlap with other binding sites for other ligands whether considering MCFAs, saturated, 
monounsaturated or polyunsaturated LCFAs. An overlap also exists between FA binding 
site 7 and subdomain IIA, this site on HSA shares 2 aa side chains with FA site 2. Site IIA 
overlaps with FA sites 3 & 4. FA site 1 acts as a primary site for the haemin ligand, and FA 
site 5 is a secondary site for propofol and thyroxine (Figure 2.6). Lastly, FA site 6 is a 
secondary site for ibuprofen and diflunisal. In summary, binding site IIA will bind small, 
medium and LCFAs. Subdomains IIB, IB & IIIB will bind MCFAs & LCFAs, with 
subdomains IB & IIIB showing the greatest similarities. Further FA binding sites may be 





The nomenclature of FAs refers to a general formula of Cm:n where m corresponds to the 
number of carbon atoms in the methylene tail, and n referring to the number of double 
bonds. Figure 2.6 shows two examples of FA binding, C18:1, oleic acid that has 18 
carbons in the methylene tail with one double bond, and C20:4 which is arachidonic acid 




Figure 2.6. Schematic representation of the binding of up to 7 Myr molecules. 
(Bhattacharya et al, J of Mol Biol, vol 303, Issue 5, 721 – 732, 2000) 
 
The colour coding for albumin domains with bound Myr is the same as described in Figure 2.3. C18:1 is 
monounsaturated oleic acid and C20:4 is polyunsaturated arachidonic acid. Binding of the FA for sites 1 
to 5 will be similar, if not the same. Numbers 1 to 7 indicates the binding sites for FA. 
 
In accommodating larger FAs some of the binding site/tunnels on HSA adapt to 
accommodate the larger molecule, thus making the site “flexible;” this is shown in Figure 
2.7. (Curry et al, 2001). The binding of FAs at sites 2 & 4 are different to that at site 5. The 
cross sectional dimensions of sites 2 & 4 increase to as much as 1 - 2Å, with the upper part 
of site 2 wide, while site 4 broadens in two regions (Figure 2.7). Site 2 is said to be the 
most enclosed FA binding sight in HSA, enclosing the whole FA when bound thus 
shielding it from solvent effects. Site 2 binding causes a rotation of domain I relative to 
domain II. Conversely, site 5 is relatively inflexible and remains long and narrow. This 








Figure 2.7.  Comparison of the binding site for FA site 2, 4 & 5 on HSA for the FA C20:4. 
( Carter et al, J Mol Biol, 314, 955 – 960, 2001) 
 




The FA binding sites are summarised in Figure 2.8, which shows the location of the FA 
binding site in the subdomains for each of the 9 binding sites now known. The different 
lengths of the FA are superimposed, and are shown as coloured ball and stick models in the 
binding pockets. Of the 7 FA sites previously mentioned two additional sites (site 8 & 9) 
have now been found located close to the base of the inter-domain crevice between the 




                                                                             
                  Site 1                 Site 2               Site 3 & Site 4     Site 5 
 
  Site 6     Site 7     Site 8          Site 9 
                                                               





Considering capric acid, C10:0, which represents a saturated FA, one of the methylene tails 
that bind to site 6 also assists in forming the hydrophobic end of the site 8 pocket, showing 
possible cooperative interactions between the two site. At the other end of site 8 there is a 
ring of polar residues that included Lys 195, Lys 199, Arg 218, Asp 451 and     Ser 454, 
with the formation of an H-bonding of the carboxylate FA to the side chain of   Ser 454. 
Site 8 is located at the base of the crevice between subdomaims IA – IB –IIA on one side 
and   IIB – IIIA – IIIB on the other. Conversely, site 9 lies further up the inter-domain 
crevice; this site is very exposed with only limited contact of the FA with the protein. A 
salt-bridge between Glu 187 (in domain I) and Lys 432 (in domain III) across the top of the 
crevice helps to keep this FA in place, with the interaction of the FA with the side chain of 
Lys 190. Interaction at site 9 has only been seen for C10:0 because the residues involved in 
binding at this pocket are so far apart due to the movement of domains I and III as a result 
of other FA binding, this produces a 1 – 2 Å narrowing of the crevice that exists between 
these two domains. 
 
A common set of 7 binding sites exists for FA (MCFA & LCFA), with an additional set of 
4 sites found for the simple MCFA. Site 7 (IIA) is the primary site for short chain fatty 
acids (SCFA) but not for LCFA. Esterase activity through Tyr 411 is inhibited by MCFAs 
up to C10:0. A weaker inhibition is observed by LCFA due to the fact that this is a weak 
site for LCFA. MCFAs bind preferentially to IIA and IIIA. At least one high affinity site 
for LCFA is found in domain I, another is found in domain III.  There is a great amount of 
overlap of the binding sites with a commonality in several of the sites. The importance of 
FA in the crystallographic determination of the structure of albumin has already been 
stated (Curry et al, 1998). The presence of FA in recent drug binding studies by 
crystallography has made possible the elucidation of more subtle structural determinations. 




and measure meaningful data, albeit under extreme conditions (Sugio et al, 1999). There 
exist only a limited number of specific drug binding sites on albumin known as site I and 
site II, with site II being the preferential binding site for most drugs (Sudlow et al, 1975). 
There also exist other low affinity sites as well as high affinity sites for the same ligand 
(Dröge et al, 1988). On the binding of a ligand HSA undergoes conformational changes, 
the most important is the N – B transition. Additional binding sites can be found between 
the fusion of sites IIA & IIIA, also subdomain IIB is involved in some instances as well. 
 
2.5.iii.  Mechanism of Binding to Subdomain IIA (Sudlow site I) 
 
Salicylic acid (SA) and its derivatives are all examples of a special class of ligands that 
will bind to both IIA and IIIA within albumin. Binding site IIA is formed by six helices 
that contains two sub-chambers, possibly one of these chambers is for the FA7 site. 
Ligands that prefer site IIA tend to be bulky hetrocyclic anions with the charge situated 
centrally within the ligand. Ligands preferentially binding to this site tend to be aromatic. 
The Sudlow site I binding cavity within albumin is large, flexible and able to accommodate 
chemically diverse ligands with high affinity. Site IIA is said to contain several individual 
ligand binding sites that bind independently or can mutually influence each other (Chuang 
et al, 2006). The major pocket is created by the smaller disulphide double loop (h5 & h6) 
that is found within the interdomain connection (Frofanov et al, 1997). The two disulphide 
bonds in the smaller double loop are thought to experience a change in conformation upon 
binding, changing from the g – g – g form to the more extended g – g – t and g – t – g 
conformations, resulting in the relative rotation of the domains. Trp 214 that is located at 
the bottom half of the h4 helix of IIA, moves from a hydrophobic to a hydrophilic 
environment. Competitive binding exists at this site (Kragh-Hansen, 1985), examples 
include warfarin that competes with bilirubin but is not displaced by phenol red. The 




warfarin 33% more selectively than the R-isomer (a more detailed account is given in 
Chapter 5); the presence of domain I is thought to be important for the binding activity of 
this site. Subdomain IIA is affected by the N-B transition, binding warfarin and bilirubin 
tighter at pH8 and above. Other residues implicated in the functionality of this site are Lys 
199 and His 242. 
 
The binding of a ligand such as salicylic acid at subdomain IIA involves the participation 
of many amino acids. Residues Leu 219, Phe 223, Leu 234, Leu 238, Leu 260, Ala 261, Ile 
264, Ile 290, Ala 291 and Glu 292 are all close to the aromatic ring of the carboxyl group 
of salicylic acid on docking. The carboxylate group itself interacts with Arg 257, Arg 222 
and Lys 190 of the protein, His 242 is also thought to be involved when determined by     
X-ray crystallography (Carter et al., 1992). Figure 2.9 illustrates the early crystallographic 
determination showing just how the ligand is situated in this binding pocket. The binding 
of 2,3,5-triiodobenzoic acid (TIB) is identical to salicylic acid but the presence of the 
iodine gives this molecule a handle in that allows easier spectroscopic  measurements to 
detect and measure ligand orientation. TIB was the preferred molecule used in early 
crystallographic determination. The binding cavity is situated within the double loop 




Figure 2.9.  Stereo view of subdomain IIA binding 2,3,5-triiodobenzoic acid (TIB) 





2.5.iv.  Important Residues in the Site I Binding Site (Subdomain IIA) 
 
There are common features present within the binding sites of albumin. However, there are 
specific residues within the binding pocket that if removed, will debilitate, hinder or cease 
the binding functionality of that pocket. Within subdomain IIA several residues are 
implicated, for example Lys 199 is the site of esterase activity (Curry et al., 2001). HSA 
possesses enzymatic activity that was first observed in 1951. This activity was seen in both 
subdomains IIA & IIIA with the activity of IIIA being the more dominant (Yang et al., 
2007). For example, aspirin acetylates HSA under normal physiological conditions via Lys 
199 with the transfer of its acetyl group (see Equation A). 
 
Both aspirin and salicylic acid bind to albumin, both at similar locations. However, the 
molecular orientations of the ligands on binding are different with aspirin producing a 
rotation of 30° to accommodate the acetylation, converting Lys 199 to acetyl-lysine (Yang 
et al., 2007). Esterase activity occurs via a two step process, although no direct evidence 
has been found. The first stage involves the binding of aspirin to site IIA with the acetyl 
group of aspirin pointing towards Lys 199. The second stage is Lys 199 attacks the acetyl 
group of aspirin. It should be noted at this stage that the esterase activity of salicylic acid 
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Subdomain IIA presents a large hydrophobic cavity, truncated compared to the cavity of 
IIIA as a result of the presence of bulkier hydrophobic side chains. The entrance of this 
binding pocket is surrounded by positively charged residues (K195, K199, R218 & R222), 
with Lys 199, His 242 and Arg 257 functioning sterically and electrostatically in ligand 
binding (Tuan et al., 2006). A second cluster of positive residues is found at the bottom of 
the sock shaped pocket (Y150, H242 & R257) that permits simultaneous interaction at the 
two clusters. 
 
2.5.v.  Mechanism of Binding to Subdomain IIIA (Sudlow site II) 
 
Binding site IIIA is a T-shaped hydrophobic pocket with two hydrophilic entrances with a 
separation of 10Å. The entrance contains residues that interact with the carboxyl groups of 
the binding ligand. Like site IIA, this pocket is also formed from six helices. However, h3 
& h4 form the floor, h1 & h2 form the sides and h5 & h6 form the roof of the internal 
cavity. The binding pocket of IIIA is smaller and narrower than that of IIA and cannot 
accommodate the binding of long ligands since it is less flexible than IIA. The binding at 
this pocket is stereoselective, for example, L-tryptophan binds preferentially to the           
D-isomer. Within the pocket are two regions of H-bond partners, the first is located across 
the interface of domains II & III through Ser 342 & Arg 348 in subdomain IIB and Arg 
485 in sudomain IIIA. The second region is located at Arg 410, Tyr 411 & Ser 489, all 
found in IIIA. Within the pocket Arg 410 & Tyr 411 are thought to be the most important 
residues. Bound FAs occupy tunnels between the helices that are lined with hydrophobic 
residues. Myr4 interacts with Arg 410 in IIIA and Myr3 interact with Arg 485 in 
subdomain IIIA and residue 348 in subdomain IIB. The sequence Arg-Tyr*-Thr-Arg has 
been found to be important for the activity and functionality of this site. It was later found 
that the active residue Tyr* located at position 411 in the tip of the loop was the important 




subdomain the binding of salicylic acid and its derivatives have been considered in depth. 
Pro 384, Leu 387, Ile 388, Phe 395, Leu 407, Leu 430, Val 433, Ala 449 and Leu 453 all 
interact with the aromatic ring, with influences from the hydrocarbon chains of Arg 485 
and Glu 450. Arg 410 interacts with the carboxyl group with influences from the oxygen of 
Tyr 411, (Figure 2.10.). Typically, TIB was used as the marker ligand to investigate the 
characteristics of this binding pocket, since like salicylic acid, TIB binds to both site IIA 
and IIIA in albumin and exhibit similar binding orientations. The binding cavity is situated 
close to h1(III). One main polar cluster exists at the entrance and on one side of the pocket; 





Figure 2.10  Stereo view of subdomain IIIA binding 2,3,5-triiodobenzoic acid (TIB) 
( Carter et al, Nature, 358, 209 – 215, 1992) 
 
2.5.vi.  Important Residues in the Site II Binding Site 
 
Arg 410 and Tyr 411 project into the middle and overlap with the centre of the site II 
binding site, and play an integral part in the functionality of this site. The functionality is 
reliant on the close proximity of the two residues, Tyr 411 being approximately 2.7Å from 




through electrostatic interaction between the ligand carboxylate and the guanidine portion 
of the residue (Kragh-Hansen et al, 2001). The aromatic ring of Tyr 411 and the phenolic 
oxygen both play a key role. Diazepam binds to this site but does not possess a carboxyl 
group and therefore the two points of contact for Tyr are the important features (refer to 
Chapter 5 for more detail). Tyr 411 seems to be the vital moiety and key to the binding in 
this pocket (Kragh-Hansen et al, 2001). Also located in the site II binding pocket are two 
FA binding sites for molecules FA3 & FA4, with the carboxyl of FA4 interacting with Arg 
410 & Tyr 411. The combination of the two residues is said to play an important role in 
“modulating the affinity of HSA for a variety of ligands” (Kragh-Hansen et al, 2000). It 
has also been found that these two residues are highly conserved in a variety of species in 
evolution (along with Arg 218 in site I).  
 
2.6.  Quantification of Ligand Binding 
 
The pharmacokinetics of drug binding to plasma proteins such as albumin is very 
important as its binding will affect the concentrations of the unbound drug, its distribution 
in the body and its elimination (Curry et al, 2001). Warfarin is an example of a drug that 
binds to albumin in quantities as much as 99% under normal therapeutic conditions; this 
gives rise to a small volume of distribution and a low clearance. It is vital to know and 
understand the binding mechanism of any drug, its chemistry and activity within the body 
in order to ensure effective and optimum use. The quantification of the binding of a ligand 
to a protein can be achieved by two different approaches, one is the thermodynamic 
treatment derived from the stoichiometric equilibrium constant Ki, and the other method is 
using non-linear mathematical computer fits. 
 
There are many methods and techniques employed to analyse binding, all offer advantages 




method that can give all the information required. Each method offers only a proportion of 
the information, thus highlighting the fact that each method has built in inherent problems. 
Often the structure of the macromolecule is unknown. Therefore, studying binding effects 
may only add to the confusion. Breaking the macromolecule down into fragments that are 
more manageable is an act in itself that is problematic. Fractions, often created from the 
natural breaks that are present within the protein, often referred to as domains if multiple 
domains are present in the macromolecule, will exhibit characteristics that may or often 
may not be found in the intact protein itself. Albumin is one such protein that has been 
systematically studied for binding over the years even when its structure was unknown and 
not fully characterised. This may explain the diversities in determining just how many 
binding sites are present.  
 
A prerequisite to understanding binding is to understand the structure of the 
macromolecule under investigation. Often binding will evoke a structural change to the 
macromolecule at a local level. However, changes can occur on a more global scale that in 
turn may affect the functionality of the remaining binding sites. This kind of response is 
referred to as an allosteric mechanism. The macromolecule can be envisaged as a 
“molecular transducer” that will respond to, and is somewhat controlled by the modulating 
effects of a ligand, that can control the molecular shape and response to subsequent ligand 
binding. In the simplest case, ligand binding involves the stoichiometric binding of a 
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If more than one binding site is present for the same ligand, then there is often a dominate 
site that will always bind preferentially; this is called the primary binding site. Subsequent 
ligands that bind may have to be modified in some way, such as orientation, in order that 
they may also be accommodated on the macromolecule. The modifications in the 
macromolecule on binding of the first ligand may act as a trigger to allow subsequent 
ligands to bind; equally, it may also act as an inhibitor for further interactions. In this thesis 
the larger macromolecule (the protein) is considered to be a host (H) which will accepts the 
binding of a smaller guest molecule (G). The choice of which entity is referred to as the 
guest and which the host is probably best set by the mathematical treatment. Thus, for 
example, a small peptide is often referred to as a ligand when it binds to a metal ion. On 
the other hand, the metal ion is termed the ligand when binding to a protein. In a binding 
process, the largest species involved is often trivially referred to as the host. In 
mathematical terms, the species that is being monitored (with a fixed concentration) is best 
termed the guest, the other molecule the host. In practice, the binding of ligands to proteins 
is more complicated when considering large multi-binding site proteins. The equilibrium 
can be described by the expression,  
[ ] [ ] [ ]
[ ] [ ] [ ]
Host + Guest Host:Guest
H + G HG
→←
→←
             (1) 
The quantification of this process concerns the concentration of the various species and the 
solution conditions. The binding constant (or association constant) is defined as: 
[ ]




=               (2) 
where [Hf] is the equilibrium concentration of the free host (protein), [Gf] is the 
equilibrium concentration of the free guest (ligand) and [HG] is the equilibrium 
concentration of the complex. This is the relatively simple picture for a [1:1] binding to 




ligands present and whether the ligands, 
i) compete for the same binding site on the protein. 
ii) enhance the binding of one, or the other, or both of the ligands present at the same 
or different binding sites. 
iii) mutually reduces the binding to one, or the other, or both of the binding sites if 
different or at the same binding site if the same. 
iv) bind to different sites on the protein;  
 
There are two main algebraic approaches associated with the characterisation of ligand 
binding. The first approach is based largely on pre-computer mathematical method and is 
described in detail in books such as that published by Wyman and Gill. The second method 
is a more pragmatic approach with simpler algebra requiring a more computer-based 
approach to directly simulate unmodified experimental data. The two approaches overlap, 
are complementary and will be only briefly reviewed here. The reader is referred to the 
original texts for a more detailed discussion. 
 
2.6.i.  Classical Determination of Binding Constants 
 
2.6.i.(a)  1:1 Macromolecule:Ligand Binding 
 
The ability to investigate binding interactions relays something about the forces of 
interaction between the two molecules, and the relative stability of the resulting complex. 
Classically, ligand binding has been quantified following the schemes of Hill (1910), 
Scatchard (1949), Klotz (1946) and Job (1949). Scatchard originally assumed: 
 
i)  Ligands are bound to independent binding sites on the protein. 
ii) There exits groups of binding sites with the same binding constant. 




In the classical treatment, the binding process is explicitly considered in terms of proteins 
and ligands. The equilibrium constant is derived from the association of the protein and the  
ligand. Thus,  
Protein   +   Ligand   →←    Protein:Ligand 
       [P]free      +      [L]free   →←    [PL]            (3) 
The association constant (Kass) is defined as, 
    
[ ]




=               (4) 
where [PL] is the concentration of the complex, [P] is the free equilibrium concentration of 
the protein and [L] is the free equilibrium concentration of the ligand. Kass is also 
abbreviated as K and is related to the dissociation constant (Kd), where K = 1/Kd. An 
important parameter to consider is the number of moles of ligand bound per mole of 
protein defined by Scatchard as ' v ', which is the degree of binding and can be defined as : 
   
[ ] [ ]








             (5) 
Substituting equation (4) into (5) gives: 
   
[ ] [ ]
[ ] [ ] [ ]
. . [ ]
1 [ ]
K L P K L
v
P K L P K L
= =
+ +
            (6) 
Equation (6) can be rearrange to give the ratio of filled to unfilled sites, thus: 







              (7) 
where (1 v− ) is the fraction of unoccupied sites. Scatchard multiplies equation (7) by the 
term (1- v ) / [L] to give: 




= −                (8) 
If [ ]/v L  (on the ordinate) is plotted against v  (on the abscissa) a straight line is obtained 
for a single site binding, with the slope of –K and an intercept of K. The Hill plot takes 











              (9) 
If ( )log / 1v v−  is plotted against log [L], a straight line is obtained with an intercept of 
log K. A typical way to plot a binding curve is by plotting v  against log [L]; this shows a 
sigmoid relationship. Plotting the equations in different forms brings out the different 
attributes of the binding relationship, and allows a better understanding of the underlying 
factors of the mechanism of binding. For example, the Hill plot and the binding curve both 
give information on the cooperativity of the binding process (see later). Equation (6) can 
be rearranged to give: 




= +              (10) 
v  is a measure of the extent of binding and is dependent on the total protein concentration. 
If there is more than one binding site, then by Scatchard’s assessment equation (6) can be 
expressed in terms of reciprocals where the number of binding sites are taken into 
consideration: 
   
1 1 1 1
.
[ ]nK L nv
= +              (11) 
Equation (11) highlights several different plots that can be constructed to investigate the 
binding characteristics of a specific interaction. A double reciprocal plot of 1/ v  against 
1/[L] produces a linear regression line with a slope of 1 / nK and an intercept of 1/n with 
the ordinate axis. This is known as the Klotz plot (Kragh-Hansen, 1990).  
 
2.6.i.(b)  Multiple Binding Sites on a Protein 
 
A protein can possess multiple binding sites for the same ligand, this is usually seen in 
proteins that contain multi-domains such as human serum albumin. When a ligand has 




binding configurations can exist depending on which site is occupied first. There will be a 
binding constant, which will be specific to each site. The greater the number of binding 
sites the greater becomes the complexity of the mathematics required to analyse the 
experimental data. Thus a two binding site case can be treated simply as a global bound / 
unbound case, as the first site followed by the second site binding case, or as a multi-
equilibrium case with “micro” individual binding constants. This can be best illustrated 
diagrammatically as shown in Figure 2.11.a. 
 

















Figure 2.11.a.  Schematic Representation of the Binding Sites on a Protein. 
 
As discussed earlier, albumin has many binding sites (Klotz et al., 1979). The binding of a 
ligand to a particular site can depend upon the occupancy of other sites.  One binding 
ligand can induce changes in site accessibility due to stereochemical bulk or protein 
conformation changes (2ry, 3ry or 4ry) that can affect the binding of another ligand. In the 
extreme, the binding of one ligand may completely inhibit the binding of subsequent 
ligands.  The location of binding sites within the macromolecule will play a vital role in 
binding capability, and will control the type, shape and size of the ligand that will be 
accepted at the site. Therefore, although different multi-binding configurations cannot be 
discriminated for in terms of binding site constants, they may play an important role in the 




is further complicated by the shear numbers of binding sites that could be present as 
represented in Figure 2.11.b., the possibilities that can exist for three and four binding sites 
show the complexity of the situation and highlights the problems associated with 
























(ii)  Three Ligands Binding to a Protein. 
 
P PA1 PA2 PA3 PA4















(iii)  Four Ligands Binding to a Protein. 





Binding to a Protein containing One strong Site and One weak Site 
 
For a strong and a weak binding site with values differing by over an order of magnitude, 
Figure 2.11.a.i. can be reduced to Figure 2.11.a.ii. with K1 = K1' and K2 = K2'. The analysis 
can be taken as a two step process applying the Scatchard analysis to two concentration 
regimes. 
Two Independent Binding Site Models 
 
A relatively simple approach to demonstrate independent but identical ligand binding is to 
consider the binding of oxygen to two sites on haemoglobin, according to the solution 
shown in Figure 2.11.a.iii. There are two possible binding constants associated with this 
protein K1 and K2 where,  
   P   +  L   →←    PL  1
[ ]




=          (12) 
   PL   +  L   →←    PL2  22
[ ]




=         (13) 
 
Equations (12) and (13) looks at the individual binding at each binding site. However, the 
binding can be considered from the prospective of the overall reactions with respect to the 
un-reacted protein with binding constants now termed β1 and β2. The two sets of constants 
are equated by K1  = β1 and K1 K2 = β2. Now the reactions can be expressed as: 
   P   +  L   →←    PL  1
[ ]
[ ] .[ ]
PL
P L
β =          (14) 
   P   +  2L →← PL2  22 2
[ ]
[ ] . [ ]
PL
P L
β =          (15) 
The degree of binding is expressed as, 
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Unlike the single site model, there is no simple linear relationship that can express this type 
of binding; the binding will have to be analysed by non-linear data fitting methods. In 
terms of the Scatchard or Hill type format, in taking the ratio of sites filled to the sites 
unoccupied for two sites, the fraction of unoccupied sites is expressed as / 2v v− . The 
Scatchard equation becomes: 
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           (17) 
Therefore, at low concentrations of ligand, [ ] 0L →  









             (18) 
At high concentrations [ ]L → ∞  






             (19) 
The Hill plot (log ( )v v/ 2 −  against log [L]) will only show linearity at the extreme 
conditions. There will be two intercepts on the y-axis, one at the lower limit asymptote of 
log ((1/2) K1) and the other at the higher limit asymptote of log (2K2). Extensions to this 
approach with more complex analyses of binding processes are presented in the book by 
Wyman and Gill. 
 
2.6.i.(c)  Cooperativity and its Effects 
 
In some cases of multiple binding sites, the binding at one site can affect the binding at 
another and visa versa. An affinity increase results in positive cooperativity; a negative 
cooperativity implies a reduction in binding ability. Cooperativity is measured by 
comparing the experimental binding curve with the theoretical curve, the theoretical curve 




identical binding sites each with a binding constant of 'K', then the number of moles of 
ligand bound per mole of protein is expressed as : 








             (20) 
Taking the differential of equation (20) will give: 
   




[ ] 1 [ ] 1 [ ]
d v n K n K L
d L K L K L
= −
+ +
          (21) 
Multiplying equation (21) throughout by [L] gives: 
   
( ) ( )
2 2
2
[ ] [ ] [ ]
[ ] 1 [ ] 1 [ ]
L dv n K L n K L
d L K L K L
= −
+ +
          (22) 
In terms of equation (20) then,  
   ( ) ( )2 / 1 /
[ ]
d v
v v n v v n
d In L
= − = −            (23) 
When / 2v n= , the maximum slope is observed which is equal to n / 4.  Comparisons of 
binding curves with suspected cooperativity and curves obtained for the equivalent site 
independent binding will show if cooperativity exists.  If the curve showing cooperativity 
has a slope greater than that obtained for the reference curve then positive cooperativity 
exists.  Assessments of cooperativity are best achieved from Hill plots. Fractional 
saturation 'θ' can be defined as: 
   /v nθ =               (24) 
Determining the slope of the reference curve in equation (22) in terms of 'θ' gives: 





θ θ= −             (25) 
Therefore, the Hill plot is given by ( )ln / 1θ θ−    against ln [L] with a slope 'nH' of: 
  
( )( ) ( )/ 1 1
[ ] [ ] [ ]H
d In d Ind In
n
d In L d In L d In L
θ θ θθ− −














= + − 













             (28) 
From equation (28), the slope (of the reference curve) of the Hill plot will now be 
( ) ( )/ [ ] / 1d d In Lθ θ θ− , where the slope of the reference curve (1 )θ θ−  is given by 
equation (25). The Hill plot gives a direct measure of cooperativity at any point along the 
curve. Thus, if the slopes of both the binding curve and the reference curves are the same 
then nH = 1 showing no cooperativity. 
 
2.6.i.(d)  Competitive Binding of Ligands 
 
A protein that contains a single binding site for two different ligands 'A' and 'B' presents 
two equilibrium constants as shown: 
   P  +  A  →←   [PA]  
[ ]




=           (29) 
   P  +  B  →←   [PB]  
[ ]




=           (30) 
The degree of binding associated with each ligand is: 
[ ] [ ]






P PA PB k A k B
= =
+ + + +
           (31) 
[ ] [ ]






P PA PB k A k B
= =
+ + + +
           (32) 
The binding effects of one ligand on the binding ability of the other ligand is called linkage 
effects. Equations (31) and (32) can be rearranged to give the following relationship: 
   










           (33) 
If 'B' is present in a large excess, and the conditions are set such that the concentration of 




to the small absorption of 'B' compared to its large total volume, then equation (33) holds. 
Plotting 1 / Av  against 1 / [A] yields a straight line with an intercept on the y-axis equal to 
binding without inhibitor. In practice, the concentrations of all three components (Ligands 
'A' and 'B' and the protein) are comparable to minimise binding at the second and 
additional sites (as in the case of albumin that has several binding sites). Under these 
conditions, a straight line plot is not obtained but a hyperbolic curve. Determination of the 
binding at the second and subsequent sites is also hard to correct for. As a result of the use 
of comparable concentrations then: 
(1)   The concentration of free A and B will have to be determined. 
(2)   If by plotting 1 / Av  against 1 / [A] a straight line is not obtained then 
competitive binding exists. 
The Scatchard analysis converts equation (33) to give, 
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= −  + 
           (34) 
Experimental data should include both high and low ligand:protein ratios (i.e. high and low 
values of / [ ]Av A ). Taking the ratios in equations (31) and (32) gives, 







=               (35) 
If a plot of /A Bv v  against [A] / [B] is drawn yielding a straight line graph then the two 
ligands are competing for the same site. A slope of kA / kB  (these can be determined by 
independent experiments) is obtained. However, this plot does not take into consideration 
the binding at secondary sites, it would be better to plot Av  against [A]. It is now possible 
to construct a theoretical binding curve of 'A' in the presence of a constant concentration of 
''B'. If competitive binding is assumed at the high affinity binding site, and compared to 




calculated from independent studies of single ligand binding. [B] and Bv  can be 
determined by substituting equation (36), which is : 
   [ ] [ ] . [ ]Total B TotalB B v P= −             (36) 
where [B]Total is the total concentration of the second ligand and [P]Total is the total 
concentration of protein. Substituting into equation (32) to give, 
( )2[ ] 1 [ ] [ ] [ ] [ ] 0B Total B B Total A B Total B B TotalK P v K B K A K P v K B− + + + + + =              (37) 
This quadratic equation has two solutions for Bv . However, one of the expressions can be 
dismissed since the solution results in a negative number for [B]. Equation (36) is used to 
calculate Bv , equation (37) is used to calculate [B], the expected value of Av  is calculated 
from equation (31) and can be compared to that determined experimentally. 
 
2.6.i.(e)  Binding of Two Different Ligands to a Protein 
 
A protein can possess two distinct binding sites for two different ligands, A and B. Several 
equilibria can be considered: 
   P A PA+ ↔   
[ ]




=           (38) 






=           (39) 
   P A B PAB+ + ↔   
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=        (40) 
The degree of binding in each case is therefore, 
[ ] [ ] [ ] . [ ]. [ ]
[ ] [ ] [ ] [ ] 1 [ ] [ ] . [ ] [ ]
A A B
A
A B A B
PA PAB K A K K A B
v
P PA PB PAB K A K B K K A B
+ +
= =
+ + + + + +
       (41) 
[ ] [ ] [ ] . [ ] [ ]
[ ] [ ] [ ] [ ] 1 [ ] [ ] . [ ]. [ ]
B A B
B
A B A B
PB PAB K B K K A B
v
P PA PB PAB K A K B K K A B
+ +
= =
+ + + + + +





[ ] . [ ]. [ ]
[ ] [ ] [ ] [ ] 1 [ ] [ ] . [ ]. [ ]
A B
AB
A B A B
PAB K K A B
v
P PA PB PAB K A K B K K A B
= =
+ + + + + +
     (43) 
 
2.6.i.(f)  Mutually Reduced Ligand Binding 
 
It is possible that the mutual binding of ligands reduces their individual abilities to bind to 
the protein. This cannot be described by competitive means. The ligands, A and B, bind to 
different sites on the protein resulting in conformational changes and a reduction in CD 
signal in the case of CD spectroscopy (Kragh-Hansen, 1990). The effect of binding ligand 
B on the binding of ligand A can be quantified by the expression, 









= =              (44) 
where K is the association constants for ligands A and B, BAK  is the association constant 
for the mutual binding of ligand B first with respect to A, ABK   is the association constant 
for the mutual binding of ligand A first with respect to B and X is the coupling constant. 
There is a mutual relationship between ligand A and B with them being affected to the 
same degree. The relationship between X on binding characteristics can be summarised in 
Table 2.4.  
X > 1 Cooperative Binding 
X = 1 Independent Binding 
X < 1 Anti-cooperative Binding 
X = 0 Competitive Binding 
 
Table 2.4.  The effects of the Coupling Constant on Binding of Ligands to a Protein. 
 
From the procedure described by Kragh-Hansen the value of the coupling constant, X, can 
be calculated from the following expression (Kragh-Hansen, 1983), 
 





Equation (45) can be transformed to: 
 [ ] [ ] [ ][ ] [ ] [ ] [ ] [ ] [ ]P P K P A K B P X K K A B PTotal A B A B= + + +         (46) 
The concentration of bound ligand A, [A]Bound can be calculated from: 
 [ ] [ ] [ ] [ ][ ] [ ] [ ] [ ]A A A K P A X K K A B PBoundl Total A A B= − = +          (47) 
Subtracting equations (46) and (47) gives, 
   [ ] [ ] [ ] [ ] [ ]P A P K B PTotal Bound B− = +           (48) 
If [P]Total, [A]Total, [A], KB and [B] are known, it is possible to calculate [P]. Inserting this 
value and the known values of KA and [A] in equation (45) makes it possible to calculate 
X, which can also be calculated in terms of bound B from equation (46). 
 
2.6.ii.  Direct Analysis of Ligand Binding Measurements 
 
In pre-computer days, it was desirable to reduce the mathematics behind an analysis of 
observed data to a linear " y mx c= + " plot. Linear regression leads to values of the 
intercept (c) and the gradient (m) from which the desired parameter (e.g. Binding constant) 
can be extracted. Nowadays, computers have better enabled the fitting of non-linear 
equations using for example the Levenberg–Marquardt procedure to reproduce 
measurements themselves directly. The latter scheme provides more insight into the 
measurement process and reasonability of the calculations. Mathematically, the 
Levenberg–Marquardt method is as valid as the simpler linear regression. However, 
computer manipulation of data is required. 
 
Using CD spectroscopy as the analytical monitor, in the simplest case of a 1:1 binding 
complex formation, there are three possible conditions (Drake, 2001): 
 
(1) Class 1A: Non-chiral guest / chiral host. Single binding site. 
(2) Class 1B: Chiral guest / non-chiral host. Single binding site. 





For the purposes of CD certain criteria have to be fulfilled. The guest must possess an 
“accessible ordinary electronic absorption” (Drake, 2001). Both the guest and the host may 
possess a CD in the free solution, the host CD being detected at the chosen detection 
wavelength. Chirality must exist between the associations of the guest/host pairing that is 
detectable at the designated detection wavelength; this gives rise to four possibilities 
(Drake, 2001, and Strat, 1998). In this thesis, any CD due to a host (albumin) is considered 




Consider the simplest case where there is a 1:1 binding relationship, 
 
Free guest shows no CD signal at guest based detection wavelength. 
Free host shows no CD signal at the detection wavelength. 
The bound guest (the complex) shows a CD signal at the guest detection wavelength. 
 
If HT is the total host concentration, GT is the total guest concentration, at equilibrium the 
free host concentration (protein) is Hf and the free guest concentration (ligand) is Gf. The 
complex concentration HG can be determined from the following expression, 
    Hf + Gf    →←     HG 
with    HT = Hf + HG             (49) 
and    GT = Gf + HG             (50) 
 
From equations (49) and (50) the association constant 'Ka' can be determined and 
calculated as,  
K
HG
H Ga f f
=
.




The detectable CD signal is produced from the induced signal upon binding of the guest to 
the host and is detected at the guest detection wavelength, therefore,  
. .calc HG HGA A l HGε∆ = ∆ = ∆             (52) 
where ∆Acalc is the calculated differential absorbance, ∆ εHG is the differential extinction 
coefficient of the complex detected at the guest wavelength and l is the pathlength. For the 
purpose of CD, the concentration of the guest (ligand) is kept constant and the host 
concentration (protein) is varied until the entire guest concentration encounters the host 
(i.e. excess host). The extent of binding ( i
−
) is the average number of guest molecules 
bound per molecule of host and can be expressed as,  
   i
G G
H












           (53) 
Equation (53) can be rearrange to give, 




















          (54) 
i
−
 is a measure of the extent of binding and is dependent on the total host concentration 
(note, when HT is the independent variable, the extent of binding is now given by the 
expression j HG Gt
−
= /  and is dependent on the bound guest molecules complex). 
Equation (53) can be rewritten in terms of the independent (x = Gf) and dependent (y = i
−
) 
variables to give equation (55). 







              (55) 
p, q and r are constant where p=K, q=1 and r=k. Equation (6) can be expressed in terms of 
reciprocals to give, 
   
1 1 1 1
i nK G nf




Note this expression is the same as that determined in the classical analysis shown in 
equation (11). The same graphical plots (Scatchard plot, Hill plot etc.) can be represented 
here; the quantities Hf, Gf, HG and εHG are unknown from equations (49), (50), (51) and 
(52), with HT and GT known, these quantities can also be expressed by the following 
equations: 
Hf  =  HT - HG             (57) 
Gf  =  GT - HG             (58) 
    HG = K . Hf  Gf            (59) 
Substituting equations (57) and (58) into equation (59) will give two possible expressions 
for the theoretical differential absorbance: 
2 2
1
. . 1 ( . . 1) 4 . .
( )
2
T T T T T T
T
K H K G K H K G K H G
HG H
K
+ + − + + −
=        (60) 
2 2
2
. . 1 ( . . 1) 4 . .
( )
2
T T T T T T
T
K H K G K H K G K H G
HG H
K
+ + + + + −
=        (61) 
Where HG1 is the complex formed from the theoretically negative contributions of the 
quadratic expression, and HG2 is the complex formed from the theoretically positive 
contributions of the quadratic expression. Substituting equations (60) and (61) into 
equation (52) will give: 
    1 1.calc HGA HGε∆ = ∆             (62) 
    2 2.calc HGA HGε∆ = ∆             (63) 
Now if equations (60) and (61) are both used in the formulae then two possible expressions 
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+ + + + + −




Only ( )1calc TA H∆  gives the realistic solution. In these and future equations ∆A refers to 
the CD that would be observed in a 1cm pathlength cuvette. An example of Case 1A 
binding is represented in the binding of diazepam to HSA. The mathematical function that 
represents the realistic expression of the experimental data is seen in ( )1calc TA H∆ . 
Case 1A' 
Free guest shows no CD signal at guest based detection wavelength. 
Free host shows a CD signal at detection wavelength. 
The bound guest (the complex) shows a CD signal at guest based detection 
wavelength. 
Keeping the concentration of the guest constant while varying the concentration of the host 
and using the same nomenclature, at equilibrium, 
   HT = Hf + HG              (66) 
   GT = Gf + HG              (67) 
The association constant is given by the expression, 





              (68) 
Adopting the same principals as for Case 1A, the induced (theoretical) CD signal of the 
bound guest is given by, 
   ∆ ∆ ∆A A Acalc HG Hf= +  
   . .calc HG H fA HG Hε ε∆ = +  
   ( ). .calc HG H H TA HG Hε ε ε∆ = − + ∆            (69) 
Ideally ∆ εHG can be determined directly (experimentally) and represents the molar CD of 
the complex (HG) detected at the guest detection wavelength; ∆ εH is the molecular CD of 
the host alone (free). The resulting complex concentration is determined by the same 




   ( )1 1. .calc HG H H TA HG Hε ε ε∆ = − +            (70) 
   ( )2 2. .calc HG H H TA HG Hε ε ε∆ = + +            (71) 




Free guest shows a CD signal at guest based detection wavelength. 
Free host shows no CD signal at detection wavelength. 
The bound guest (complex) shows a CD signal at guest based detection wavelength. 
 
Under these conditions, the free chiral guest (ligand) is modified on binding will also 
generates the optical activity. The modified CD associated with the guest is now altered 
according to equation (65), 
   ∆ ∆ ∆A A Acalc HG Gf= +  
   . .calc HG G fA HG Gε ε∆ = +  
   ( ). .calc HG G G fA HG Gε ε ε∆ = − +            (72) 
Again εHG, the molar CD of the complex detected at the guest based detection wavelength 
has to be determined; ∆ εG is known. The complex concentration is determined and the 
calculation of the theoretical CD gives two possible solutions when equations (61) & (62) 
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+ + + + + −
∆ = − +        (74) 
This case is represented by the titration of (+)-S-Ibuprofen binding to cyclodextrin or the 








Free guest shows a CD signal at guest base detection wavelength. 
Free host shows a CD signal at detection wavelength. 
The bound guest (the complex) shows a CD signal at guest detection wavelength. 
 
This is characterised by the existence of both the guest and host having detectable CD 
signals at the detection wavelength together with the complex. Here the relationship of the  
bound complex will be given by: 
   ∆ ∆ ∆ ∆A A A Acalc HG Gf Hf= + +  
   . . .calc HG G f H fA HG G Hε ε ε∆ = + +  
   ( ). . .calc HG G H G T H TA HG G Hε ε ε ε ε∆ = − − + +          (75) 
εHG is unknown and has to be determined with detection based at the guest detection 
wavelength. The molecular CD of the guest, ∆ εG, is known together with the molecular 
CD of the host alone, ∆ εH. Once again, two possible solutions for the theoretical CD are 
found if equations (61) & (62) are substituted into equation (75): 
   ( )1 1. . .calc HG G H G T H TA HG G Hε ε ε ε ε∆ = − − + +               (76) 
   ( )2 2. . .calc HG G H G T H TA HG G Hε ε ε ε ε∆ = − − + +                 (77) 
Where HG1 is the complex formed from the theoretically negative contributions of the 
quadratic expression, and HG2 is the complex formed from the theoretically positive 
contributions of the quadratic expression. ( )1calc TA H∆ is the realistic expression of the 
experimental data. An example of this case is in the dimerisation processes of chiral 






Although the treatment of the data for all four cases was fitted in terms of CD, this method 
can be adopted for other techniques. The assignments of the guest and host terms are 
interchangeable provided that the correct mathematical treatment is conducted. If the 
experiments were conducted such that the host concentration (protein) is now kept constant 
and the guest concentration (ligand) varied then the four expressions for ∆Acalc would not 
be affected and would remain the same. 
 
When fitting the expressions, two unknown parameters exists which are the molar CD of 
the bound complex ( ∆ εHG) that is associated with the bound complex and the equilibrium 
constant (K). ∆ εHG can be determined from the limiting value of ∆Aobs (∆Alim), obtained by 
titrating a fixed guest (ligand) concentration to a variable concentration of host. From this 
'K' can be determined using CD. Values of 'K' that are detectable by this method are in the 
region of 103 to 106 M-1. There is some ambiguity that may exist in CD where there is an 
overlap of the guest and host signals, this usually occurs for wavelengths less than 290nm 
and for this reason studies below this wavelength should be avoided or investigated under 
very defined conditions. An example of this case can be seen in Cu++ binding to a peptide. 
Cu++ absorbs at 600 – 800nm, however to monitor the titration at this wavelength large 
quantities of copper and peptide will be required and the transitions are weak. In order to 
overcome this problem the titration is conducted at a wavelength of around 230nm which 
will require much smaller quantities. At this wavelength there is a reversal of roles in that 
the Cu++ is treated as the host keeping its concentration variable while the peptide is treated 
as the guest at fixed concentration. Although the spectral changes at this wavelength are 
complex in terms of the CD, only the guest (peptide) and the complex (Cu++/peptide) will 








2.6.ii.(a)  Binding of Ligands to Two Sites on a Protein 
 
When dealing with proteins there is always the possibility that more than one binding site 
exists for the same ligand (e.g. aspirin). If there are two binding sites present then these can  
be classified in the following way,  
Class 2A: Non-chiral guest / Chiral host – two binding sites. 
Class 2B: Chiral guest / Non-chiral host – two binding sites. 
Class 2C: Chiral guest / Chiral host – two binding sites. 
Four possible cases can be highlighted in terms of analysing the data, these are: 
 
Case IIA:  - Free guest shows no CD signal at guest base detection wavelength. 
     - Free host shows no CD at the detection wavelength. 
      - The bound guest (complex) shows a CD at the guest detection wavelength. 
 
Case IIA': - Free guest shows no CD signal at guest based detection wavelength. 
      - Free host shows a CD signal at the detection wavelength. 
  - The bound guest (complex) shows a CD signal at the guest based detection  
   wavelength. 
 
Case IIB:  - Free guest shows a CD at the guest based detection wavelength. 
 - Free host shows no CD signal at the detection wavelength. 
- The bound guest (complex) shows a CD signal at the guest based detection    
  wavelength. 
 
Case IIC:  - Free guest shows a CD at the guest based detection wavelength. 
 - Free host shows a CD signal at the detection wavelength. 
- The bound guest (complex) shows a CD signal at the guest based detection  






Adopting the same format by keeping the guest concentration fixed and varying the host 
concentration (protein), as the host is added the guest will see two possible binding sites 
that it can bind to (site 1 or 2). There will be an association constant associated with both 
sites, and if one site binds more strongly, then there will be four possible association 
constants, K1s, K1w, K2s and K2w. 
ε2. H G 2











Figure 2.12.  Schematic Representation of the Binding of a Ligand to Two possible Sites. 
 
Where K1s is the binding constant for the guest at the first binding site (1), with ‘s’ 
denoting the strong site. K1w is the binding of the guest to the second site (2) with site (1) 
being vacant, ‘w’ denoting the weak interaction. K2s represent the binding of the guest to 
the second site (2) with site (1) occupied. K2w is the binding of the first site (1) with site (2) 
filled (Figure 2.12). Three assumptions are made. The first is that there are two binding 




The last assumption is that there is independent binding at the two sites where K1s = K2s 
and K1w = K2w.  If we define the following quantities as: 
 
HT = the total concentration of the Host. 
GT = the total concentration of the Guest. 
Hf = the concentration of the free (unbound) Host. 
Gf = the concentration of the free (unbound) Guest. 
HG1s = the concentration of the first complex – binding constant K1s. 
HG1w = the concentration of the second complex – binding constant K1w. 
HG2w = the concentration of the third complex – binding constant K2w. 
HG2s = the concentration of the forth complex – binding constant K2s. 
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Binding is dependent upon two unknown concentrations, Hf and Gf that refers to the free 
Host and Guest concentrations respectively, and are given by the expressions: 
SwwsfT HGHGHGHGHH 2211 ++++=  
SwwsfT HGHGHGHGGG 2211 22 ++++=           (82) 
Substitution of the complex concentration as defined in equations (78) to (81) into equation 
(82) gives equation (83). 
Where, 
2 2
1 1 1 2 1 2. . . . . . . . . .T f s f f w f f s w f f w s f fH H K H G K H G K K H G K K H G= + + + +  
                 (83) 
2 2
1 1 1 2 1 2. . . . 2. . . . 2. . . .T f s f f w f f s w f f w s f fG G K H G K H G K K H G K K H G= + + + +   
 
And 
( )2 21 1 1 2 1 2. 1 . . . . . . 0f s f w f s w f w s f TH K G K G K K G K K G H+ + + + − =  
                 (84) 
       ( ) ( )2 1 2 1 2 1 1. 2 . 2. . . . 1 . . 0f s w f w s f f s f w f TG K K H K K H G K H K H G+ + + + + − =   
 
By defining additional functions where, 
   C1 = K1s . K2w  +  K1w . K2w               (85) 
  ( ) ( )2 1 1 12. .T T T s wC H H G C K K= − +            (86) 
  ( ) ( )3 1 1 . 1T s w T TC H K K H G= − +            (87) 
And, 
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From equation (84), the free Guest and Host concentration can be determined respectively. 








E H C H
G H E H
E H C
= − −             (92) 
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f T
s f T w f T s w f T w s f T
H
H H
K G H K G H K K G H K K G H
=
+ + + +
   (93) 
The induced CD signal (theoretical) that is derived from the bound guest is, 
1 1 2 2calc s w s wA A A A A∆ = ∆ + ∆ + ∆ + ∆           (94) 
where ∆A1s is the CD associated with the [1:1] complex of the guest bound to the strong 
site. ∆A1w is the CD associated with the [1:1] complex of the guest with the weak site. 
∆A2s is the CD of the [2:1] complex of the guest with the strong site, the weak site is filled, 
and ∆A2w  is the CD of the [2:1] complex of the guest with the weak site, the strong filled.  
Expression (94) can be rewritten to give, 
 
  1 1 1 1 2 2 2 2. . . .calc s s w w w w s sA HG HG HG HGε ε ε ε∆ = + + +         (95) 
 
Equation (84) can now be written to incorporate the expressions of equation (78) – (81) to 
give, 
2 2
1 1 1 1 2 2 1 2 2 1. . . . . . . . . . . .calc s s f f w w f f w s f f s w f fA K H G K H G K K H G K K H Gε ε ε ε∆ = + + +      (96) 
Where, 
ε1s = Molecular CD of the 1:1 Guest:Host complex formed to the strong site (strong 
binding constant). 
ε1w = Molecular CD of the 1:1 Guest:Host complex to the weaker sites (weaker 
binding constant). 
ε2 = Molecular CD of 2:1 Guest:Host complex with the binding of the Guest to 
both binding sites of the Host. 
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- Free guest shows no CD signal at the guest based detection wavelength. 
- Free host shows a CD signal at the detection wavelength. 
- The bound guest (complex) shows a CD signal at guest based detection 
wavelength. 
 
On binding of the Guest to the Host, an induced CD signal is observed at the detection 
wavelength and is defined as: 
   1 1 2 2 fcalc s w s w HA A A A A A∆ = ∆ + ∆ + ∆ + ∆ + ∆         (98) 
1sA∆  is the CD of the [1:1] complex of the guest binding to the strong host binding 
site. 
1wA∆  is the CD of the [1:1] complex of the guest binding to the weak site. 
2sA∆  is the CD of the [2:1] complex formed from the guest binding to the strong 
site, the weak site is occupied. 
2wA∆  is the CD of the [2:1] complex of the guest binding to the weak site, the 
strong site is occupied  
fH
A∆  the CD of the free host. 
Equation (98) can be rewritten in terms of the extinction coefficients and concentrations to 
give: 





1sε∆  is the molar CD of the first complex with the stronger binding constant at the 
guest based detection wavelength (has to be determined). 
 
1wε∆  is the molar CD of the second complex with the weaker binding constant at 
the guest based detection wavelength (has to be determined). 
2ε∆  is the molar CD of the third complex (both sites filled) at the guest detection  
      wavelength (has to be determined). 
 
Hε∆  is the molecular CD of the free Host (its value known). 
 
Now equation (95) becomes, 
 
  1 1 1 1 2 2 2 2. . . . .calc s S w w w w s S H fA HG HG HG HG Hε ε ε ε ε∆ = + + + +       (100) 
 
The determination of the free Host Hf is given by equation (93). The theoretical CD can be 
calculated from the substitution of the concentrations in expression (96) to give: 
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= +
+ − + +
 





S f T W f T s w f T w s f T
H
K G H K G H K K G H K K G H
ε
+ + + +
     
(101) 
Case IIB 
- Free guest shows a CD at the guest based detection wavelength. 
- Free host shows no CD signal at the detection wavelength. 
- The bound guest (complex) shows a CD signal at guest based detection 
wavelength. 
 
The calculated CD of the complex will give an expression of: 








A∆  is the CD of the free Guest at the Guest detection wavelength. Thus, the 
molecular CD ( )Gε  of the Guest only (its value known) will be given by the revised 
expression of equation (102) that becomes:  
1 1 1 1 2 2 2 2. . . . .calc s s w w s s w w G fA HG HG HG HG Gε ε ε ε ε∆ = + + + +               (103) 
Therefore, Gf will be determined by the expression derived in equation (92) that gave, 
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= − −            (92) 
The calculated CD will now be expressed as: 
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   (104) 
Case IIC: 
- Free guest shows a CD at the guest based detection wavelength. 
- Free host shows a CD signal at the detection wavelength 
- The bound guest (complex) shows a CD signal guest based detection  
wavelength. 
Considering the bound complex then the calculated CD will be given by: 
   1 1 2 2 f fcalc s w s w G HA A A A A A A∆ = ∆ + ∆ + ∆ + ∆ + ∆ + ∆       (105) 
where 
fG
A∆  is the CD of the free Guest detected at the Guest based detection wavelength. 
fH
A∆  is the CD detected for the free Host. If Gε∆  and Hε∆  are the molecular CD’s of the 
free Guest only and the Host only respectively and are both known, then the calculated CD 
now becomes: 





The free Host and Guest concentrations can be derived from equations (93) & (92) 
respectively.  
 
2.6.ii.(b)  Cooperativity of Binding Sites 
 
Positive and negative cooperativity can exist, the former bringing about an enhancement in 
the observed binding and the latter leading to an decrease. A Host with 'y' binding sites, all 
exhibiting independent binding activity will, on interaction with the Guest, bind 'x' 
molecules to give a binding constant K1x where : 
 K1x = K . (Number of empty sites on HG(x-1) / (Number of occupied sites on HGx)  
   1x
( 1) 1
K . .K K
y x y x
x x
− − − +
= =         (107) 
where K  is the binding constant at each site. Therefore at the (x+1)th site : 





y x y x
x x
− + − −
= =
+ +
        (108) 
Taking the ratio of equation (107) to (108) gives : 
   1( 1)
1
( 1) .




K x y x
+ −=
+ − +
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greater than the calculated value of 
( ) .





.  Negative cooperativity is the 
reverse situation of positive cooperativity in that the ratio is less than the calculated value. 
In the situation of non-cooperativity both the ratio and the calculated value are the same. 
 
When two binding sites are present, with one site binding strongly and the other weakly, 
then according to equations (78) and (79) the overall binding constant in the first instance 




   11 1 1s wK K K= +            (110) 
with   1 1s wHG HG HG= +            (111) 
The binding constants associated with the second site as expressed in equations (80) and 
(81) will now give an overall expression of: 
   2 2 2s wHG HG HG= +           (112) 
Substituting equations (73) and (74) in equation (112) gives : 
   22 2 1 2 1( . . ) . .w s s w f fHG K K K K H G= +         (113) 
Also the substitution of equations (64) and (65) in equation (91) will give: 
   1 1( ) . .s w f fHG K K H G= +           (114) 
Using equations (93) and (94) binding at the second site can be represented as: 
   2 1 2 112
1 1
. .w s s w
s w
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Therefore, cooperativity can now be defined as: 
   
( )
2 1 2 112
2
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. .w s s w
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         (116) 
All binding constants can be obtained from fitting routines. 
 
2.6.ii.(c)  Competitive Binding of Two different Guest to a Single Host Site 
 
When two different types of guest molecules exist in solution (Guest A and Guest B) with 
a host containing one binding site for both guests, there will exist competition at that 
binding site. The degree of binding for each guest molecule will be dependent upon the 
binding constants of each, the guest molecule with the highest binding constant will bind in 
preference to the other molecule so will form the largest amount of complex. However, 
there will exist a dynamic equilibrium between all the molecules in proportion to their 





   f fA fB A BH G G HG HG→+ + +←         (117) 
Where Hf is the concentration of the free host,  GfA is the concentration of the free guest A,  
GfB is the concentration of the free guest B, HGA is the concentration of the complex 
between the host and guest A and HGB is the concentration of the complex between the 
host and guest B. In terms of the total host concentration HT : 
  HT  =  Hf  +  HGA  +  HGB           (118) 
And  TA fA AG G HG= +             (119) 
  TB fB BG G HG= +             (120) 
Where GTA and GTB are the total concentrations of guest A and B respectively.  The 
binding constant (KA and KB) for each complex will be: 








=            (121) 








=            (122) 
In this equilibrium there will be five unknowns: Hf, GfA, GfB, KA and KB.  If the 
concentrations of both guest molecules are kept constant with a varying concentration of 
total host, then the concentration of total guest A, total guest B and the total host 
concentrations can be determined experimentally. For both species the amount of free 
guest will be: 
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The resulting mixture will contain five species all contributing to the final CD signal at the 
detection wavelength, these are the free Guests, free Host, and that due to the bound 
complexes formed from the two ligands. The observed CD will be given by: 
   
A B fA fB fcalc HG HG G G H
A A A A A A∆ = ∆ + ∆ + ∆ + ∆ + ∆       (127) 
Therefore: 
( ) ( ) ( ) ( ) ( ) ( ). . . . .
A B A A B Bcalc T HG A T HG B T G f T G f T H f T
A H HG H HG H G H G H H Hε ε ε ε ε∆ =∆ + ∆ +∆ +∆ +∆
                           (128) 









































CHAPTER 3:  Spectroscopy 
3.1.  Introduction 
In the wave theory, light is considered as an oscillating electric field.  Associated with any 





Figure 3.0 : Electromagnetic radiation. 
 electric field, - - - - magnetic field 
 
Oscillating electric and magnetic fields are consequences of each other.  As interactions are 
with molecules usually involving charged particles (eg electrons), only the electric field is 
explicitly considered.  The electric field is illustrated in Figure 3 2. along with the 5 main 





1. Wavelength                   Energy, (E=hc/λ) 
2. Intensity                  Extinction coefficient, 
     (A=ε.c.l) 
3. Velocity    Refractive index,  
    (n=c/ν) 
4. Polarisation    Circular, elliptical, 
    linear 
5. Propagation direction               Light scattering, 
    reflection, emission 
Figure 3.1 : The oscillating electric field of light and its properties. 
 
3.1.i. The wavelength and energy of light 




= =                          (1) 
where E represents the energy, h is Planck's constant, ν is the frequency of the absorbed  
Chapter 3 107
radiation, c is the velocity and λ is the wavelength of light . Equation (1) indicates that the 
shorter wavelengths give rise to higher energy and vice versa, longer wavelengths possess 
less energy.  This thesis is concerned with UV light (180-400nm) and visible light (400-
750nm), which has enough energy to excite electrons albeit at the same time associated 
vibration and rotational motions are also excited, to give a spectroscopic features width. 
Nevertheless, only loosely held electrons are excited in this wavelength range.  Such 
electrons are found in localised regions of a molecule called the chromophore. 
 
3.1.ii.  The absorption of light 
 




The relationship between the incident beam Io and the transmitted beam It is defined as the 
absorbance,  








               (2) 
 
Beer’s law relates absorbance to concentration and pathlength in an expression shown as, 
 
    A = ε. c. l               (3) 
 
where, c is the concentration in moles/litre and l is the pathlength in centimetres. The 
extinction coefficient “ε” is effectively a proportionality constant that quantifies how 
strongly a particular transition will absorb light. The larger the value of ε the greater will 
be the probability of absorption. Even if light of the right wavelength (energy) is available 
it may or may not be strongly absorbed if ε is not of the right order of magnitude (Drake, 
1994). Table 3.1 gives values for the extinction coefficients. The conditions for absorption 
are quite specific in that, for an allowed absorption ε  has to be at least equal to or greater 
than 10,000 and the electric dipole moments must be greater than zero, since
2
D µ= , where 
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D represents the dipole strength and is the area under an absorption curve. When the value 
of 0µ = , then ε  is very small, of the order of 100, and the transition will be forbidden. It is 
important to note that it is the electric dipole moment that will determine the value of the 
extinction coefficient that will in turn indicates whether absorptions are forbidden or 
allowed (Dr. A. F. Drake, unpublished). 
 
Extinction Coefficient 'ε' Absorption 'A' 
<10 Very weak absorption 
100 - 1000 Weak absorption (Forbidden) 
≈10,000 Strong absorption (Allowed) 
≈50,000 Very strong absorption (Allowed) 
Table 3.1.  Conditions in ε for absorption. 
 
3.2.  Characteristic Electronic transitions in Organic Molecules 
 
As light is absorbed, a charge displacement ensues that produces a transition electric dipole 
moment “ µ ”. If a molecule contains a single C=C double bond then the resulting 
electronic charge displacement will produce a π-π* transition at ~200 nm. If more than one 
double bond exists within the molecule as in the case of conjugated organic molecules, 
conjugation will lead to electron delocalisation and the electronic transition will be shifted 
to lower energy (longer wavelengths).  In molecules that contain less than a conjugation of 
8 double bond, the solutions appear colourless to the human eye as absorption takes place 
in the UV region.  Successive addition of a double bond after 8 produces a shift in the 
absorption wavelength, appearing yellow at first and changing through to red as the 
conjugation increases. 
 
Organic molecules containing isolated double bonds produce π - π* transitions, absorbing 
at wavelengths between 180 - 195nm. Cyclic organic compounds such as benzene, purine 
etc. have delocalized π-electrons that can be excited more easily to the π* state. This is also 
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true for linear polyenes such as carotene which absorbs in the visible region of the 
spectrum. The carbonyl groups (C=O) gives an n - π* transition at approximately 300nm 
(Figure 3.2.), shifted to approximately 210nm in esters and carboxylic acids (Drake, 1994). 
Amides produce an n - π* transition around 200nm and a π - π* transition at 190nm. The 
presence of transition metals ensures that there are electrons in d-orbital available for 




 Figure 3.2.  The electric dipole moment transitions. 
(Dr. A. F. Drake (unpublished presentation)) 
 
3.3.  Optical Activity and the Generation of Circularly Polarised Light 
 
Optical activity can be defined as the differential interaction of left and right handed 
circularly polarised light with a chiral molecule.  Optical Rotation is the differential 
velocity (refractive index) whereas Circular Dichroism (CD) is the differential absorption 





 270nm               205nm              195nm               218nm




 n − π∗
195nm
 π − π∗
210nm






















3.3.i.  Optical Rotation 
 
Linearly polarised light can be considered to be the resultant of two circular components 
(one left handed and the other right handed circularly polarised). (Figure 3.3.).  
 
Figure 3.3. : The rotation of the plane of linearly polarised light. 
(Slide courtesy of Dr Alex F Drake) 
 
When linearly polarised light passes through an optically active medium, the two circular 
components travel with different speeds (refractive indices); the result is a rotation of the 
plane of the incident linearly polarised light (Drake, unpublished,).  If the right circular 
component (RCPL) travels faster then the left circular component (LCPL), the result is a 
clockwise rotation of the plane of linear polarisation. The reverse is true if LCPL travels 
faster giving an anticlockwise rotation of the plane of linear polarisation. 
 
The observed rotation (αobs) of the plane of the linearly polarised light is called optical 
rotation and is given by the expression: 
Chapter 3 111






 = − 
 
             (4) 
l is the pathlength, λ is the wavelength, nL and nR represents the refractive indices for left 
and right circularly polarised light .  The specific rotation [α] is now defined to take into 
consideration the concentration (c) in g/dl of the sample and the pathlength (l) of the cell in 
decimetres, therefore: 
     [ ] ,100 /obs c lλλα α= ⋅ ⋅              (5) 
The molecular rotation (Φλ) takes into consideration the molecular weight of the sample 
(MW) where, 
     [ ] . /100MWλ λαΦ =              (6) 
In a region of absorption, the two circular components will travel with differential speeds 
and be absorbed to different extents.  The emergent beam is now becomes elliptically 
polarised.  The angle and orientation of the major axis of the elliptical light beam indicates 
the sign and magnitude of the optical rotation.  The ellipticity ( major axis intensity/minor 
axis intensity) is a measure of circular dichroism. 
 
3.3.ii.  Circular Dichroism (CD) 
 
CD is the differential absorption ( A∆ ) of left and right circularly polarised light, which is 
defined with reference to the Beer-Lamber law as :  
   ( ) ( )L R L RA A A c l c lε ε ε∆ = − = − ⋅ ⋅ = ∆ ⋅ ⋅             (7) 
 
The values of A∆ is very small with an order of magnitude between 0.00001 – 0.01.  In the 
early days before 1960, ∆A was too small to be measured directly.  Instead CD was 
measured as the ellipticity (“θ”) induced in an incident linearly polarised light beam.  The 
ellipticity unit unfortunately still remains historically; however, it is possible to 
interconvert molar ellipticity and molar circular dichroism with the relationship: 
 θ=32982 ∆A             (8) 
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The Molar Ellipticity [Θ], measured in degrees cm2 dmol-1, is defined as: 
 [ ] 3298.2 εΘ = ∆              (9) 
This relationship shown at equation (9) originates from the derivation of the ellipticity of 
polarisation that takes into consideration the tangential angle of the electric field vectors of 
the left and right circular polarised light, shown in equation (10) and represented 
diagrammatically in Figure 3.3.b., 








           (10) 




 Figure 3.3.b. The formation of elliptical 
polarised light (violet) constituted from the 
unequal distribution of right (blue) and left (red) 
circular polarised light. 
(http://en.wikipedia.org/wiki/Circular_dichroism) 
 
When ER = EL, then 0θ = and the resulting light is linearly polarised. If either of the 
components of ER or EL is equal to zero, then this means that there is complete absorption 
of light of one of the components in one direction, thus, 45θ = °and the light is circularly 
polarised. CD can only be measured in the region of the absorption, i.e. ∆A and ∆ε; optical 
rotation (α), that is nL – nR, can be detected throughout the entire electromagnetic 
spectrum.  A CD spectrum contains relatively few individual components; ORD at a given 
wavelength is the resultant of contributions from all transitions in the molecule, assignment 
and explanation of spectral bands becomes far more complicated.  CD is now the preferred 
analytical technique used to study chirality and molecular conformation (Dr A. F. Drake, 
unpublished). 
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3.4.  Circular Dichroism and Chromophore Classes 
 
If a chiral molecule preferentially interacts with left CPL, then L RA A>  and the resulting 
CD will be positive; preferential absorption of right CPL gives R LA A>  and the resultant 
CD will be negative.  If a sample exhibits optical activity a helical displacement of charge 
will ensue resulting in the rotational strength “R” that is defined as the area under the CD 
band.  For any electronic transition, the rotational strength (R) is defined by the area under 
the CD band as : 
{ }Im .R mµ=             (11) 
 
where µ and m are the collinear transition electric and magnetic dipole moments of the 
spectroscopic transition.  The Im (imaginary) part is taken as angular moment (magnetic 
moment) is imaginary in quantum mechanics. The ensuing helical displacement of charge 
(being either clockwise or anticlockwise) will be dependent on mutual orientations of µ 
and m (Figure 3.4.). 
 
 
Figure 3.4.  Helical charge displacement during an electronic transition. 
(A. F. Drake, 2001) 
Right handed charge displacement 
anti-parallel colinear moments
interacts preferentially with
left circularly polarised light
AL>AR     positive CD
Left handed charge displacement 
anti-parallel colinear moments
interacts preferentially with
right circularly polarised light
AL<AR     negative CD
µ
m
Right circularly polarised light
µ
m
Left circularly polarised light
The interaction of circularly polarised light with a helical charge displacement
The emphasised electric vectors of the light beam correlate with the appropriate helical motion.
The propagation direction of the light beam with respect to the chromophore is the same as the ordinary absorption
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Only if the chromophore itself is chiral do electronic transitions have collinear electric and 
magnetic transition dipole moments.  To explain circular dichroism, chiral molecules are 
divided into four classes : inherently dissymmetric, coupled oscillators (exciton coupling), 



















































































































Figure 3.5.  Classes of chromophores. 
(A. F. Drake, 2001) 
 
3.4.i.  Class 1: Inherently Dissymmetric 
 
In this situation the chromophore itself is chiral, and therefore will produce transitions that 
will posses an electric dipole moment together with a collinear magnetic dipole moment.  
 
3.4.ii.  Class 2: Coupled Oscillator (Exciton Coupling) 
 
When two or more non-conjugative chromophore are present within the molecule in close  
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proximity the resultant effect is more complicated, in that not only the individual 
chromophores have to be considered, but their effect with respect to each other. The 
induced effect of the chromophores interaction is called exciton coupling. Both CD and 
UV can measure multiple chromophores yielding meaningful stereochemical information 
about the exciton coupling and alignment (Dr A. F. Drake, unpublished). The transition 
electric dipole of one chromophore can interact with transition electric dipoles in other 
chromophores. Exciton splitting results from the chromophore interaction with maximum 
effects seen when the excitation energies are similar. The CD bands are opposite in sign for 
exciton splitting and are often seen under a broad featureless single absorption band. 
(Lightner et al, 2000). 
 
The generation of both UV and CD exciton spectra are as a result of the intrinsic electronic 
spectral properties of the chromophore together with their relative distance in relation to 
each other, and their orientation. The ensuing electronic transition of the chromophore is a 
result of induced electronic dipole-dipole coupling, where for two chromophores 
represented by either “X” and “Y”, either X=Y as in the case of identical chromophores,  
or X ≠ Y for non-identical chromophores. Only one of the chromophores needs to be 
explicitly excited. The electronic dipole transition of the excited chromophore will interact 
with the second chromophore resulting in the delocalisation of the excitation (also referred 
to as the exciton), distributing that excitation over the two (or more) chromophores 
producing exciton splitting (Lightner et al, 2000). This is an important class of which 
proteins and DNA are members. 
 
Exciton splitting produces distinct absorption bands in the UV spectrum, a single broad 
UV band is observed for allowed excitation transitions. The UV absorption from the 
exciton splitting will produce a corresponding CD spectrum that corresponds to the 
orientations of the dipoles, showing characteristic positive and negative cotton effects. The 
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greatest CD and UV changes are seen when the excitation energies are similar. There are 
three extreme orientations of the chromophores as shown in Figure 3.6. depicting the 
alignment of the dipoles, these are as follows, in-line, oblique and parallel. The possible 
orientations will have defined spectral optical splits in the UV that may or may not 
generate CD spectra. For dipoles in-line, a red shift is produced in the UV, this is due to the 
fact that only lower energy excitations will be allowed. For stacked chromophores, these 
give a blue shift in the UV band due to the fact that only higher energy excitons will be 
allowed. Both are limiting cases as no CD will be found as there is no chirality associated 
with their alignment. In the case of oblique alignments, both the higher and lower exciton 
transitions are allowed. The resultant UV will be the summation of the contributors, and 
may be seen as split or un-split which will be governed by the level of energy. The CD will 
be generated as a result of overlapping positive and negative Cotton effects (Lightner et al, 
2000). 
 
Figure 3.6. Orientation differences in exciton coupling of two chromophore. 
(Lightner et al, 2000) 
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The condition where exciton coupling is in the oblique position will only generate CD 
spectra. Within the oblique position there are two possible exciton orientations that are 
energy dependent. Configuration I is where the electric transition dipole moments are 
aligned in a head to tail arrangement (↑↓). In this configuration a right handed helical 
displacement of charge results at low energy that will give rise to positive CD spectra at 
longer wavelength (Figure 3.7.). Conversely, configuration II results from the electric 
transition dipole moment aligned in a head to head arrangement. Here there is a left handed 















Figure 3.7.  Exciton coupling of bichromophores in the oblique position. 




3.4.iii. Class 3: Symmetric Isolated Chromophore in a Dissymmetric Environment 
 
This situation relates to a transitions in a chromophore that inherently have either one of 
the transition moments, or neither of them. CD spectra will only be generated if the 
chromophore is located in a dissymmetric environment. A ketones is an example of a 
chromophore in this category that produces an n-π* transition, this will produce a transition 
magnetic dipole moment but will not produce the collinear electric dipole moment or visa 
versa. ε is very small.  Induced CD certainly falls into this class. 
 
3.4.iv.  Class 4: Vibronic Effects 
 
This effect occurs when the chromophore becomes distorted due to non-symmetric 
vibrational components. Dimethylallene is an example of this class of chromophore where 
the CD will be the result of the chiral distortion of the allene chromophore (Dr. A. F. 
Drake, 2001).  
 
3.5.  The Application of Circular Dichroism Spectroscopy (CD) 
 
CD spectroscopy is a specialised form of UV spectroscopy in that a differential absorption 
occurs, but instead of plane polarised light being used as in UV spectroscopy, the 
differential absorption of circular polarised light is determined. When both forms of 
circular polarised light interacts with an optically active sample, for absorption to take 
place there will need to be a helical charge displacement of the ground state electrons of 
the chromosphere to the energetically allowed excite state, the interaction being the result 
of either LCPL or RCPL. The resulting electronic displacement in the chromophore is 
either left handed or right handed and is as a result of both a translational and rotational 
motion, clockwise or anticlockwise. CD spectroscopy is very intuitive in being able to 
detect and monitor conformational changes in macromolecules such as peptides and 
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proteins, monitoring any environmental changes experienced by chiral or induced chirality 
in molecules. Being able to use CD in such a diverse manner utilises its inherent 
characteristics that has seen the use of CD spectroscopy expand at such a rate in the last 50 
years, that now CD has become mainstream with most institutions having access to an 
instrument. 
 
The secondary structure of proteins and peptides can be analysed by CD spectroscopy. 
This technique requires small quantities of sample, a big advantage over other techniques 
that require a lot more sample than may be available, or may prove too expensive to 
produce. Quantities of between 0.3 - 0.5mg/ml are required to produce an adequate sample 
yielding meaningful CD data. CD spectroscopy is relatively fast with high sensitivity. It 
can be used to study and monitor many structural changes within the protein, changes such 
as denaturation studies, binding and displacement studies, solvent changes, the effect of 
changing pH, temperature effects both high and low and kinetic studies are but a few 
examples. CD is a good tool for classifying and characterising proteins and peptides before 
more detailed work is carried out such as x-ray crystallography and NMR studies.  The CD 
spectrometer monitors the changing absorption of chiral molecules such as proteins with 
changing wavelength. When considering large proteins, using CD spectroscopy for the 
initial investigation can be a significant tool in identifying secondary structure that is 
relatively quick, a clear advantage over more conventional methods. Several structural 
conformations have been identified by CD that give a characteristic profile, these are the α-
helix, β-sheet, β-turn, left handed helix (PII) and the irregular structure (Figure 3.8), these 








Figure 3.8.  Structural contributions of secondary structure 
components of proteins by CD. (Drake et al, 1994) 
 
CD has the ability to asses the folded state of proteins (containing 40 residues or more), or 
peptide (containing 39 residues or less), and has the ability to investigate and monitor 
multi-domain proteins and its various unfolded intermediates. A critical number of residues 
have been determined to produce the functionality of a domain and this has been 
determined to be between 40 – 50 residues. Domains in themselves can be considered as 
structured folded “self-stabilising” entities in that although they form an integral part of the 
protein, they themselves are units that possess both defined secondary and tertiary 
structures specific for a particular function. Within the domain regions are unstructured 
sequences that will exists creating loops of varying length, this allows specific regions of 
structure within the domain to be brought together allowing the generation of ordered 
regions, thus creating binding pockets, tunnels or sites that create the active site of the 
protein. Several domains can exist within a protein that may be structurally similar; 
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however, the primary structure of the domains may be different. CD has the capability to 
detect and monitor such regions within the peptide/protein.  
 
3.5.i.  Secondary Structure Conformation of the α-Helix 
 
One of the most commonly found structures in proteins and peptides is the α-helix. The 
CD of the α-helix is derived from two main transitions, the n-π* and π-π* transitions that 
are associated with the amide backbone (Figure 3.9.). There is a negative CD peak at 
220nm produced from the n-π* transition of the protein. A second negative peak is located 
at 208nm and a third maximum, a positive found at 192nm, the latter two peaks are the 
result of interacting π-π* neighbouring transitions. Since the structure of proteins and 
peptides are more complex involving more than one structural component, the effects of 
the other structures, if present, will dilute the overall contribution of the helix 
conformation. This principle is true for all the other structures.  
 
 
Figure 3.9.  CD spectrum of an α-helix showing the electronic contributions. 
(www.proteinchemist.com/cd/cdspec.html) 
 
Exciton coupling of π→π* transitions that lead to two contributions : 
i) a positive (π→π*) at 192nm perpendicular to the molecular helix 
ii) a negative (π→π*) at 209nm parallel to the molecular helix 
iii) a third contribution is a negative, red-shifted to 222nm. 
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3.5.ii.  Secondary Structure Conformation of the β-Pleated Sheets 
 
β- structure can be formed from both parallel and anti-parallel strands that can vary in both 
width and length in contrast to an α-helix that can only varies in length (Woody et al, 
1994). The profile of the CD spectra for the β-sheet is seen in Figure 3.10. The CD profile 
of the β-sheet is characterised by a negative maximum at 216nm produced from the n-π* 
transition, and a positive maximum of similar size found at 195nm formed from the π-π* 
transition. The variation in the CD spectra of the β-sheet varies readily with solvent and 
chain length. 
 
Figure 3.10.  CD spectrum of a β sheet showing the electronic contributions. 
(www.proteinchemist.com/cd/cdspec.html) 
 
Two contributions, a negative at 218nm (n→π*) & a positive at 196nm  (π →π*) 
 
3.5.iii.  Secondary Structure Conformation of the β-Turns 
 
The CD generated for this type of structure is weak with a negative peak around 225nm due 
to the n-π* transition, a strong positive maximum at 200nm due to the π-π* transition and a 
strong negative maximum found around 185nm. The spectrum of the β-turn is red shifted 
by between 5-10nm from that of the spectrum produced by the β- sheet (Figure 3.8.). 
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3.3.iv.  Secondary Structure Conformation of the Left –handed P2 Helix 
 
The left-handed P2 helix is a specific type of structure that is only found in peptides (not 
proteins) with limited chain length. The CD is characterised by a positive absorption 








A positive at 212nm (n→π*), RCPL, left handed charge displacement, AR>AL 
A negative at 195nm (π →π*), LCPL, right handed charge displacement, AL>AR 
 
3.5.v.  Secondary Structure Conformation of the Irregular Structure 
 
The CD of the irregular structure is characterised by a weak negative absorption located at 
around 220nm and a stronger negative peak located at around 200nm. Peptides and 
proteins that fall in this category are shown to possess none of the other structural 
components mentioned previously (Figure 3.8.). 
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.3.5.vi.  Aromatic Side Chains and Disulphides 
 
Proteins that contain an aromatic group (Trp, Tyr and Phe) show in both the UV and the 
CD spectra weak transitions, absorbing around 260nm (Tyr and Trp ~280nm) with an 1Lb 
band that is electronically electric dipole forbidden (Figure 3.12.).  Tyr absorption is 
detected at 280nm with two other additional vibronic bands detected at 285nm and 290nm.  
The high symmetry of the molecule results in a small extinction coefficient and also makes 
it the least responsive to environmental changes. Phe tend to be masked by stronger 
absorbing groups such as tyrosine (Tyr) and tryptophan (Trp). Absorptions are also seen at 
215nm and 180nm due to the 1La and B bands. 
 
Changing the pH of the Tyr environment to between pH9 and pH10 results in a red shift to 
295nm produced from the 1Lb band in the near UV CD band; Trp produces the most 
complex absorption and CD spectra in the near UV region (Figure 3.12.). Two distinct 
regions of detection are observed, the first lying between 250 - 300nm produced from the 
1Lb and 
1La bands, and although the absorption of the 
1Lb band is weak its fine structure is 
well developed thus easily distinguished from the other aromatics. The second absorption 
is detected at between 287 - 292nm, and although stronger in terms of energy produced 
from the 1La band, its fine structure is practically non-existent. The 
1La band is more 
sensitive to environmental changes. 
 
 
Figure 3.12.  The UV spectra of the aromatics (Phe, Tyr and Trp). 
Note: pH shown is the pH of the solutions containing the amino acid residues 
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There exist within the disulphide two n-σ* transitions in the near UV region of the 
spectrum, these are weak when measuring the UV, but the CD can be relatively strong. The 
dihedral angle in disulphides is very important as disulphides can be left handed or right 
handed, normally around ±90° and will give an absorption maximum between 250 - 
260nm. As the angle changes and moves away from the 90° position a split in the 
absorption is detected, one maximum moves to longer wavelength and the other moves 
towards the shorter wavelength region giving rise to a CD signal with opposing signs. The 
fine structure observed in the CD for Trp is now lacking in the disulphides, sometimes a 
tail is seen which extends past 300nm. 
 
3.5.vii.  Near UV CD Spectra and Extrinsic Chromophores 
 
The predominant features detected in this region are due to Phe, Try, Trp and disulphide 
contributions, these are relatively weak when compared to that detected for the secondary 
structure in the far UV CD region (wavelength ranging between 260 - 185nm). The 
working range of the near UV CD region is between 340 - 240nm, but it is possible to 
study a wider wavelength range working as far out as 700 - 340nm. This is important when 
studying ligand binding if a suitable chromophore is chosen such that its absorption falls 
within this working range. There are some molecules that although they possess a strong 
absorption are achiral and do not possess a CD signal, examples of these are dyes such as 
phenol red and bromocresol blue. However, when such ligands are added to a strongly 
chiral molecule such as proteins, an induced CD signal is obtained in the region of the 
absorbing ligand. An extrinsic chromophore is produced due to the presence of the chiral 
molecule (protein) that can now be measured and monitored. The sign and magnitude of 





3.5.viii.  The Ultra-violet / Visible Absorption Spectrometer 
 
Absorption spectrometers determine and measure the intensity of light at different 
wavelengths. There are four main components: 
i) Light of the appropriate wavelength can be generated using a tungsten - 
halogen lamp (350 - 1000nm), and a deuterium lamp is also used (200 - 
400nm). Nowadays, DC xenon (Xe) lamps are used in CD and pulse Xe 
lamps are now being used in UV/Vis. 
ii) A monochromator that selects the measurement wavelength situated 
between the lamp and the sample housing. 
iii) A sample compartment, where the sample is placed during measurements. 
iv) A light detector, in the form of a photomultiplier or silicon diode.  
 
Penetration into the UV, particularly towards and below 200nm is limited by three factors. 
The first is that there is interference by the absorption of oxygen in air that is very strong 
and causes major interference artefacts. Far UV light (<200nm) induces the conversion of 
O2 to ozone (O3) which is corrosive and will attack the components of the spectrometer, 
ozone absorbing at 254nm. Secondly, there is a problem of reduced transmittance of 
optical components below 200nm producing interference when measuring spectra, this 
effect can only be reduced at great expense (Donney et al, 1993). The last factor that has to 
be considered is the effects of solvent absorption that is particularly strong below 200nm, 
this effect cannot be eliminated but can be reduced if the appropriate solvent is selected, as 
some solvents are more transparent than others, or by a reduction in optical pathlength of 











3.5.ix.  Circular Dichroism Instrumentation  
 




Figure 3.13.  The JASCO J720 Spectrophotometer. 
( A. F. Drake, 2001) 
 
The light source in the form of a xenon lamp (this lamps covers the whole spectral region 
of the UV/Vis range) delivers a focused, stable high intensity beam to provide a constant 
output. The beam passes first through a monochromator that transforms it into 
monochromatic light and polarizes it linearly; this then enters the photoelastic modulator. 
The modulator (in the Jasco design) uses a Piezo device that works at a fixed frequency of 
50kHz and is designed to create sinusoidal waves. The modulator is responsible for 
creating the LCPL and RCPL by introducing a phase lag 'δ' coursed from the ''periodic 
variation in the polarization'' of the impinging light beam (Drake, 1994). The emergent 
beam passes through all ellipticities from left circular, elliptical, unchanged linear, 
elliptical through finally to right circular, all created at a fixed wavelength and constant 
intensity giving Io. If a chiral sample is now placed in the sample compartment and 
scanned through all ellipticities at each wavelength throughout the region where the sample 
is optically active, some of the ellipticities will be differentially absorbed creating a CD 
spectrum. Now, a change in intensity is detected that shows wavelength specificity and is 
represented by Ix. and is the intensity detected from the modulator at a specific wavelength 
that can be due to either absorption of left or right CPL. Therefore, 
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   ∆A = log(Io / Ix) = log(Io/IL) - log(Io/IR)                                                (12) 
then, 
 
   ∆A = (AL - AR) = (IR - IL) / (IR  IL) = VAC / VDC                               (13) 
 
 
VDC is the voltage detected when an absorbing optically inactive sample is put into the 
sample compartment; its output is constant but very small. Likewise is VAC that is 
detected as a result of the differential absorption of the optically active sample. Both VAC 
and VDC are amplified by the photomultiplier by the same amount, such that the 
difference between them is conserved and is proportional to ∆A over the entire wavelength 
region measured and for all conditions. VDC is a measure of the light intensity and is also 
a measure of the ordinary absorption (Drake, 1994) measured on a separate output channel 







































CHAPTER 4: Spectroscopic Characterisation of Human Serum Albumin 
 
4.1.  Introduction 
 
The size of albumin has made its study by NMR difficult, and has enabled only the 
assignment of <100 residues out of 585. Crystallographic studies have also been 
problematic. It has been relatively easy to produce crystals of HSA, but the quality has 
been poor, yielding little to no high resolution diffraction patterns until fairly recently. 
Only a few scientists have been able to achieve meaningful data by x-ray, the earliest 
group to produce outstanding results was Carter and co-workers (Carter et al, 1990). More 
recently there has been a plethora of information resulting from crystallographic studies 
most notably from Curry and co-workers (Curry et al, 1998 & 2006) who have shown the 
importance of fatty acids in the crystal formation of albumin and the effect it has on the 
binding ability and activity of the molecule. Others including Muravskya and co-workers, 
Chuang and co-workers and Sugio and co-workers are but an important few that have 
contributed greatly to this field (Muravskya et al, 2004;  Chuang et al, 2006;  Sugio et al, 
1999). 
 
Using CD spectroscopy, different samples of albumin have been characterised by 
observing spectroscopic changes in two regions, the near UV region (340 - 240nm) and the 
far UV region (260 - 185nm). Each region is indicative of specific changes that may occur 
within the protein; the near UV characterises changes that occur within the environment of 
the aromatic residues and disulphides, and the far UV region represents changes that occur 
in the secondary structure or the backbone region of the protein. Recombinant human 
serum albumin (rHSA) was the preferred protein used throughout most of this thesis. 
However, in order to ensure that changes observed were not as a result of the methods 
employed in obtaining the protein, the characterisation of rHSA was compared with 
several types of albumin including native and defatted albumin (nHSA & dHSA 
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respectively) for structural integrity and binding abilities. Wherever possible, all three 
types of protein were investigated and compared. Some experiments were also conducted 
on the glycosylated form of nHSA referred to as L27 HSA (only a small amount of this 
sample was available so experimentation was restricted). Two fractions of albumin 
corresponding to domain I and domain I+II, were also investigated and characterised. All 
six samples were investigated for pH and temperature changes. 
 
Secondary structure analysis for all the samples of albumin were made and used to 
investigate structural changes in the presence of chemical and structural perturbations. All 
secondary structure predictions were calculated using the protocol formulated by K. M. 
Malik (Malik, Thesis, 1997). Principal component regression (PCR) was the algorithm 
used, the form of the CD spectra of proteins under analysis being similar to that of the CD 







Routines as discribed by K. M. Malik
(Thesis 1997)
 
Figure 4.0.  Schematic representation of principal component regression 
 
 
4.2 Experimental Procedures  
4.2.i.  Procedures for pH Investigation 
 
pH studies were conducted in the presence and absence of a buffer, the buffer of choice 
was Britton Robinson buffer (B/R) chosen for its buffering range of pH2 to pH12. When 
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freshly prepared B/R attains approximately a pH2; albumin was dissolved at pH2 and the 
titration conducted measuring the UV and CD spectra at regular pH increments. In the 
absence of a buffer, albumin samples were dissolved in distilled water and divided into two 
equal portions. One of the samples was used to investigate increasing pH using 0.1M and 
1M sodium hydroxide as the pH adjusting solutions, and the other sample was investigated 
for low pH adjustments made with 0.1M and 1M hydrochloric acid. The volumes of both 
acid and alkali required to adjust the pH were minute in comparison to the total sample 
volume of albumin used to conduct the experiment, the adjustments were made using a 
calibrated 10µl or 20µl Gilson pipette. Therefore the dilution factor was considered to be 
minimal if not negligible.  
 
4.2.ii.  pH Titration Data Fitting 
 
When conducting a pH titration the data can be fitted using the Mathcad 8 Professional 
computer programme adapted by Dr A. Drake (unpublished) for an equilibrium equation 
where : 
[B]  +  [H+]  =  [BH]+              (a) 
Then, 
[ ]






=               (b) 
Also, 
obs B BHA A A∆ = ∆ + ∆               (c) 
where obsA∆  represents the observed changes in absorbance, BA∆  is the changes in 
absorbance associated with the base and BHA∆ . Combining equation (b) with equation (c) 
will give the CD expression given by the expression:  
( ) ( )
















            (d) 
where ( )obs pHε∆  is the theoretical CD value observed at a given pH, Bε∆  is the molar 
CD at the base limit and BHε∆  is the molar CD at the acid limit. This equation can be  
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extended to incorporate more than one Ka. 
 
4.2.iii.  Procedures for Temperature Analysis 
 
Temperature studies were conducted by a variety of methods. The simplest temperature 
investigation was conducted with the sample being heated by increasing increments from 
room temperature to 95oC in the spectrometer, heated by a brass cell holder block 
connected to a thermostatically controlled water bath. The CD was measured in both 
wavelength regions (340 – 240nm & 260 – 185nm) at regular temperature intervals with 
the heated sample being allowed to equilibrate at the desired temperature before measuring 
both the CD and the sample’s true temperature that was measured via a thermocouple in 
direct contact with the sample solution in the cell. The second method of temperature 
investigation involved sequential heating, then quenching the albumin sample back to 
room temperature. Albumin was heated to a predetermined temperature in the 
spectrometer, allowed to equilibrate and then scanned in both regions recording the 
temperature of the sample at the time of scanning. The sample was then allowed to cool to 
room temperature where the two regions were scanned again. The heated sample was then 
further heated to a higher predetermined temperature and the process of scanning, cooling 
and re-scanning repeated until the sample had been heated to the highest temperature 
setting.  
 
The third method of temperature analysis was to investigate the effects of temperature 
using incubated samples of HSA that were pre-heated in the absence of a ligand but in the 
presence of a buffer. A large sample volume of albumin of known concentration was 
heated in a water bath to a predetermined temperature, at equilibrium an aliquot of the 
heated sample was removed and cooled to room temperature (RT), the rest of the albumin 
solution remained in the water bath. The temperature of the bath was then increased and 
the sample was allowed to equilibrate at the higher temperature before removing and 
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cooling a further aliquot. This process was repeated for temperature ranging from RT to 
95oC with the exact temperature of the sample removed recorded. Each heated sample 
removed was cooled down to RT before measuring both the UV and CD spectroscopy. All 
the measured samples were compared for possible structural changes and differences. 
 
The final method of temperature analysis was to investigate the effects of temperature by 
CD at fixed wavelength, monitoring the unfolding of the protein as a direct response to 
heating. The spectrometer was adjusted to monitor at fixed wavelength with respect to 
time. This process was conducted in two ways. The first method was to allow the 
spectrometer to start recording at fixed wavelength at RT; a stopwatch was then started 
simultaneously with the start of the scan. The circulating water bath was adjusted to its 
maximum temperature (97°C) and using the thermocouple placed in direct contact with the 
sample in the cell, the temperature of the sample was recorded at regular temperature 
increments, whilst recording the time when the temperature was measured. The unfolding 
of the protein would typically take approximately 40 minutes from start to completion. 
This method was quite rapid and once the protein started to unfold, there was no way of 
stopping or allowing the sample to equilibrate at the temperature before measuring.  
 
To compensate for such rapid and unpredictable unfolding, the method for this type of 
heating cycle was modified by adjusting the heating rate by discrete manual incremental 
adjustments to the water bath to allow for a more controlled heating rate. Although this 
meant that the running time for scanning had considerably increased (approximately 3 
hours), this method allowed for more discrete temperature increases, a more controlled 
heating rate that allowed for a period of time for the sample to equilibrate before recording 
both the time and temperature at which the scan was taken. By this method the 
spectrometer was set to monitor at a fixed wavelength but using a longer time period for 
scanning. The spectrometer was started simultaneously with the stopwatch with the water 
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bath set to RT. The water bath was then manually adjusted to 50°C (the temperature below 
the point at which HSA showed any signs of denaturation), allowed to equilibrate, and both 
the time and temperature recorded. The water bath was then increased by a predetermined 
amount and once again allowed to equilibrate before recording the time and temperature at 
equilibrium, in this way the temperature, with reference to time, could be used to 
determine the changes in CD. This process was repeated for temperatures up to 97°C. 
 
4.2.iv.  Calculations for Temperature Fit 
 
The experimental data obtained from the temperature studies was also fitted using the 
Mathcad 8 Professional programme adapted by Dr A. Drake (unpublished) adapted to fit 
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Integrating equation (1) and substituting for K gives: 
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Where T is the measured absolute temperature, Tm is the melting temperature or transition 
midpoint, ∆εobs(T) is the calibrated molar CD value at a given temperature; ∆ε1 is the 
molar CD observed for the lower temperature state and ∆εu is the molar CD observed for 
the upper temperature state. A theoretical curve is generated of ∆εobs(T) against T for given 
values of k and Tm. Similar to pH data fitting there is the provision to fit more than one 
transition, this is indicated in equation (3), 
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where subscript 1 and 2 denotes the first and second transitions. Independent melting  
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processes are assumed here. 
 
4.2.v.  Recombinant Human Serum Albumin Production (rHSA) 
 
Delta Biotechnology Ltd based in Nottingham has pioneered recombinant albumin 
production. In 1986 Delta, together with BASF, were able to express rHSA from cultured 
yeast on a large scale (Hinchcliffe et al., 1986 & Quirk et al., 1989). The drive towards 
recombinant products has been governed partly in responses to viral contamination, but 
also because of the worldwide demands on albumin with rHSA currently under clinical 
trials. Native human albumin is prepared by fractionation of plasma from blood donors and 
used as a therapeutic agent to restore and maintain blood volume. Albumin is also used as 
a stabilizing agent in vaccine formulations and as a medium for various imaging 
procedures such as X-rays. The production of human albumin each year is in the hundreds 
of tons but because of the possible potential of viral transmissions of diseases such as HIV 
and hepatitis, the drive to recombinant products is prevalent. The production of the 
recombinant product involves neither human nor animal-based raw materials. Therefore, 
the recombinant product is much safer, as the genetically engineered protein is expressed 
by yeast cells with virtually zero risk of viral contamination, high purity giving a product 
that is structurally equivalent to HSA (Schindel et al, 2003). 
 
cDNA from human liver cells are used to express the appropriate mRNA. The plasmid is 
transferred to yeast cells using standard molecular biological techniques. rHSA is secreted 
in the culture by the yeast in quantities of the order of 40 - 55mg/ml of mature albumin. 
With rHSA production by this method, 3% of the product is fragmented forming both 
known and unknown fragments. Small amounts of prepro and proalbumin have also been 
detected. The protein is then lyophilised and would normally contain between 3 - 5% 
water; this value could rise to as much as 15% if stored in a humid environment. The Food 
and Drug Administration (FDA) require caprylate and N - acetyl - DL tryptophanate to be 
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added as part of the pasteurisation process, around 0.08mM/g of each are required to attain 
the specifications laid down by the FDA. Experiments using rHSA were undertaken after 
all additives were removed. Additives have been shown to interfere with the binding of 
some ligands used in this project. 
 
4.2.vi.  Purification of Human Serum Albumin 
 
A prerequisite to the requirement of the purification of HSA is to preheat the protein to    
60°C for ten hours to destroy any possible viral contamination. Caprylate (a (MCFA) 
and/or N- acetyl - DL tryptophanate are added prior to the heat treatment to protect the 
protein, stabilizing it against any adverse heating effect. However, the amount of stabilizer 
present can sometimes affect the ability of the protein to bind some ligands (Peters, 1996). 
With this in mind, albumin was dialysed against water to remove small ligands including 
salts. All samples were dialysed, lyophilized and stored in the refrigerator until used. 
Dialysis only removed small ligands and proved ineffective against stabilizers where 
denaturation conditions were required. To remove MCFA and LCFA, the purification 
protocol using activated charcoal as described by Chen and co-workers was employed 
(Chen et al., 1967). Samples were dialysed and lyophilized and stored as described above. 
Albumin treated by charcoal is referred to as defatted albumin (dHSA). 
 
4.2.vii.  Materials 
 
All HSA samples with the exception of L27 HSA were supplied courtesy of Delta 
Biotechnology (Nottingham, UK). L27 HSA was supplied courtesy of a personal gift to  
Dr. A. F. Drake. Concentrations of the protein ranged between 0.3 to 0.6mg/ml were 
dissolved in either phosphate buffer (P/B) (supplied by BDH, UK), Britton Robinson 
buffer (B/R) (comprising of citric acid 21.01g/l, sodium citrate 29.41g/l and 
Chapter 4 137
diethanolamide 21.02g/l), also supplied by BDH, UK, analytical grade (B/R having a 
buffering range between pH2-pH12) or distilled water. 
 
4.2.viii.  Absorption Spectroscopy (UV) 
 
UV spectra for all samples were measured using an Aviv 17DS spectrophotometer or a 
Varian 2390 spectrophotometer with a spectral bandwidth of 0.2nm, scanning at a rate of 
60nm/min at intervals of 0.2nm. A 1cm pathlength cell was used in the wavelength region 
between 340nm to 240nm. For regions below 260nm either a 0.02 or an 0.05cm cell was 
used. All samples were measured at room temperature. Some of the binding experiments 
involved the filtering of small volumes of samples through micro-filters, this yielded 
volumes of 200µl or less. To cope with such small volumes specially designed cuvettes 
were used to allow the UV to be determined. Examples of such cuvettes are shown in 
Figure 4.1.a.  
 
To ensure continuity throughout measurements, the same cuvettes were used to measure 
both the UV and the CD for the sample in the specified region with the exception of the 
small volume samples that used the specifically designed cuvettes shown in Figure 4.1.a., 
specifically designed for the UV spectrometer only with a pathlength of 1cm. In addition to 
the use of a specially designed cuvette, the space in the cell was not entirely filled with the 
solution of the sample, the cell was masked and positioned in the spectrometer to ensure 
maximum throughput of light passed through the sample only. This ensured that the 
spectrometer light beam was targeted and concentrated through the sample only, so that the 













(a) (b) (c) 
Figure 4.1.  A selection of cells used to measure UV and CD spectra. 
 
(a) 1cm Micro cell with black walls and Teflon stopper used for small volumes (0.2ml). 
(b) 1cm Cylindrical cell used when the volume of the sample is not a restriction (2.8ml). 
(c) 0.05cm Cylindrical cell used when volume of sample is a limiting factor (0.28ml). 
 
 
4.2.ix.  Circular Dichroism Spectroscopy (CD) 
 
Two CD instruments were used to measure the spectra, either the JASCO J600 
spectropolarimeter or the JASCO J720 spectropolarimeter with conditions of slit 
bandwidth of 1-2nm, a scan speed of 10nm/min at a time constant of 4sec with the data 
acquisition every 0.2nm. All instruments were calibrated to ensure consistent and accurate 
results; this meant that the spectra from both instruments could be compared without fear 
of any erroneous or unspecified errors affecting the results. Three cells were used 
depending on the wavelength region investigated, between 340-240nm (near UV CD 
region) a 1cm cuvette was used. For the wavelength region of 240-185nm (far UV CD 
region) either a 0.02cm or a 0.05cm cuvette was used. The data was corrected for 
concentration and pathlength per mean residue to determine the extinction coefficient ∆ε 








4.3.  pH Characterisation of Albumin 
 
Albumin will inherently exhibit a pH of between pH 6.8 – pH7 when dissolved in water 
(concentration of 6.02 x 10-6M); a role utilised when buffering and maintaining the pH of 
the blood. Albumin is quite resistant to small changes in pH (Kragh-Hansen, 1990). The 
CD spectra of the different forms of albumin were first determined and compared for 
structural differences; the results are show in Figure 4.2. The magnitude and characteristics 
of nHSA, dHSA and rHSA were essentially the same. The presence of a small amounts of 
fatty acid or the effects of recombinant preparation did not affect neither the secondary nor 
the tertiary environment significantly, yielding spectra of similar magnitude and form in 




















































































Figure 4.2.  Spectroscopic characterisation of the different forms of HSA. 
 
A.  Far UV CD region in 10mM P/B, pH7.2, 0.05cm 
B.  Near UV CD region in 10mM P/B, pH7.2, 1cm cell 
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The CD spectra shows a protein rich in α-helix content (52% calculated by PCR) and a small amount of 
β-sheet (16%), the remainder (32%) was found to be irregular structure. Crystallographic studies found 
albumin to contain 67% helix, 23% extended chain and ~10% exists as turns. The values of the 
secondary structural components calculated by PCR were much lower for helical composition than that 
obtained by X-ray crystallographic studies even though both methods showed a rich helical content. As a 
first approximation and with the lack of meaningful crystallographic data PCR gives a good initial 
indication on structural analysis and a first approximation of the structural composition of the 
protein/peptide under investigation. In view of this PCR was used as a tool to investigate changes in 
structural forms rather than absolute values. The use of PCR will highlight trends and changes in 
structural composition when chemical and/or physical perturbations are applied. The near UV CD region 
reveals a protein whose aromatics are buried deep within the protein, shielded and protected from any 
environmental perturbations.  
 
The glycosylated sample L-27 HSA (6.02 x 10-6M) showed structural changes in both regions of the 
spectrum with the loss in both secondary structure and tertiary environment; the reductions were 
calculated to be a 5% reduction in α-helical content with an 8% reduction in β-sheet and an associated 
increase in irregular structure of 12.5% (Figure 4.2). Glycosylation occurring at the ∈-amino group of 
lysine 525 within albumin (Shaklai et al, 1984), and clearly the affects of the presence of a sugar 
molecule has a marked effect on the way in which the protein folds and the overall interaction of the 
three domains with respect to each other. It is clear that the presence of sugar will also have chemical 
implications on the glycosylated protein such as the way in which it might interact and bind to other 
molecules, drug interaction and perhaps the biochemistry of the whole molecule could be compromised. 
All these factors need careful consideration and are beyond the scope of this thesis due to the lack of 
glycosylated material. Some preliminary investigations were undertaken however, and this will give 
some indication of the effect glycosylation has on the characteristics of the protein. 
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One of the essential characteristics of albumin is that the structural changes experienced with changing 
pH are completely reversible. Figure 4.3. shows the results of the response of nHSA with changing pH. 
CD spectroscopy was sensitive enough to detect subtle changes in both the secondary and tertiary 
environment of the protein, with the greatest loss in structural content found at the extreme pH regions 
that were detected at pH 4.0 and below and above pH 10.0, relative stability was attained between the 
extremes conditions. Subtle changes were detected between pH 5 to pH 3 (Figure 4.3.c. & d.). A residual 
amount of structure always remained in the core of the protein showing that some of the core 
hydrophobic structures remained shielded from the surrounding solvent environment. Plotting at fixed 
wavelength revealed similar trends throughout the entire albumin series of samples studied. In the near 
UV CD region the aromatic contributions were exposed in the extreme pH regions, but remained 
sufficiently buried not to pose a significant problem for the integrity of the protein’s tertiary structure. 




























































































 Experimental Data nHSA 220nm
 Experimental Data nHSA 208nm
 T heoretical Mathcad Fit 220nm



















 Exper imental Data at 255nm
 Exper imental Data at 287nm
 Theoretic al Mathcad Fit 
 Theoretic al Mathcad Fit 
 
 
Figure 4.3.  pH titration of nHSA in water in both the far and near UV CD regions 
 
A.  Far UV CD spectra of the pH titration in H2O, 6.02x10
-6M, 0.05cm cell 
B.  Near UV CD spectra of the pH titration , 3.00x10-5M (2.0mg/ml), in H2O, 1cm cell 
C.  Fixed wavelength plot of the pH titration in the far UV CD region 




Interestingly, the fixed wavelength plot in that aromatic region at 255nm behaves similarly to the 
changes measured in the secondary structure region. Only the measurements detected at 287nm in the 
aromatic region showed the greatest susceptibility to changing pH, suggesting that throughout the entire 




Superimposing all three whole HSA samples reveals that all the albumin samples behaved in a very 
similar fashion in response to pH changes (Figure 4.5.). The subtle changes detected were not significant 
enough to show any real or measurable differences that would indicate any structural or preparation 
differences between the samples. 
 














































---- Theoretical Mathcad Fit

































---- Theoretical Mathcad Fit


















Figure 4.4.  Fixed wavelength plots of recombinant and defatted HSA – pH titration. 
 
Fixed wavelength plot of HSA in H2O, 6.02x10-6M, 0.05cm, far UV CD plot 

































Figure 4.5.  Superposition of the fixed wavelength plot of all the whole albumin samples. 
 




One of the first characteristic that was revealed by the pH titration was that when the data was fitted with 
Mathcad, three transitions were observed in the secondary structure region for wavelengths 208nm and 
220nm. However, in the tertiary wavelength region, depending on which wavelength was viewed, either 
two or three transitions were observed as shown in Table 4.0. The first transition for all the samples 
studied gave a pK in the region of 3.0, with nHSA and dHSA showing the greatest similarities. The 
second transition at wavelength 208nm showed the greatest diversity with dHSA showing the lowest 
value for pK. All the transitions at 220nm revealed close similarities.  
 
HSA Samples 
4.51 x 10-6 M 
pK at 208nm 
Backbone 
pK at 220nm 
Backbone  
pK at 255nm 
Aromatic  




1st 2nd 3rd 1st 2nd 3rd 1st 2nd 1st 2nd 3rd 
nHSA 2.6 5.9 10.5 2.7 5.9 11.6 4.2 11.6 4.2 6.3 10.7 
dHSA 2.7 4.6 10.9 3.0 5.7 10.7 3.6 11.6 3.0 6.5 11.1 
rHSA 3.0 6.2 11.4 3.0 5.9 11.0 4.0 11.5 3.5 6.1 11.7 
 




In the aromatic region of the spectrum only two transitions were observed at 255nm, but 
three transitions were detected at 287nm, this was reflective of the changing environment 
of the aromatic residues. It was clear that the two wavelength reflected different changes 
with the first transitions of each wavelength showing greatest diversity for all the HSA 
samples studied. Later on in this chapter pH studies of nHSA in the presence of small ions 
were conducted and compared with nHSA in the absence of ions. The changing 
environment in the presence of small ions on the protein will be compared and more fully 
studied.  
 
Briton Robinson buffer (B/R) is a universal buffer with a wide buffering capacity and was 
chosen to investigate changing pH for this very reason. When the pH titration was repeated 
in the presence of B/R buffer the results revealed a transition at neutral pH different from 
that obtained when the titration was conducted in water (Figure 4.6.). B/R buffer, when 
freshly prepared attains a low pH value (~2.5) and the samples were prepared at this pH 
and titrated to higher values within the working range of the buffer (pH2-12). Between the 
pH regions of pH4 - pH8 a dramatic decrease in elipicity was observed in all three samples 
to varying degrees as shown (Figure 4.6.). Since B/R buffer contains a cocktail of boric 
acid, acetic acid and o-phosphoric acid, it was evident that one or a combination of several 
of the constituents in the buffer interacted with the protein resulting in the secondary 
structural changes observed. The effect in rHSA with the buffer was not as pronounced as 
that seen in the other samples indicating a certain degree of resilience; this may be as a 
result of the way in which the recombinant protein was produced. The effects of fatty acids 
also helped to protect the protein in some manner, resulting in a less dramatic effect on the 
protein in response to changing pH environments. In this way, the presence of fatty acids 
showed to have a stabilising effect on the protein, supporting the fact that in nature 
albumin contains naturally occurring bound fatty acids may act in this way. The greatest 
effect was detected at 208nm, and although the similar effects were seen at 220nm they 
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were not as pronounced. Maybe by dissolving the protein at such a low pH produced some 
kind of pH shock that provoked the protein into behaving in this manner. It is clear from 
the previous pH studies that there is a transition that occurs between pH6 and pH7, it is 
during this range that further interactions with ions take place. In any event, what was 
certain was that this buffer could not be used in further work with albumin due to its 
interactions at physiological pH.  
 



















































Figure 4.6. :Fixed wavelength plots of the three forms of HSA, 6.02x10-6 M 
in B/R buffer, 0.05cm; A = ∆ε220 versus pH and B = ∆ε2o8 versus pH. 
 
 
4.3.i  Conclusion of pH Studies 
 
One can conclude from the initial investigation of pH that by monitoring the CD at 
different wavelengths different information can be extracted. If was possible to isolate and 
detect all the known transitional forms of albumin under pH considerations. The two 
regions as monitored by CD reflects the different transitions with the backbone susceptible 
to revealing the extended, neutral and aged forms of the protein, and the aromatic region, 
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namely at wavelength 255nm being the only wavelength able to detect the fast form of the 
protein. It is possible that at wavelength 287nm the fast form was also detected, however, 
the results from Table 4.0 were not as conclusive as for wavelength 255nm. Both 
wavelengths regions of the aromatic regions revealed the aged form with only wavelength 
287nm detecting the neutral transition.  
 
Initials studies by CD concurs with the findings of other techniques in that it is possible to 
study the different transformation forms of albumin by the use of pH, provided that the 
correct wavelength region is selected and monitored. None of the protein samples studied, 
however, could detect the basic form under pH considerations, this eluded the studies and 
in all forms relative stability was observed in the region (basic form isolated at pH8). There 
was notably a transition that underlies the neutral region that was isolated by CD studies 
and that was the transition that was detected between pH6 – pH6.5, highlighted profoundly 
when Briton Robinson buffer was used. The most pronounced effect was observed in 
dHSA, possible giving an indication of the lack of fatty acids present within the sample 
and the important role they play protecting the conformational forms of HSA under neutral 
conditions. The view is further supported by the results found in nHSA that appeared to be 
more resilient against that type of perturbation, thus producing a more diminished effect. 
rHSA proved to be the most resilient hardly being affected by the buffer , this could be as a 
result of the mode of synthesis.  
 
4.4.  Temperature Characterisation of Albumin by Circular Dichroism 
 
One of the attributes of albumin is its ability to withstand heating to temperatures not 
exceeding 60ºC without deleterious effects, its size together with its secondary and tertiary 
structures shield the vital hydrophobic core structural components thus maintaining the 
integrity of the protein. The reversible changes that occur is thought to be due to the 
separation of domain I and domain II at these temperatures (Rezaei-Tavirani et al, 2006), 
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the unfolding was thought to be due to the presence of an unfolded intermediate as shown 
in Scheme 1. Under the unfolding process of Scheme 1 domain II is said to unfold first. 
 
Native Unfolded Reversible Unfolded Irreversible→ →← ←  Scheme 1 
 
Studies have also shown that albumin's binding ability has not been compromised at these 
temperatures, and indeed heating albumin to 57ºC has become incorporated as part of the 
purification process in albumin preparations. Initial stability studies have shown once 
albumin had been heated to temperatures exceeding 57ºC the structural alterations that 
result remain fixed in the protein, with little to no recovery on cooling once temperatures 
above 60˚C is exceeded. Any recovery in structure was lost once the protein was reheated 
to the original temperature. For temperatures not exceeding 70ºC, the irreversible changes 
that occur is thought to be due to the irreversible unfolding of domain II (Rezaei-Tavirani 
et al, 2006). For temperatures exceeding 70 ºC produces the irreversible unfolding of 
domain I (Flora et al, 1998). Watzel and co-workers did not believe the unfolding of 
albumin occurred in such a simplistic picture, but believed that the unfolding occurred as a 
multistate process according to Scheme 2 (Watzel et al, 1980). 
 
Native Extended Form  Intermediate Form Unfolded Form→ → →← ← ←  Scheme 2 
 
This can be rewritten as, 
                                                 N E  I U→ → →← ← ←   Scheme 3 
Where E represents the separation of domains I & II, I represents the intermediate 
transition where domain II unfolds and domain I remains intact, and U represents the partly 
unfolded state where both domain I & II are both in the unfolded state, domain III is said to 
remain intact with no unfolding (Shaklai et al, 1984). There is a general loss of helix that is 
unrecoverable (Walleyik, K., 1973), with Cys 34, a free SH group located in a pocket, 
forming disulphides with other domains, assisting in intermolecular cooperation that 
allows some of the protein to retain its structure (Flora et al, 1998).  
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Differential Calorimetry Spectroscopy (DCS) studies have revealed two peaks for the 
unfolding of HSA, that of a major and minor peak. The minor peak was detected at 65 ºC, 
attributed to the reversible changes; the major peak was attributed to the irreversible 
changes that were detected at 70 ºC (Saboury et al, 2003). Deconvoluting shows the minor 
peak to possibly be constructed of three transitions that can be broken down and 
represented in Table 4.1, and are suspected to be due to the links between the domains 
(Sugio et al, 1999). The last transition that occurs at 42 ºC is also the maximum fever 
temperature in the body at pathological conditions. The presence of FA as that found in 
nHSA only produces two transitions when studied by DSC (Farruggia et al, 2001).  
 
Sub-Transitions ∆H,  kJmol-1 Tm,  ºC Tm,  K 
I 248 27 300 
II 260 35 308 
III 333 42 315 
 
Table 4.1.  DSC results showing the transitions of the minor peak of HSA. 
(Rezoei-Tavirani et al, J of Biochem & Mol Biol, Vol 39, No. 5, 530 – 536, 2006) 
 
 
4.4.i.  Variable Temperature Wavelength Scans by CD Spectroscopy 
Intact Protein Samples 
 
All of the HSA samples studied showed similar trends. The effect of heating albumin was 
studied by two methods, at variable and at fixed wavelengths. Initial investigations 
involved the heating of HSA to a predetermined temperature, once at equilibrium the 
corresponding far UV CD spectra was measured within the wavelength regions of 260nm 
to 185nm (this is referred to as a variable wavelength scan), and its secondary structure 
was calculated. The temperature was increased by a suitable increment, once heated to the 
designated temperature the sample was allowed to equilibrate and its corresponding far UV 
CD measured. The same sample was scanned between temperatures of 20°C and 97°C, 
measuring at suitable temperature increments; this was referred to as the first temperature 
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cycle as the sample was heated through the whole temperature range once. The heated 
sample was then cooled to room temperature and reheated through a second temperature 
cycle to determine whether any further denaturation could be induced (known as the 
second temperature cycle). The CD spectra, melting curves together with secondary 
structural changes were plotted and the results are shown in Figures 4.7 to 4.10.  
 
When considering the secondary structural changes, trends rather than absolute values 
were monitored and studied. All the HSA samples behaved in a similar manner to heat 
denaturation with the unfolding of the protein and the loss of α-helix. However, the β-sheet 
content and the irregular structure seemed to mirror each other, following parallel paths 
with the increase in content of both structural forms as a result of temperature increases. 
This was also true of the glycosylated form (L27-HSA) even though its initial content in 
terms of structure was different, the loss in α-helix was distributed evenly between the β-
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Figure 4.7.  Heat denaturation studies of nHSA in 10mM P/B 
 
A=  Temperature cycle of nHSA ,6.02x10-6M, P/B, pH7.2, 0.05cm. 
B=  Second temperature cycle in P/B. 
C=  Secondary structural changes in the first denaturation cycle. 
D=  Secondary structural changes in the second denaturation cycle. 
E=  Fixed wavelength plot heated through two temperature cycles. 
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The melting of HSA was not a single smooth isotherm as was expected, but seemed to 
show intermediate transitions indicative of domain or inter-domain unfolding; this was 
most prevalent in rHSA and L27-HSA as shown in the fixed wavelength plots of Figures 
4.9. and 4.11. Like DSC, CD analysis revealed more than one transition on heating 
albumin with the consistent lost of a proportion of its helical content, even in the reversible 
section below 60°C. It was not possible to determine the exact number of transitions only 
that several (approximately 3 transitions) were found throughout the entire melting curve. 
The other albumin samples did display similar effects but the transitions were more subtle 
and not as well defined. The effects of these inter-molecular transitions were reproducible, 
and in order to isolate and characterise them more fully heat denaturation studies were 
monitored at fixed wavelengths. By monitoring at fixed wavelength and varying the rate of 
heating to incorporate much more discrete temperature increments, it may be possible to 
isolate and determine the intermediate transitions more precisely. As with the variable 
temperature scans, a second temperature denaturation cycle was also studied at fixed 
wavelengths in order to elucidate further possible changes in the denatured sample.  
 
The investigations highlighted a core of protein structure that could not be perturbed even 
when the sample was boiled and/or reheated. There was a further loss in structure but this 
was minimal. The transitions seen in both temperature cycles were discriminate in terms of 
Tm values (the mid-point in the transition temperature) and values of K. The results were 
determined using a fitting routine in the Mathcad software package (Mathsoft plc), with the 
algorithm formulated especially to incorporate CD data (developed by T Bui, Thesis 1998). 
The results are summarised in Table 4.2. and the fitted overlaid data are shown in Figure 
4.10 for both temperature cycles. From the Mathcad fit it was evident that the first 
temperature cycle contained on average three transitions whereas the second cycle contains 
two, this was true for all the intact HSA samples studied. 
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Figure 4.8.  Heat denaturation studies of dHSA in 10mM P/B. 
 
A=  Temperature cycle of dHSA, 6.02x10-6M, P/B, pH7.2, 0.05cm 
B=  Second temperature cycle in P/B. 
C=  Secondary structural changes in the first denaturation cycle. 
D=  Secondary structural changes in the second denaturation cycle. 
E=  Fixed wavelength plot heated through two temperature cycles. 
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Figure 4.9.  Heat denaturation studies of rHSA in 10mM P/B. 
 
A=  Temperature cycle,6.02x10-6M, P/B, pH7.2, 0.05cm 
B=  Second temperature cycle in P/B. 
C=  Secondary structural changes in the first denaturation cycle. 
D=  Secondary structural changes in the second denaturation cycle. 







              
 
 
Figure 4.10.  Superposition of the three forms of albumin using the Mathcad fit 
 
a =  The first temperature cycle revealed that the melting curves of dHSA and rHSA showed similar 
melting profiles, while that for nHSA highlighted a slightly higher Tm.  
b =  The second cycle reflected greater similarities between nHSA and dHSA with rHSA being the 
exception. On cooling, dHSA showed some signs of recovery which allowed it to follow a similar 
path to nHSA. All samples at concentration 6.02x10-6M. 
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Figure 4.11.  Heat denaturation studies of L27-HSA in 10mM P/B. 
 
A=  CD spectra of the heat denaturation of L27-HSA ,6.02x10-6M, P/B, pH7.2, 0.05cm 
B=  Fixed wavelength plot of L27-HSA. 




Using the Mathcad fits, the Tm and K values were determined for each of the whole 
albumin samples and Table 4.2. was constructed for comparison of the first and second 
temperature cycles. 
Intermediate States of 1st Cycle 2nd Cycle 
  1st 2nd 3rd 4th 5th 
nHSA Tm (K) 310.0 340.0 355.0 343.0 357.0 
 Kx10-3 18 25 40 25 90 
dHSA Tm (K) 304.0 334.5 353.0 311.0 350.0 
 Kx10-3 18 31 40 30 18 
rHSA Tm (K) 313.0 336.5 352.0 334.0 348.0 
 Kx10-3 18 45 40 35 16 
L27-HSA Tm (K) 329.5 336.5 347.0 - - 
 Kx10-3 12 35 60 - - 
Table 4.2. Melting temperatures and the equilibrium constant  
of the different forms of HSA for two temperature cycles. 
 
Table 4.2. highlights that for the various forms of HSA, three main intermediate 
transitional states were isolated for the various whole forms of albumin, with similar 
equilibrium constants for the first and third transitional intermediates observed with the 
exception of L27-HSA. However, the Tm was noticeably lower for dHSA than for nHSA 
and rHSA, with L27-HSA showing no similarities to the other forms. Both the K values 
and the Tm for the second intermediate transitional state showed no similarities in all of the 
forms studied, no general trends were observed, each sample behaving slightly differently. 
It should be noted that the DSC results listed for nHSA in Table 4.1. gave different results 
to that observed by the CD analysis, with at least two transitions observed in DSC 
occurring at much lower Tm temperatures than the CD. This suggests that the two 
techniques may be observing different structural changes, as will be shown later the fixed 
wavelength measurements isolates approximately seven potential intermediate transitions, 
showing that the DSC could have isolated temperature transitions not found by the variable 
wavelength scans. The exception to the general rule observed was that found for L27-HSA 
Chapter 4 159
that seemed to give a much higher value for Tm and a much lower K value for the first 
transition. The third transition was equally as diverse revealing a much lower Tm and a 
much higher K value for this transition. One would expect the folding of the protein to be 
somewhat different in L27-HSA in order to accommodate the presence of the additional 
sugar molecule. However, one would expect this change to be small. Indeed the CD 
analysis revealed a 5% loss on helical content and an 8% loss of β-sheet content. In 
binding the sugar, the folding geometry has changed sufficiently to alter the melting 
profile, and although three melting transitions are observed, their values are all different 
from any of the other three whole albumin samples studied. 
 
Although the second transitions for the first temperature cycle were energetically higher 
than that of the first, they showed diversity between the different forms of albumin that 
made it difficult to generalise or summarise. Considering the values of K for the first 
temperature cycle, two distinct groups emerged, the intermediate transition state 1 and the 
intermediate transition state 3. No obvious trends however were observed for the values of 
Tm, all samples of albumin studied showed differing results with no general trends 
observed. For the last transition in the first temperature cycle nHSA, dHSA and rHSA 
showed exactly the same values for K, with L27-HSA proving once again to be the 
exception, melting at a much lower temperature; 
 
The second temperature cycle highlighted the existence of two further transitional 
intermediate states with no correlation between the different forms. All samples showed a 
small degree of initial recovery in some structure on cooling after the first temperature 
cycle, shown as an increase in magnitude in the CD spectra suggesting some sort of 
internal reorganisation (see Table 4.3.). This however was transient, once heating 
recommenced, this recovery was soon lost and further denaturation resulted even though 
this was minimal. Figures 4.7.d. to 4.9.d. showed that the main conformational change 
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observed occurred within the β-sheet and irregular structures, with the α-helix content 
remained relatively constant. It appears that the α-helix content of the protein was mostly 
affected during the first denaturation cycle with the subsequent increase in the other two 
structural components. The reverse was true for the second temperature cycle where the 
helical content was relatively unaffected. 
 
From the CD studies, it is hard at this present time to show what the inter-transitional states 
truly represent. It is clear that HSA undergoes some structural rearrangement and 
unfolding with the unfolding of domain II that is said to occur preferentially first, followed 
by domain I.  Domain III is said to remain unaffected and intact throughout the whole 
heating process, and although this fact cannot be either confirmed or disproved, this theory 
will be investigated at a later stage in this thesis when preheated samples of the whole 
protein will be tested for binding ability using specific marker ligands known to bind to 
specific sites  
 
Protein Structure Initial Content 
(%) 
% Structure after 
1st Temp Cycle 
% Recovery 
(after heating) 
% Structure after 
2nd Temp Cycle 
nHSA α-Helix 52.7 25.4 26.9 25.0 
β-Sheet 16.3 23.1 31.6 24.7 
Irregular 31.0 51.5 41.4 50.3 
dHSA α-Helix 52.2 21.1 29.8 27.8 
β-Sheet 15.6 28.5 25.6 21.3 
Irregular 32.2 50.4 44.7 51.0 
rHSA α-Helix 51.2 20.8 14.6 8.1 
β-Sheet 15.8 28.6 37.4 41.5 
Irregular 33.0 50.6 48.0 50.4 
L27-
HSA 
α-Helix 42.7 21.3 Table 4.3. Secondary 
structure changes observed 
during the heating cycles. 
β-Sheet 21.9 32.6 
Irregular 35.4 46.0 
Domain 
1 
α-Helix 32.6 20.7 
β-Sheet 27.7 29.6 
Irregular 39.7 49.7 
Domain 
1+2 
α-Helix 39.1 21.4 
β-Sheet 24.3 29.5 




Small amounts of the domain fractions, namely domain I and domains I + II, were made 
available for select experiments, and were used to determine whether the intermolecular 
transitions observed in the intact samples were as a result of domain or subdomain 
deformation (domain fractions were also used in some drug binding studies as will be seen 
later). Initial investigations revealed a high amount of irregular structure relative to the 
whole fragments, with a high amount of β-sheet at the expense of the α-helix. This may be 
as a result of the way the fragments were generated, in that it is recognised that the 
production of some domain fractions might not fold in the recognised conformation as in 
the intact sample. Heating the fractions produced changes similar to those observed for the 
intact protein with the loss of helical structure as demonstrated in Figures 4.12.a. and 
4.13.a., with the isolation of intermolecular transitions found previously in the whole 
samples. The high amount of irregular structure was prevalent when the fixed wavelength 
plots were constructed with the % helix noticeably lower. Unlike the whole protein, the 
domain fraction’s β-sheet content and irregular structure  did not seem to follow the 
parallel paths as shown previously, but the generation of β-sheet seem to decline with the 
increase of temperature, with a more rapid formation of irregular structure. The crossover 
between the helical and the β-sheet content occurred at a much lower temperature in the 
domain fractions than in the intact protein, occurring around 60°C as opposed to around 70 
- 73°C for the intact proteins. nHSA gave the highest crossover value of  around 87°C, 
maybe as a result of its FA content. Interestingly, L27-HSA produced a crossover at 
around 65°C, midway between the domain fractions and the intact samples; this must be a 
result of the presence of sugar within the molecule and the way the sugar molecules 
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Figure 4.12.  Heat denaturation studies of Domain I in 10mM phosphate buffer. 
 
A.  CD spectra of the heat denaturation, 1.53x10-5M in 10mM P/B, pH7.2, 0.05cm 
B.  Fixed wavelength plot of the heat denaturation at 220nm and 208nm. 





























































 Experimental Data at 220nm


















Figure 4.13.  Heat denaturation studies of Domain I+II in 10mM phosphate buffer. 
 
A.  CD spectra of the heat denaturation, 1.32x10-5M in 10mM P/B, pH7.2, 0.05cm 
B.  Fixed wavelength plot of the heat denaturation at 220nm and 208nm. 
C.  Secondary structural changes caused by the heat denaturation cycle 
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HSA has three equally sized domains similar in structure, therefore it is conceivable to 
expect domain I to have 1/3 of the structural content of whole HSA and domain I + II to 
have approximately 2/3 of the intact structural content. Experimental analysis of the 
fractions has found domain 1 to contain more than 2/3 of the total helical content, and a β-
sheet content much higher than that found in the whole protein. One must consider that by 
producing fractions the mechanism of folding may be compromised resulting in the end 
product not being a true representation of that fraction if present in the intact sample. 
Secondary and tertiary structural constraints are not only affected by the primary sequence 
but also by the size of the protein as a whole, various interactions that may have been 
present previously may no longer exist. Table 4.4. shows the percentage structure of rHSA 
compared to the domain fractions that were derived from rHSA and introduced a structural 
factor which should adjust the percentage to allow for size. The factor was derived from 
the multiplication of the percentage structure and the number of residues present. The table 
shows that even taking into consideration the number of residues present in each fraction, 
the changes observed were more than can be explained by a multiplying factor. The 

















rHSA  α-Helix 51.2 3.0 20.8 1.2 
585 β-Sheet 15.8 0.9 28.6 1.7 
 Irregular 33.0 1.9 50.6 3.0 
Domain 1  α-Helix 32.6 0.6 20.7 0.4 
195 β-Sheet 27.7 0.5 29.6 0.6 
 Irregular 39.7 0.8 49.7 1.0 
Domain 
1+2 
 α-Helix 39.1 1.5 21.4 0.8 
390 β-Sheet 24.3 0.9 29.5 1.2 
 Irregular 36.6 1.4 49.1 1.9 
 
Table 4.4.  Percentage comparison of rHSA with the Domain fractions. 
 
The structural content determination was based on the Principal Component Regression with the algorithm 
based on the CD spectra comparison from the protein calibration data set. 
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Heating the samples through the first temperature cycle reflected more consistently with 
expectations in terms of secondary structural content for the intact samples. Domain I 
contained one third of the helical content of the intact, and domain I + II containing two 
thirds, the other structural content also follow suit. Table 4.5. shows the thermodynamic 
properties of the domain fractions after the first denaturation cycle with reference to rHSA 
as comparison. Domain I + II exhibited three transitions in the first denaturation cycle, 
whereas domain 1 only possessed two. All of the intact samples of HSA studied gave a 
value for their first transition enthalpy of 18 x 103kJmol-1, neither of the fractions reflected 
this (compare Table 4.1. and 4.5.). The Tm of the fractions were also non reflective of the 
whole protein giving much higher values, only L27-HSA gave a similar value to the 
fractions, much higher than the other three intact proteins. 
 
Intermediate States of 
Transition 
1st Heat Denaturation Cycle 
1st 2nd 3rd 
rHSA Tm (K) 309.0 334.0 351.0 
Kx103 18 30 25 
Domain 1 Tm (K) 311.5 339.0 - 
Kx103 23 30 - 
Domain 1+2 Tm (K) 324.0 333.0 347.0 
Kx103 10 80 9 
Table 4.5.  Properties of the Domain fractions 
 
The 2nd intermediate transitional state revealed that although the values of K varied vastly 
with the domain fractions giving a much higher value in the case of domain I + II, and 
much lower value for domain I, the Tm’s were similar. The 3rd intermediate transitional 
reveals once again the similarities in domain I + II to the intact protein, the absence of this 
transition in domain 1 may prove to be the significant factor to differentiate the ligand 
binding abilities between the two domain fractions (see Chapter 5). It is worth noting that 
values for the second intermediate transition between domain I and rHSA supports the 
theory that domain II unfolds first, leaving domain II relatively intact.  
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4.4.ii  Fixed Wavelength Measurements by CD Spectroscopy 
 
The unfolding of a protein can be monitored at a fixed wavelength with respect to 
time/temperature. The CD spectrometer was set to monitor HSA unfolding at 220nm, one 
of the negative maxima, to determine whether the small intermediate transitional state 
observed previously during the variable wavelength scans could be isolated, highlighted 
and characterised. The spectrometer was initially set to record over a fixed period of        
30 minutes for all of the HSA samples used, including the domain fractions; all the results 
are shown in Figure 4.14. as an overlay so that all samples cold be compared under the 
same conditions. Once again, the transitions highlighted in the full scans were evident in 
the fixed wavelength scans, showing the same triple transitional states when the data was 
corrected and put through the Mathcad package (Figure 4.14.b.). 


























Figure 4.14.a.  Superposition of the corrected data for the fixed wavelength plots 
of HSA. 
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 Calculated Mathcad Fit
Domain 1+2, 2.68mg/ml in P/B, pH7.04, 0.05cm cellDomain 1, 2.63mg/ml in P/B, pH7.04, 0.05cm cell
L27-HSA, 2mg/ml in 10mM P/B, pH7.04, 0.05cm cellrHSA, 2mg/ml in 10mM P/B, pH7.04, 0.05cm cell














































Figure 4.14.b.  Mathcad fits of the fixed wavelength plots for the 30 minute scans, 
corrected for temperature, of the different forms of HSA. 
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Calculating the first derivatives for the melting curve of the intact samples of albumin for 
nHSA, dHSA and rHSA (data not shown) isolated between 7-10 peaks that may relate to 
the interstate transitional states. In order to try to characterise these transitions fully, scans 
were repeated and measured over a longer period of time, increasing the temperature by 
single degree increments, this was done to locate the exact position of the transitions. 
However, instead of clarifying the situation, the single degree increments reduced the 
clarity of the transitions, no further information could be extracted or gained. The Mathcad 
fits revealed three main transitions for the whole proteins and for the domain I + II fraction 
in line with the results previously determined, and for domain I, two intermediate 
transitional states were found. All results were consistent with that determined by the 
wavelength scans in terms of intermediate transitions, however, the values determined for 
tm and K were different (Table 4.6.). 
Intermediate States of  1st Temperature Cycle 
Transitions 1st 2nd 3rd 
nHSA Tm (K) 332.5 339.5 350.8 
 Kx103 18 35 50 
dHSA Tm (K) 330.5 336.0 350.8 
 Kx103 18 35 50 
rHSA Tm (K) 330.0 338.8 350.6 
 Kx103 18 46 35 
L27-HSA Tm (K) 332.5 338.9 351.1 
 Kx103 18 35 70 
Domain I Tm (K) 328.7 349.0  
 Kx103 45 15  
Domain I + II Tm (K) 327.5 335.0 350.0 
 Kx103 68 47 30 
 
Table 4.6.  Mathcad fit of the fixed wavelength scans for 
       the unfolding of the albumin samples. 
 
 
The first intermediate transition gave a value of K=18 x 103 for all intact samples, even for 
L27 HSA, somewhat agreeing with the results of the variable wavelength scans, except for 
L27 HSA that was found to have K=12 x 103. With respect to the domain fractions, the 
Chapter 4 169
values of K were much higher than those detected for the variable scans with a possible 
discrepancy of 22 x 103  & 58 x 103 for domain I and domain I + II respectively. These 
results for the domain fractions seem questionable, however, when you consider that for 
the intact samples gave values of K that were identical, perhaps the two techniques may 
not be monitoring the same transitions; this will be investigated further when pre-heated 
samples are considered. Considering the Tm values for all the samples, the values were 
found to also be considerable higher by as much as 22K for the intact samples and 16K for 
the factions. The disparity in the second and third intermediate transitions were not as 
dramatic and proved to be more consistent with those determined previously. 
 
4.4.iii  CD Analysis of Pre-Heated HSA Samples 
 
The effects of pre-heating HSA was investigated in one of two ways. The first method 
involved pre-heating a stock solution of HSA of known concentration in a thermostatically 
controlled water bath of known temperature (e.g. 50oC). Once the desired temperature was 
reached within the sample, an aliquot was removed and cooled to room temperature. The 
temperature of the bath was increased (e.g. 58oC) and another aliquot was removed after 
equilibrium was attained and maintained within the sample. This process was repeated 
until a selection of samples were acquired, each heated to different but predetermined 
temperatures from the same stock solution and all cooled to room temperature and can be 
referred to as the pre-incubated samples. The pre-incubated samples were then measured 
with the CD spectrometer, heating each sample from RT to 90oC monitoring at fixed 
wavelength (λ in nm). The results are shown in Figure 4.15.; HSA seems to follow a 
specific melting profile referred to as the primary melting curve as shown for the data 
determined for the pre-incubated sample heated to 50oC, the melting profile is shown in 
Figure 4.15. All the pre-incubated samples joined the primary melting curve at a 
designated position determined by the temperature to which the sample was incubated, 
each joining the primary melting curve at the exact temperature to which it was incubated 
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at. Since all the incubated samples were cooled to room temperature, as seen previously 
some recovery was obtained on cooling but this was minimal. Once heated, any residual 
gain in structure was soon lost; the melting curves seem to follow parallel paths until the 
incubated temperature was achieved. Heating HSA to temperatures not exceeding 60oC 
had little effect on the structural integrity of the protein thus affirming that heat treatment 
process of albumin.  

















































Figure 4.15.  Melting curves of the incubated samples of rHSA,  
  6.02x10-6M in 10mM P/B, 0.05cm cell. 
 
A second thermal method was employed that involved the use of a single stock solution of 
protein that was heated through a series of small temperature cycles; a stock solution of 
HSA (concentration 0.4mg/ml in 10mM P/B) was made up to ensure all samples used in 
this experiment derives from the same stock solution. A sample was taken and places into 
the CD spectrometer, the water-bath was set to a known temperature (50˚C) and allowed to 
heat. As the bath heated the spectrometer was initiated and the unfolding of the protein 
monitored at fixed wavelength until the designated temperature was reached, and the 
complete melting for that temperature had been achieved. Once at equilibrium further 
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measurements were recorded, then the thermostat on the water bath was reduced to room 
temperature and the sample was allowed to cool, monitoring its cooling curve by CD in the 
process. When the sample had reached room temperature the thermostat was adjusted to 
the maximum temperature (95˚C) and the sample monitored for its complete unfolding. 
This process was repeated, each time choosing a higher designated temperature and 
monitoring its melting curve, cooling curve and then complete unfolding curve for each 
temperature increment chosen, producing cycling heating curves for temperatures up to 
75oC. The results are displayed in Figure 4.16. and Table 4.7. 
 
Like the pre-incubated samples, rHSA followed a designated and well-defined primary 
melting curve. Both the pre-incubated samples and the heated samples, at the same 
designated temperature, followed exactly the same melting curve which was characterised 
by that temperature. The length of time to which the samples were heated played no 
significance to the end results and was not a determining factor, i.e. no time dependence. 
The unfolding of the protein was instantaneous, producing consistent, yet reproducible 
degrees of unfolded intermediates characteristic to that temperature (Figure 4.14.). Like the 
variable wavelength scans, little/no denaturation was detected for temperatures below 
58oC. However, for temperatures exceeding 60˚C, varying degrees of denaturation were 
detected that were characterised by the temperature to which they were heated. It was 
possible to determine the degree of denaturation samply by the profile of the CD spectra 
and by the secondary structural content at that temperature. No matter how the sample was 
heated HSA always rejoined the primary melting curve and followed the same profile of 
unfolding when heating resumed. The criterion that affected HSA was the specific 
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Figure 4.16.  Melting profiles of rHSA showing the primary melting curve. 
Heating Curve → Cooling Curve → Melting Curve 
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It is clear from Figure 4.16. that there is a definite and well define melting profile that 
albumin will follow when heated. Regardless of what temperature to which the protein is 
heated and cooled down to RT, once heating recommences, the protein will rejoin the 
melting profile at the point at which it was previously heated to and unfolds/melts along 
the preferred melting curve. As shown in Figure 4.16.(c)., no visible effects of heating is 
seen within the protein until a temperature of 58˚C is achieved, then small changes are 
observed attributed to the domains and/or inter-domain separation. Heating to 60˚C gives 
bigger visible effects on the protein, but from previous measurements, although there 
appears to be some sort of loss in structural integrity, this is due to the residues between the 
domains, the domains themselves remain intact at this temperature. For temperatures 
greater than 60˚C, there is a sequential and reproducible loss is structure that is define by 
the temperature to which the protein is heated, the loss in structure by this stage is 
permanent with little to no recovery in structural integrity. It is clear from these results that 
the degree of denaturation can be defined by the temperature to which the protein is heated. 
Analysis of the data from Figure 4.16. is presented in Table 4.7. 
 
Initial Heating Property 
 
Heating Transition 
      
    1st             2nd             3rd 
Melting Transition 
 
1st                2nd               3rd 
328K  (50˚C) Tm 
K x 103 






328K  (55˚C) Tm 
K x 103 
321.0 
5.0 






328K  (58˚C) Tm 
K x 103 
321.0 
5.0 






328K  (60˚C) Tm 











328K  (65˚C) Tm 










328K  (70˚C) Tm 








328K  (75˚C) Tm 









Table 4.7.  Properties of the transitions of  the temperature processes of Figure 4.14. 
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Table 4.7. reveals the physical measurements of the melting curves for all the temperatures 
studied.  At 55˚C a small melting transition is revealed at 321K of 5x103. When the sample 
was heated to 58˚C the same transition observed at 55˚C was observed at 58˚C. The 
turning point seems to appear around 60˚C where two possible transitions were observed in 
the melting curve. Cooling the 60˚C sample and then reheating thought the whole 
temperature range to maximum temperature highlighted a further three possible transitions, 
the lowest occurring at 305K (32.0C) in the melting. For the 65˚C melting cycle, two 
transitions were isolated in the melting curve and two in the heating curve. For the higher 
melting cycles, two transitions were observed in the heating and one transition found in the 
melting curves. The table reveals that HSA can be characterise by temperature and proves 
that it is possible to isolate HSA’s intermediate, unfolded and partially unfolded 
transitional states. 
 
4.5.  Small Ion Interaction with Albumin 
 
Albumin contains a large number of ionisable residues; 116 have acidic groups with 98 
carboxyl residues and 18 phenolic-OH. There are also 100 basic residues consisting of 60 
amino (lysine), 16 imidazolyl (histidine) and 24 guanidyl groups (arginine) (Bordbar et al, 
2004). This is important when you consider that HSA provides 80% of the osmotic 
pressure within the body, of which 30% is attributed to the physical presence of albumin 
itself, the other 50% is attributed to the presence of cations such as sodium and potassium 
that associate with the negative charge of albumin (RezaeiTavirani et al, 2006). Albumin 
makes up about 55% of the total protein concentration in the blood. When studying the 
physical attributes of the protein with binding, depending on the physical technique used, 
different dynamic and structural information will be obtained that will be dependent on the 
technique (Lucas et al, 2006). At pH7 a net charge distribution of -9 across domain I and 
the N-terminal is found, with a charge of -8 across domain II and +2 across domain III and 
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the C-terminal. From this, it can be seen that a net negative charge exists across domains I 




Figure 4.17. Schematic representation of HSA showing the 
domain regions of overlap. 
(Modified from Reference: J. Phys. Chem. B 2008, 112, 4884-4891) 
 
The diagram shows the influences that each domain has with respect to the other, 
and the points of inter-domain contact. The charge distribution is also shown in 
red. 
 
The interaction of HSA with small ions can have a profound effect both on its tertiary 
structure and binding capability. An example of the effect of ion binding is seen in the 
interaction of calcium chloride ions (0.002M) in the presence of 0.16M sodium chloride 
(Foster et al, 1974), warfarin is found to have reduced binding capability in this 
environment. Medium and long chain fatty acids are also known to have a marked effect 
on the binding ability of the protein, reducing its interaction with some ligand and in some 
cases prohibiting it completely (diazepam is known to be inhibited by the presence of 





their structural effects on HSA when bound in varying molar concentrations. The ions 
considered are shown in Table 4.8. 
 
Ion Studied  Concentration Concentration Protein Experiment 
Sodium Citrate   nHSA Concentration Studies 
Sodium Sulphate 200mM 1M nHSA pH Titration 
Sodium Chloride 200mM 1M rHSA, 
nHSA 
pH Titration 
Sodium Acetate - 1M nHSA pH Titration 
 
Table 4.8.  Study of small ion interaction with albumin. 
 
Two concentrations were studied, the pH titration determined and comparisons made in 
both the near and far UV CD regions, these results are shown in Figures 4.16. to 4. 20.; 
sodium citrate is found in the blood with a concentration of around 0.1mM. It has been 
reported that citrates have a marked effect on HSA and its binding ability so concentrations 
of 10-1M to 10-5M were investigated both in the near and far CD UV regions. No changes 
in both of these regions were detected, if sodium citrate were to have an effect, there were 
no changes seen in either of the secondary and tertiary structural regions (no changes in 
extinction coefficient). 
 
4.5.i.  Results of Small Ion Interaction with HSA 
 
Considering the ions mentioned in Table 4.8., the binding of ions to HSA was monitored 
for structural changes over the pH range between 1 and 14 in the far UV CD region. Two 
concentrations were chosen and their results were compared with the results obtained from 
nHSA in the absence of any ligands and reported earlier in this chapter ( see Figure 4.2.). 





























































 Experimental Data at 220nm




















































































 pH Increased to 7.04 (pH1.47)
 pH Decreased to 7.01 (pH12.40)
 
 
Figure 4.18.  Characterisation of nHSA in the presence of 200mM NaCl. 
 
A. pH Titration of nHSA, 4.51x10-6M in 200mM NaCl, 0.02cm cell 
B. pH Titration showing the % Structural Changes 
C. Near UV CD of nHSA, 4.51x10-6M in 200mM NaCl,1cm cell 
D. Absorption Spectra of 4.51x10-6M of nHSA in 200mM NaCl, 1cm cell 
E. Differential Structural Changes of nHSA in the presence of 200mM Nacl 
F. Absorption Spectra of nHSA after readjustment of pH, 1cm cell 
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Figure 4.19.  Characterisation of nHSA in the presence of 1M NaCl. 
 
A. pH Titration of nHSA, 4.51x10-6M in 1M NaCl, 0.02cm cell 
B. pH Titration showing the % Structural Changes 
C. Near UV CD of nHSA, 4.51x10-6M in 1M NaCl,1cm cell 
D. Absorption Spectra of 4.51x10-6M of nHSA in 1M NaCl, 1cm cell 
E. Absorption Spectra of nHSA after readjustment of pH, 1cm cell 
F. Differential Structural Changes of nHSA in the presence of 1M NaCl 
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 Experimental Data at 220nm






























 Experimental Data at 255nm












































 Increased to pH7.52 (pH1.56)
 Decreased to pH7.46 (pH12.55)
 
 
Figure 4.20.  Characterisation of nHSA in the presence of 200mM Na2SO4. 
 
A. pH Titration of nHSA, 4.51x10-6M in 200mM Na2SO4, 0.02cm cell 
B. pH Titration showing the % Structural Changes 
C. Near UV CD of nHSA, 4.51x10-6M in 200mM Na2SO4,1cm cell 
D. Absorption Spectra of 4.51x10-6M of nHSA in 200mM Na2SO4, 1cm cell 
E. Differential Structural Changes of nHSA in the presence of 200mM Na2SO4 
F. Absorption Spectra of nHSA after readjustment of pH, 1cm cell 
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 Experimental Data at 208nm
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This sample was strongly affected





























 Increased to pH7.24 (pH3.47)















Figure 4.21.  Characterisation of nHSA in the presence of 1M NaSO4. 
 
A. pH Titration of nHSA, 4.51x10-6M in 1M Na2SO4, 0.02cm cell 
B. pH Titration showing the % Structural Changes 
C. Near UV CD of nHSA, 4.51x10-6M in 1M Na2SO4,1cm cell 
D. Absorption Spectra of 4.51x10-6M of nHSA in 1M Na2SO4, 1cm cell 
E. Absorption Spectra of nHSA after readjustment of pH, 1cm cell 
F. Differential Structural Changes of nHSA in the presence of 1M Na2SO4 
Chapter 4 181

































































 Experimental Data at 220nm
































































 Increased to pH7.25 (pH1.56)


















Figure 4.22.  Characterisation of nHSA in the presence of 1M CH3COONa. 
 
A. pH Titration of nHSA, 4.51x10-6M in 1M CH3COONa, 0.02cm cell 
B. pH Titration showing the % Structural Changes  
C. Near UV CD of nHSA, 4.51x10-6M in 1M CH3COONa, 1cm cell 
D. Absorption Spectra of 4.51x10-6M nHSA in 1M CH3COONa, 1cm cell 
E. Absorption Spectra of nHSA after readjustment of pH, 1cm cell 






4.51 x 10-6 M 
pK at 208nm 
Backbone Region 
pK at 220nm 
Backbone Region 
pK at 255nm 
Aromatic Residues 
Transitions in pH Titration 1st 2nd 3rd  4th  1st 2nd 3rd  4th  1st 2nd 3rd  4th  
nHSA 2.6 5.9 10.5  2.7 5.9 11.6  4.2 11.6   
dHSA 2.7 4.6 10.9  3.0 5.7 10.7  3.6 11.6   
rHSA 3.0 6.2 11.4  3.0 5.9 11.0  4.0 11.5   
nHSA in 200mM NaCL 3.8 5.8 12.4  4.0 5.8 12.2  4.1 12.3   
nHSA in 1M NaCL 3.0 - 11.4  3.0 - 11.0  4.0 11.5   
nHSA in 200mM Na2SO4 4.4 - 12.1  4.5 - 12.4  3.8 12.3   
nHSA in 1M Na2SO4 3.4 8.4 12.3  3.5 8.5 12.3  3.8 12.2   
nHSA in 1M CH3COONa 3.9 - 12.2  3.9 - 12.2  3.3 12.2   
 Secondary Structure Tertiary Structure 
 
Table 4.9.  Comparative pH Studies of the different forms of HSA in different ionic environments. 
Chapter 4 183
It is evident that the presence of ions can have a profound effect on the properties of 
albumin and the way in which it behaves in changing environments as shown in Table 4.9. 
With the exceptions of 200mM NaCl and 1M Na2SO4, all the ions studied have eliminated 
the second transition in both wavelengths studied in the secondary structure region, only 
two out of the potential three transitions previously observed were detected. In the 
aromatic region, of the wavelengths monitored, the two transitions that were detected 
previously still remained. Considering the secondary structural region first at 208nm, the 
addition of ions increased the first transition from pK= 2.6 to values in excess of pK = 3.0, 
with the highest value observed for 200mM Na2SO4 attaining a value for the pK = 4.4. As 
previously stated the second transition only exists for the 200mM NaCl and the 1M 
Na2SO4 samples with values of pK = 6.4 and 8.4 respectively. It was the second transition 
found in the 1M Na2SO4 sample that was proven to be distinctly different from that found 
in the native sample, and was found to be 2.5 units higher than that found for the native. 
The albumin structure was perturbed sufficiently enough to eliminate the second transition. 
The third transition proved equally diverse with 1M NaCl producing a pK value of almost 
1 unit higher that that of the native. The other ions produced values nearly 2 units greater 
than the native. When considering the transitions at 220nm the values proved equally as 
diverse and reflected the same or similar trend as that detected at 208nm. In the tertiary 
wavelength region the protein was monitored at 255nm. With the two transitions observed 
the first transition produced a general lowering of the pK detected. The second transition 
generally increased. It is evident that the presences of ions could have a profound influence 
on the structural properties of albumin, and this would suggest that it could have an 
influence on the way ligands could potentially bind.  
 
When considering the differential structural changes in the presence of ions, for 200mM 
NaCl, an increase in structure was detected between pH4 and pH6 with an increase in α-
helical content only as shown in Figure 4.16.b. The relative amounts of β-sheet remained 
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constant but there was a corresponding change in irregular structure at the same point 
indicating that the increase in helix was as a direct result of a decrease in irregular 
structure, the protein became more structured. Figure 4.16.e. highlighted this mutual 
change corresponding to the F-form of the protein conformation. Outside the pH range of 4 
to 10 were seen the biggest changes and variations from that seen in the native, and this 
was true for all the ions investigated. 
 
When nHSA was dissolved in 1M NaCl no unexpected changes were observed as shown in 
Figure 4.19. Relative stability was attained between pH4 and pH10, with only the high pH 
region showing changes in the UV spectra plot (see Figure 4.19.d.). Albumin in the 
presence of 1M NaCl meant that the pH changes in both regions exhibited irreversible 
changes. The greatest changes shown were under alkali conditions with the UV 
highlighting the greatest amount of light scattering, this was indicative of aggregation. 
There was some aggregation observed under acidic conditions, however, the amount was 
not as significant.  
 
The presence of 200mM Na2SO4 did not affect the nature of nHSA in the middle region of 
the pH range (p5H to pH10) but did affect the protein in the extreme regions; this was not 
uncharacteristic of the protein. However, UV changes in both the low and high pH regions 
were seen (Figure 4.20.d.), with the reversibility to pH of the protein greatly compromised, 
shown in Figure 4.20.f.; the effect of 1M Na2SO4 gave detectable changes over the entire 
pH range with the greatest changes observed in the low pH region. At pH3.47, the sample 
became turbid suggesting aggregation and was greatly affected by light scattering as shown 
in Figure 4.21.d., no further measurements were possible. Secondary structure analysis 
revealed that one of the biggest changes, other than at pH3.47, was observed at around pH6 
with an increase in α-helix, this was compensated by a corresponding decrease in β-sheet. 
Another significant change was seen around pH9 with a decrease in helix and an increase 
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in β-sheet. At this concentration of Na2SO4 only the reversibility at high pH was 
compromised; the affect of 1M CH3COONa did not seem to have any untoward effects on 
the protein conformation behaving as was expected (Figure 4.22), only between pH4 and 
pH6 were slight changes detected. Since no significant effects were seen at 1M equivalent 
of CH3COONa, measurements at a lower concentration were unnecessary.  
 
4.6.  Denaturantion Studies using Guarnidinium Hydrochloride and Urea 
 
The complexity of the albumin molecule and its binding ability has made it a topic of much 
investigation. Albumin’s metabolic pathway and the mechanism of its ability to unfold on 
binding have still not been fully characterised, especially in terms of its partially unfolded 
intermediates. Because of albumin’s multi-domain properties make it even more 
complicated to study by denaturation studies, as each domain/subdomain may be able to 
act independently of each other, folding and unfolding independently to each other 
domains. The interdomain helices may also play a vital and/or independent role affecting 
the overall conformation seen (Muzammil et al, 2000). Certain chemical can be used to 
induce partial unfolding in proteins by causing varying degrees of denaturation. 
Guanidinium Hydrochloride (GuHCl) and urea (U) are two such chemicals whose rate of 
denaturation of the protein is concentration dependant. GuHCl is considered to be the 
stronger denaturant by destabilizing the electrostatic interactions of the protein, binding to 
the protein via the peptide bond. Small amounts of these chemicals have been shown to 
increase the binding of some ligands as a result of opening the protein sufficient enough to 
either expose the binding site or make it more assessable, this usually occurs at low 
concentrations of the denaturant. Many studies have been conducted with denaturants and 
albumin, but little is known about the exact mode or nature of the mechanism resulting 
from the actions of the denaturant. It is believed that the two denaturants work in different 
ways on the protein and can involve the generation of intermediates. Indeed conflicting 
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information has been published when the same denaturant has been investigated by 
different scientists (Flora et al, 1998). 
 
For concentrations of less that 1M GuHCl local changes within domain II are said to take 
place, but for concentrations between 1M – 6M global changes occur that affect the whole 
molecule, initially with the separation of domains I & II, then followed by the unfolding of 
domain II. The chemical unfolding of the protein can be shown in the following scheme, 
 
1 2 3Step Step Step
N E I U→ → →← ← ←  Multiple Step Transitions 
where N is the native protein, E is the extended protein, I represent the intermediate state 
where domain II is unfolded but domain I remain intact, and U is the unfolded state. The 
use of urea in denaturation experiments have shown that urea works differently to GuHCl 




N U→←       Single Step Transition 
where N is the native protein but U* represents the partially unfolded intermediate. Urea is 
said to only affect domain II leaving domain I intact (González-Jiménez et al, 2002). 
 
Two denaturants were used in this investigation; urea and GuHCl were added separately to 
rHSA (0.4mg/ml) in the concentration range of 0.1 to 10M equivalent of the denaturants. 
Both urea and GuHCl encourage unfolding in the protein, the degree of unfolding was 
dependent upon the concentration of denaturants present and the type of denaturant used. 
Two distinct sets of results were obtained: urea exhibited minimal effects for 
concentrations up to 2M equivalent, above this concentration the protein unfolded in 
approximately two stages. Conversely GuHCl affected the protein at a lower concentration 
of 1M equivalent, inducing a much sharper change also unfolding the protein in two stages 




























Figure 4.23.  Denaturation studies of rHSA at 220nm. 
 
 
Like with heat denaturation, chemical denaturants unfolds the protein in multi-stages, 
unfolding specific areas within the protein that could correspond to changes within the 
domains or subdomains. The denaturation effects in urea required more than 3M 
equivalent to induce any response, this denaturant only produced one transition that could 
be detected by CD analysis. Conversely, GuHCl produced two defined transitions that 
could be detected by CD thus reinforcing the theory of intermediate transitions produced as 
a result of chemical denaturation. Once the protein begins unfolding due to the presence of 
the denaturant, the path of the two denaturants followed distinct routes that seemed to be 
dependent on the denaturant used. The amount of detectable unfolded intermediates was 
approximately four, less that that found by heat denaturation. There exists the possibility of 





HSA was found to be quite a robust protein withstanding heat denaturation for 
temperatures up to 58°C and pH changes between pH4 to pH10. Albumin’s ability to show 
such restraint may explain its versatility as a blood protein and a scavenger, mopping up 
any excess ligands found in the blood. Temperature studies highlighted the conformational 
stability of the unfolded intermediates; it was shown that by heating the protein to a 
predetermined temperature, HSA would unfold by a specific, reproducible and measurable 
amount that could be determined. The behaviour of albumin to heat denaturation enabled 
the melting curve to act like a fingerprint for the partially unfolded intermediate state. Each 
state of denaturation could be exactly fitted to the general melting profile curve determined 
when the protein was heated from room temperature to 95˚C. On cooling the sample, little 
to no recovery was evident. However, the heated intermediate would, upon reheating, re-
enter the melting curve at the point of exit; there was a residual core structure for albumin 
that could not be denatured (suggested to be domain III), calculated to be approximately 
25% helix, 25% irregular structure and 50% β-sheet. Heating the sample through a second 
cycle had little effect on the protein and on the residual unperturbed core that remained 
from the first temperature cycle.  
 
pH had a similar effects to that of the temperature studies in that it promoted specific 
conformational changes within the protein that were specific to that pH and reproducible, 
and like that of the temperature studies, the pH studies proved just as distinctive. However, 
unlike heating, the pH changes were totally reversible once physiological conditions were 
restored. Five possible intermediate states were highlighted that reflected the 
conformational states of albumin while possibly binding or off-loading, and may also 
reflect the possible conformational states that revealed the movement of amino acids to 
accommodate potential ligand binding. pH studies have highlighted their potential use in 
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the isolation and identification of intermediate state. Further work will be undertaken in 
this thesis using the pH unfolded intermediates on the affects of ligand binding with a view 
to elucidate or evaluate the characterisation of HSA.  
 
The use of small ions as inhibitors in binding studies revealed significant structural 
changes in the secondary region, with the elimination of the second transition seen in the 
pH titration in three of the five samples studied. The modification in the secondary 
structure of albumin was as a direct result of the binding of the ions with all the pK’s 
increasing in the secondary regions. The pK's in the tertiary region remained remarkably 
unaffected, proving that the ions only affect the secondary structure of the protein and may 
be used in the body as a way of affecting or controlling the binding activity of albumin. CD 
studies showed no significant changes with respect to secondary structure with exceptions 
of 200mM NaCl and 1M Na2 SO4 that gave increased helical content in the pH range 
between pH4 to pH6, this was at the expense of the β–sheet. It can be stated that although 
ions may have a significant effect on the binding abilities of other ligands to albumin, the 
structural changes as determined by CD spectroscopy were found to be subtle, and in some 
cases almost insignificant. However, as determined by the pK’s, marked effects were 














The nature of albumin and its response toward heat, pH, denaturants and small ion 
interactions meant that any one of these could be used to investigate the binding of ligands 
such as drugs with the view to locate binding sites. Both physical and chemical 
perturbations of albumin causes partially unfolded intermediates that could reflect the 
unfolding of domains or even subdomains. If this is true it would be possible to use these 
intermediates and bind known ligands with known binding site locations to determine if 
the binding at the specified site had been affected or altered by such perturbations. pH 
would appear to be the most obvious choice as these effects are reversible and therefore 
pose the least risk to the protein, also there are five known conformational states already 
highlighted. Binding at a specific pH would represent binding at a given conformational 
state; this would allow the characterisation of that conformation and thus the site, domain 
and/or subdomain. 
 
Pre-incubated samples of albumin would be an alternative way to investigate ligand 
binding. It has been demonstrated that pre-heating albumin causes partial unfolding of the 
protein. Therefore, the use of marker ligands of known binding location would make it 
possible to determine which site on albumin was affected at a specific temperature. Thus it 
would make it possible to use pre-incubated samples of albumin to determine possible 
binding location of new and novel drugs whose binding location to albumin had not been 
characterised. With this in mind the effect of binding of two classes of ligand was 
investigated by pH, chemical denaturation and temperature, using the characterisations of 
the protein as determined in this chapter. The ligands were chosen because of their known 
specifications with the view to isolate and characterise by CD spectroscopy the binding 








































CHAPTER 5:  Small Ligand Interaction 
5.0.  Introduction 
 
The multifaceted role of human serum albumin towards the binding of ligands has enabled 
it to adopt one of the most pivotal roles in plasma binding within the body. Albumin serves 
to regulate the levels of certain drugs and metabolites and shows little specificity. The 
binding affinities of the different ligands may vary but is of the same order of magnitude as 
the specific interaction of the drug/metabolite and its specific protein (Spencer, 1970). 
Albumin acts as a depot, inactivating potential toxins by transporting them to sites where 
they can be disposed of safely. Drug pharmacokinetics all hinge on their interactions with 
HSA, that is there absorption, distribution, metabolism and excretion. Of the four 
pharmacokinetics properties, distribution is the property affected by HSA (Yang et al, 
2007). Bound drugs are protected from rapid catabolism, acting as a reservoir and 
replacing the free drug levels as the drug is consumed, thus maintaining the therapeutic 
levels and prolonging the duration of the drug (Ascoli et al, 1995). If binding is very strong 
or weak to HSA then the distribution of the drug will be poor, which would mean that the 
dose given would have to be increased, thus could lead to stronger side effects being seen. 
HSA increases the solubility of hydrophobic drugs in plasma and modulates their delivery, 
revealing the dominant role of HSA in drug dispersion (Hu et al, 2005).  
 
Albumin’s structure is especially suited for its role to bind numerous ligands, found by    
X-ray crystallography to contain salt bridges and hydrophobic interactions between IA, IB 
& IIA on one side, and IIB, IIIA and IIIB on the other side. The salt bridge between Arg 
218 and Asp 451 is 3.65Å, and if broken causes thermal instability that causes Trp 214 to 
move into a more hydrophobic environment. Trp 214 is also thought to be responsible for 
holding the two halves of HSA together (Carter et al, 1994). Another important 
consideration is the effects that each domain has on the binding abilities of the molecule. 




interaction with domain I (Figure 5.1.), and if this linkage is broken then the binding of 







Figure 5.1. Crystal structure of the two main binding 
sites of HSA. 
 
(Chuang et al, Chirality, 18, 159–166,  2006) 
 
Although extensively studied, the binding of ligands to albumin has been ambiguous in the 
determination of the number of binding sites this protein contains until recently, with the 
new generation of crystal structures that have long been waited for (Muravskya et al, 2004;  
Chuang et al, 2006;  Sugio et al, 1999., Zhu et al., 2008). Albumin was previously thought 
to contain numerous sites, but more recent studies have shown there to be only a few select 
sites (Sjödin et al., 1976 & Feske et al., 1981, Zhu et al., 2008). There are two main non 
equivalent sites found and initially formalized by Sudlow (Sudlow et al., 1976), the first 
site is referred to as "site I", located in domain IIA, thought to be an elongated sock-shaped 
pocket, binding the site-specific drug warfarin (Warf). The second site known as "site II" is 




hydrophobic entrances with a separation of 10Å (Figure 5.1.). There is an asymmetric 
distribution of hydrophobic and hydrophilic residues within the pocket of site II, with the 
cavity lined with hydrophobic residues and the surface lined with polar residues making it 
hydrophilic (Peyrin et al 1999). Site II is said to be similar to site I in that they are both 
comprised of 6 helices, however, site II is a hydrophobic cavity with distinct polar regions 
and is smaller than that of site I; Site II bind diazepam as one of its marker ligands (refer to 
Chapter 2 on Ligand Binding). 
 
Site I was previously thought to bind acidic, bulky hetrocyclic molecules containing enol 
groups that possess a negative charge centralised within the molecule. Located close to this 
site are MCFA & LCFA binding sites that have been shown to affect the binding of some 
ligands to this site, causing a reduction or an enhancement of binding by both competitive 
and/or allosteric effects (Kragh-Hansen, 1990). The binding of warfarin has been shown to 
be enhanced by the presence of fatty acids producing a 2-3 fold reduction in binding in 
their absence. Site I is thought to contain several overlapping binding sites, this can be seen 
by the close proximity of the fatty acids binding sites to the main binding cavity (Kragh-
Hansen, 2002). Ligands of diverse chemical structure bind to this region as this site is not 
as discerning as site II, examples include dicarboxylic acids and/or bulky heterocyclic 
molecules with a central negative charge. Site I is a large hydrophobic cavity formed from 
the hydrophobic side chains of the protein with 7 openings. The cavity is 17% hydrophilic 
and 83% hydrophobic with a surface area of 2236.1 Å2 and a solvent accessibility volume 
of 788.6Å3 (Perry et al, 2006). The entrance to the pocket is surrounded by positively 
charged residues, with the pocket being more truncated than that found in site II due to the 
presence of bulkier hydrophobic side chains (Chuang et al 2006). Lys-199, His-242 and 
Arg-257 function sterically and electrostatically in ligand binding. The helix h1 within site 




Site I is said to be ‘flexible’, accommodating all the chemically diverse ligands which are 
bound in high affinity. Site I is said to contain several individual ligand binding sites that 
bind independently or can mutually influence each other, an example is HSA-Myr-Warf. 
Positive contributions within the binding pocket are derived from Trp 214 and Arg 218, 
negative contributions come from residues Lys 199 and His 242, all situated within the 6 
helices that construct the warfarin binding pocket (Chuang et al 2006). Another example of 
stereoselectivity is found in tryptophan where L-tryptophan binding 100x more than         
D-isomer. Binding sites are found in the interdomain cleft between subdomain IA and IIA 
which includes Trp 214. LCFA are thought to control the binding of HSA by competitive 
and allosteric mechanisms which mainly involves domain 1, this may be a possible 
explanation as to why limited ligand binding sites are found in domain I. 
 
The properties of site II (in domain IIIA) are different to those of site I in that, the entrance 
of the pocket contains residues that interact with carboxylates from the binding ligand. 
Within the pocket of site II are two regions of hydrogen bond partners, the first is located 
across the interface of domains II & III through Ser 342 and Arg 348 in subdomain IIB and 
Arg 485 in IIIA. The second region is located at Arg 410, Tyr 411 and Ser 489 all found in 
subdomain IIIA. Within this pocket Arg 410 and Tyr 411 are thought to be the most 
important residues, although Arg 410 is not thought to be important in diazepam (Diaz) 
binding (Chuang et al 2006). The site II binding pocket is said to be ‘less flexible’ than site 
I, therefore less accommodating and is smaller and narrower than that of Site I with a 
ligand length constraint. Binding at this pocket is influenced by stereoselectivity, an 
example is shown in L-tryptophan (Chuang et al, 2006). The reverse effect has been seen 
for site II where diazepam binding is restricted or inhibited in the presence of FA. The 
revised consensus is thought to be that binding to this site is by hydrophobic and 




Tryptophan seem to offer an important contribution within this area, its modification 
affecting the binding of some ligands including warfarin (Ellis et al., 1991 & Schreiber et 
al., 1978), but has been shown not to affect ligands such as phenyl butazone and 
azapropazone (Newman et al., 1990 & Pende et al., 1991). Site II binding is thought to 
show great specificity, and is shown not to be affected by short chain fatty acids (SCFA) of 
chain length C1 – C5, but are affected by MCFA and LCFA of chain length C6 – C12 and 
C11 – C18 respectively. This pocket seems to have a critical length for ligands that it can 
and will except, determined to be around 14.7Å. Binding to this site is complicated and 
seems to be affected by many parameters, properties and characteristics such as 
hydrophobicity, chain length and charge of the ligand are all important determinants 
(diazepam having a chain length of 11.6 Å). The hydrophobic cleft of this site has an 
approximate depth of 12-16A and a width of 6-8 Å, with at least one cationic group located 
near the surface of albumin that inhibits ligands carrying positive charges. The main forces 
for binding at this pocket are the hydrophobic interactions. Carboxyl groups are also 
thought to be required for effective binding to this site (Maruyama et al, 1993).  
 
There are many drugs that exhibit chirality, a property whose importance was established 
as far back as 1886 when Pasteur observed the differences in the chiral salt of tartaric acid. 
Two optically active isomers (enantiomers) were found that rotated the plane of 
polarization, the “natural form” that rotated the light to the right so called dextrorotatory (d 
or + enantiomer), and the other form that rotated the light by the same amount but in the 
opposite direction, rotating the light to the left or levorotatory (l or - enantiomer) 
(Williams, 1991).  Mason and others have served to reinforce this concept, establishing the 
fundamental rules that elucidate chirality as we know it today (Mason, 1988 & 1989). 
Enantiomers have in the main identical physical characteristics; optically activity is a 




has the ability to measure the optical activity of different chiral forms and determine 
absolute values, a fact utilized throughout this thesis when considering drugs and cocktails 
of drugs. A further fact to consider in the pharmacology of drugs is that the active drug in 
plasma is the unbound or free drug. Absorption of the drug occurs in the intestine by 
passive means. When the drug is administered orally, lipophilicity is paramount. Albumin 
is thought to exhibit enantioselectivity showing chiral discrimination, in these 
circumstances the equilibrium constants for both enantiomers (KR & KS) have to be 
considered. Nonsteroidal anti-inflammatory drugs (NSAID) are found to bind 
stereoselectively to HSA, the degree of separation is dependent on the drug. Some drugs, 
however, are not stereoselective and the enenatiomers are found to bind to the protein 
equally. Another fact that has to be considered is that isomers are metabolised by two 
different enzyme systems and to produce two different rates of metabolic clearance 
(Chuang et al, 2006). The two enantiomers may interact differently with either the protein 
or receptor site, thus this will affect their distribution and effect. 
 
Albumin also possesses enzymic properties that were first observed as far back as 1951. 
This enzymic activity is located within site III, with Trp 411 and histidine being the active 
residue responsible for esterase activity. Arg 410 has also been implicated in esterase 
activity (Yang et al, 2007). Esterase activity has also been seen in site IIA but to a lesser 
degree. Here acetylsalicylic acid is converted to salicylic acid by hydrolysis with Lys 199 
being implicated as the active residue, since during the hydrolysis of aspirin the acetyl 
group is transferred to Lys 199 forming acetyllysine. The crystal structure has revealed that 
although both aspirin and salicylic acid bind to HSA via Lys 199, their acetyllysine 
orientations were quite different with salicylic acid rotated approximately 30˚ to 




199 is facilitated by the protonated of Lys 195 which is also a necessary step. Lys 199 is 
found to have an unusually low pKa of 8 (Kragh-Hansen et al, 2002).  
 
This chapter endeavours to give a better understanding of the binding characteristics and 
specifications of the two main binding sites of HSA, and to determine whether any other 
binding locations can be detected and determined. Also considered are the effects of major 
and minor perturbations within the protein and its response to binding. Lastly the affects of 
multiple ligands with there possible displacements are also investigated. It is clear that the 
complexity of albumin and it dominant feature within the blood make it an intriguing 
protein to monitor, and by virtue of its complexity, has meant that much of albumin’s 
intimate binding sites are still elusive. It is intended that this study will add to the clarity 
and elucidation of albumin’s most intimate details. 
 
5.1  Benzodiazepine Binding 
 
Benzodiazapine and its derivatives are widely used in the medical treatment of depression 
























Figure 5.2.  Structure of benzodiazepine, the derivatives are obtained by 
substitution of different functional groups in positions R1 - R5. 
 
Diazepam (Diaz), a derivative of benzodiazepine, is referred to as a characteristic marker 




is between 8 – 10 Ǻ and lies between two helices. The distributions of hydrophobic and 
hydrophilic residues have been determined to be asymmetric (Peyrin et al, 1999). 
Subdomain IIIA is the site on albumin that has been determined to be the major ligand 
binding site, found to be potentially the first site that is targeted. However, its binding 
characteristics are very specific and is very receptive to enantiomeric selectivity as will be 
shown later with the type of conformer preferentially selected to bind at this site. The 
presence of FA equally have dramatic effects on site IIIA pocket’s binding ability (Curry 
et al, 2001 ). Within the binding pocket helices h3 & h4 form the floor of the pocket, h1 & 
h2 form the sides of the pocket, and h5 & h6 for the roof of the internal cavity (Kragh-
Hensen et al, 2001). When diazepam binds to HSA there is an expansion of the binding 
pocket to accommodate the incoming ligand. However, its expansion is not as great as that 
of subdomain IIA that has been shown to be a more flexible binding pocket. 
 
 
Figure 5.3.  X-ray crystral structure of diazepam binding  
to subdomain IIIA on HSA. 
(Curry et al, J.of Mol Biol, vol 353, Iss 1, 38-52, 2005) 
 
The binding is in the absence of FA and in accordance with the findings of Carter and 
He in 1992. The protein is colour coded to reflect the domains and subdomains. The 




When FA binds to site IIIA, then the bound FA forms tunnels between the helices that are 
lined with hydrophobic residues. Two FA sites are found for Myr3 & Myr4 in this binding 
location. The carboxylate of Myr3 interacting with Arg 410 while for Myr4 the interaction 
is between Arg 485 in IIIA and Arg 348 in IIB. The binding activities of IIIA has been 
closely linked to residues Tyr 411 & Arg 410 with these residues being shown to project 
into the middle of the pocket, and are in close proximity to each other with approximately 
a 2.7Ǻ separation (Figure 5.4.). Tyr 411 is thought to play a pivotal role in the functionality 
of the site, its substitution been shown to affect binding (ketoprofen), accept in the case of 
diazepam that is unaffected (Kragh-Hensen et al, 2000, Chuang et al, 1999, Matsushita et 
al, 1997). 






Figure 5.4.  Inside the pocket of IIIA showing diazepam docking. 
(Curry et al, J.of Mol Biol, vol 353, Iss 1, 38-52, 2005 & Quantum Pharmaceuticals) 
Albumin revealing its closest residues in contact with diazepam that show it to be a 
hydrophobic cavity with the main polar patch centred around Y 411 as shown in (A). Crystal 
structure of diazepam shown in a different orientation to that shown in (B). 
 
Three distinct elements have been identified for binding activity at this site, 
a. Guanidino moiety of Arg 410 that interacts with COO- group (except in the 
case of diazepam that does not contain such a group). 




c. The aromatic ring of Tyr 411 interacts with the aromatic ring of the ligand. 
 
Binding to site IIIA offers dimensional constraints, as this pocket is smaller and narrower 
than that of its counterpart at site IIA (Figure 5.5.). This site is said to be less ‘flexible’ 
since sterioselectivity is key. Unlike IIA, the binding of FA does not cause an expansion 
within the binding cavity of IIIA. With the higher binding constant of FA calculated to be 
around Ka = 107 M-1, and even taking into consideration that it is the FA’s secondary 
binding site within this area, the FA will inhibit the binding of diazepam, competing for 
the same site due to its higher affinity. There are also allosteric inhibition constraints of the 
pocket to be considered as well as cascade effects when diazepam binds. The allosteric 
constraints occur where diazepam is inhibited by the primary binding of FA to HSA, 
constricting its binding to site II. Cascade effects are seen when free FA’s displace toxins 
from site II, the toxin is then free to compete with diazepam competitively inhibiting its 
binding (Mitsuyoshi et al, 2008). All in all diazepam binding is affected by allosteric 
inhibition, competitive and cascade effects (Figure 5.6.). 
 
                                  Site I                                                                         Site II 
 
Figure 5.5. Simulation of the binding sites of HSA estimated using MOE  
based on crystallographic analysis. 
(Chuang et al, Chirality, 18, 159-166, 2006) 
 
Site I shows the warfarin molecule bound in the pocket, while site II shows the diazepam in 
situate. Diagrams indicate relative size differences between the two pockets and accessibility. 
Comparatively, there is a vast difference in size between the two pockets and a difference in 
accessibility. Clearly site II reveals the site constraints that may account for the type of ligand 








Figure 5.6.  Schematic representation of allosteric,  
competitive and cascade effects. 
(Chuang et al, Chirality, 18, 159-166, 2006) 
 
Studies using gel filtration have shown that the binding of benzodiazepines to albumin is 
mainly restricted to one site (Muller et al, 1973 & 1974), and is stereospecific (Muller et 
al, 1975). Diazepam has a KA of 18 x 10-4M
-1 for the main binding site, however, two 
weaker sites with lower equilibrium constants have been suggested which by their nature 
will be low affinity binding sites (Sjödin et al, 1976). At a pH = 3.3 the nitrogen at position 
4 becomes protonated, with a pKA = 4.5 it forms benzodiazepoxide, which can be ascribed 
to the formation of an amidinium structure shown in Figure 5.7., and results in a blue shift 
observed in CD spectroscopic measurements; there are many derivatives of 
benzodiazepine, all showing subtle changes in their CD profile. By substituting different 
substituents in the different aromatic rings (Figure 5.2.) show changes spectroscopically. 
Substitution in the B-ring results in strong changes in the Cotton effects seen at the 
positive peak at 262nm, this can be attributed to the influence of -N1=C< group. 
Derivatisation at N1 enhances the positive CD peak. Derivatisation at C2 has little / no 




and substitution of the C - ring. If the number of oxygen atoms is increased at positions C2 
and C3, the negative CD peak at 300nm increases in magnitude. In terms of energy levels, 
there is a strong π → π* transition between the substituted A and C - rings, with a 
somewhat weaker transition of n → π* from the N and O atoms, masked by the π → π* 
transition between 300nm.     
 
Figure 5.7.  Structure of amidinium ion. 
 
The observed CD spectra attributed to binding is due to ''intrinsic'' (natural optical activity) 
and/or ''induced'' or ''extrinsic'' optical activity (due to the environment of the 
chromophore). The intrinsic optical activity may be due to conformational changes around 
the chromophore side chains (Trp, Tyr, Phe and Cys), or they might arise from the 
asymmetric benzodiazepine molecule itself. NMR studies have shown the B - rings not to 
be planer, but most probably have the boat conformation. This was also supported by X - 
ray crystallographic studies (Carter et al, 1989), the structures are represented in Figure 
5.8. It is the steric interactions within the benzodiazepine (R-) & (S-) enantiomers that 
restrict the conformers to either the P- or M- conformation. Due to the high enantiomeric 
selectivity that is present in the central nervous system preferential selectivity of the (S-) 
enantiomer is favoured by the receptor site, diazepam will adapt the M-conformation in 






Figure 5.8.  The chiral conformers of diazepam. 
 
(Fitos et al, Bioorganic & Medicinal Chemistry, 15, 4857-4862, 2007) 
 
NMR studies conclude that the two isomers are in dynamic equilibrium, with the half-life 
for both isomer being much less than one second at 23°C. The coalescence temperature for 
chlordiazepoxide is 41°C, with a half-life at this temperature estimated at 0.019 sec. If 
binding is stereospecific, one isomer will bind in preference to the other, the mixture will 
no longer be racemic and will result in intrinsic optical activity. The stereospecific effects 
will in turn change the optical activity of the albumin binding site of that drug. The 
induced optical activity will be due to perturbations in the chromophore when bound to 
HSA. Intrinsic optical activity is very weak in comparison and therefore these effects can 
be ignored. 
















Figure 5.9.  Schematic representation of warfarin. 
 
Warfarin is an oral anticoagulant administered as a racemic mixture, sequestered by HSA 
such that 99% of the drug is found bound under normal therapeutic conditions, this leaves 
low levels for active distribution (Curry et al, 2001). On binding to HSA, warfarin binds to 




albumin in the presence of FA.  On binding, warfarin displaces FA7 that binds within the 
same domain, but it is FA2 located between subdomain IA & IIA that is in close proximity 
to the warfarin binding site that plays a pivotal role. When bound, FA2 causes a 
displacement of subdomain IB resulting in the rotation of helices h2 & h3, thus moving the 
side chain of Tyr 150 previously within the pocket, to a position outside of the pocket to 





Figure 5.10. An overview as determined by X-ray crystal structure of 
HSA:Myr:Waf. 
 
(Curry et al, J. Biol Chem, vol 276, iss 25, 22804-22809, 2001) 
Domain I, II & III are colour coded as red, green and blue respectively with light and dark 
shadings representing the subdomains. The FA molecules are shown as space filled molecules 
(grey is the carbon molecules and red represents the oxygen molecules). Warfarin is shown in 
yellow depicting the carbon atoms. 
 
The binding pocket found at IIA comprises of three sub chambers that are arranged in a 
‘sock like’ formation, the chambers offering specific points of interaction for the ligand. 
There are seven openings to this pocket, 17% of the pocket is hydrophilic and 83% is 
hydrophobic with a surface area of 2234.1Ǻ. There are a large number of basic residues 
within the binding cavity (Perry et al, 2006). Warfarin, being a relatively small molecule 




one sub chamber, or side pocket as it is also referred to, free for further possible ligand 
interaction, this side pocket is defined by residues Leu 219, Arg-222, Phe-223, Leu-234, 
Ile-264, Leu-257, and Ile-290. The interaction of warf:HSA is found to be hydrophobic 
with specific electrostatic interaction. The benzyl moiety interacts with residues Phe 211, 
Trp 214, Leu 219 & Leu 232, with aliphatic contacts from residues Arg 218 & His 242. It 
is particularly the interaction with Trp 214 that has been shown to be of particular 
importance, as substituting this residue results in reduced binding observed in warfarin.  
 
The coumarin moiety resides in the main sub chamber that is found furthest from the 
entrance of the binding pocket, this site also occupied by other site I ligands such as 2,3,5-
triiodobenzoic acid (TIB). Further hydrophobic interactions also include Val 241 found on 
the right hand side of the pocket and Arg 222 with electrostatic interaction offered by two 
of the three oxygen molecules from warfarin. Hydrogen bonding is found between the 
forth oxygen atom on warfarin with the side chain of His 242 and also to bound water 
molecules. However, it is the interaction of the oxygen molecules at position two, three 





Figure 5.11. Side view of the binding pocket of subdomain IIA showing 
the sub-chambers. 
 
(Curry et al, J. Biol Chem, vol 276, iss 25, 22804-22809, 2001) 
 
The view of the pocket is rotated 180˚ about the vertical axis from the view of 
whole warf:HSA:Myr complex shown in Figure 5.10. The pocket is coloured 





5.2.i.  Metabolism of Warfarin 
 
Warfarin is used in the treatment in the prevention of thrombosis, embolisms and other 
disorders by decreasing blood coagulation. Warfarin works by inhibiting vitamin K 
epoxide reductase activity for vitamin K dependent clotting factors II, VII, IX & X, as well 
as regulatory factor proteins (Costas Loannides, 2008). The phenoxide group of warfarin 



















Figure 5.12.  Warfarin anion. 
 
The warfarin carboxylate is stabilised by Arg 218, Arg 222 & Lys 195. Two amino acid 
clusters exist within the binding pocket, the first is Lys 195, Lys 199 & Arg 222 located at 
the opening. The second cluster consisting of Tyr 150, His 242 & Arg 257 is located in the 
floor of the pocket. Warfarin is found to interact with the second cluster. Ligands with two 
anions also bind to this site and interact with both clusters. The main residues are thought 
to be Lys 199 & Arg 222 in cluster 1 and His 242 in cluster 2 that are thought to be of 
importance (Perry et al, 2006).  
 
Although HSA shows little enantiomeric selectivity at this site the S(-) isomer of warfarin 
is between 3 - 6 times more potent, and is eliminated more rapidly than the R (+) - isomer 
(Banfield et al, 1983). It is thought that tryptophan is essential for warfarin binding 
(Fehske et al, 1981), and is thought to bind to site IIA of albumin (Sudlow site I). There 
have been some suggestions that there may be a second binding site for warfarin binding; 




superimposed upon the intrinsic optical activity of the drug. The enantiomers of warfarin 
vary considerably in their intrinsic activities, but differ only slightly in their affinity to 
HSA, the S (-) isomer being bound only slightly stronger than the R (+) isomer. The 
induced optical activity of the R (+) and racemic warfarin appear qualitatively similar, and 
is represented in Figure 5.13. Studies involving warfarin and structurally related drugs 
have shown that parameters other than affinities have to be considered, warfarin/HSA 




Figure 5.13.a.  CD spectra of the S (-), R (+) and racemic warfarin bound to HSA. 
(Brown et al, Molecular Pharmacology, 13, 70-79, 1976) 
 
The CD spectrum of HSA has been subtracted from the enantiomers or waerfarin: HSA & racemic 
warfarin: HSA spectrums only (i.e. observing the induced CD of bound warfarin). 
 
Both the R (+) and S (-) enatiomers bind in very similar conformations to HSA in what is 
termed an “open conformation,” enabling the coumarin groups to rotate or flip 180˚ about 
the C1-C13 bond resulting in almost superimposable conformations (Curry et al, 2001, 
Chuang et al, 2006). The acetonyl group that stems from the chiral carbon of warfarin lies 
at the mouth of the pocket, and it is this that depicts the differences between the two 
enantiomers (Figure 5.13.). When bound, both enatiomers exhibit almost identical contacts 
to the aa within the binding cavity, and it is this that accounts for the lack of 






Figure 5.13.b.  Electron density map showing the bound enantiomers 
of warfarin to HSA:Myr. 
(Curry et al, J. Biol Chem, vol 276, iss 25, 22804-22809, 2001) 
 
The metabolites of warfarin are 6- and 7-hydroxy warfarin, and RS and SS-warfarin 
alcohols which are represented in Figure 5.14., the former metabolites undergo reduction 
forming the two diastereoisomeric alcohols. The 7-hydroxy warfarin is one of the most 
important by-product of S–warfarin; the isomers of warfarin show different anticoagulant 
activities and metabolism and should be considered as two separate drugs, they are also 
dose and concentration dependent (Aoki et al, 1973). The metabolites of the enantiomer of 
warfarin are excreted in different ways, the S-enantiomer undergoes hydroxylation at the 
aromatic coumarin ring at position 7 and is eliminated in the bile, and a small amount of 
the diastereoisomeric alcohol is formed. The R-enantiomer is reduced to the RS alcohol 
and is excreted in urine; a small amount of 7-hydroxy warfarin is also formed. Both 
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There is much speculation about an alternative binding site for warfarin, and indeed 
speculation of there being a second site located close to myristate bound in close proximity 
to subdomain IB has been suggested (Curry et al, 2001, Dockal et al, 2000 & Perry et al, 
2006), the same site that is speculated to accommodate TIB. The binding constant has been 
suggested to be approximately 0.12 ± 0.15 x 10-3 M-1. Experimental data shows the c-
terminal of domain I to be important for the functionality of site II and that the 
combination of domain I & II was sufficient to bring about the binding of warfarin; 
domain III was found to be of little importance to warfarin binding (Dockal et al, 2000). 
Although site IB has been found capable of accommodating the coumarin moiety, no space 
has been found that can accommodate the rest of the drug molecule. Therefore, for this 
reason this location has been ignored. No other site has been determined for this drug. 
 
The presence of FA as previously stated has a significant effect on the binding of warfarin, 
its presence has been shown to increase warfarin binding. FA are known to cause great 
conformational changes in HSA resulting the rotation of domain I and domain III relative 
to domain II (Simad et al, 2006, Curry et al, 2001). The presence of 3Mol of FA per mole 
of HSA produces a 3 fold increase in binding of warfarin, with concentrations exceeding 
that value producing reduced binding of warfarin. Since there are FA binding sites in close 
proximity to the warfarin binding site, then at high concentrations of FA will result in 
competition between the warfarin molecule and the FA molecules. It has been determined 
that FA site 7 overlaps with site IIA and shares two aa side chain with FA site 2 (Simad et 
al, 2006). Without the binding of FA2 the side chain of Tyr 150 lies within the binding 
pocket, binding of the FA displaces Tyr 150 by binding it to the carboxylate group of the 
FA, displacing domain IB by rotating helices h2 & h3 (Curry et al 2001). 
 
After the N-B transition, ligands are bound with a different affinity to that of the N-form. 




HSA, these allosteric effects have neither still not been qualified nor the dynamics between 
the two sites. It is speculated that the point of interaction between the two domains (IB & 
IIA) is said to be for the purpose of communication (Kreigh-Hanson, 1999), with the 
greatest sensitivity of HSA observed in the N-conformation. It is thought that the transition 
to the N-B transition changes from a heart shaped molecule to an ellipsoid.  
 




Figure 5.15.  Schematic representation of salicylic acid. 
 
Derivatives of salicylic acid drug also belong to the family of drugs called nonsteroidal 
anti-inflammatory drug (NSAID), widely used throughout the world because of their 
therapeutic properties for treating a wide range of symptoms. Aspirin, the acetylated form 
of Salicylic acid (SA) is taken orally for a wide variety of conditions; it has analgesic, anti-
inflammatory and antipyretic properties, and can be used to inhibit the biosynthesis of 
prostaglandins. Aspirin increases bleeding time by decreasing platelet adhesion, and can 
also be used for pain relief and for acute and chronic inflammatory disorder, e.g. 
rheumatoid arthritis. Aspirin was the simplest of the drugs considered; nevertheless its 
importance in drug therapy is resounding. Salicylic acid’s small size and ability to bind to 
more than one site makes it an ideal tool for multi-binding ligand investigations. 
Appropriate conditions are chosen such that the preferred high affinity site is occupied, 
this would allow the second site to be probed.  
 
The pioneering work of Carter and He in 1992 in their determination of the first high 




determined by Sudlow. The findings proved the limited binding was seen in mainly 
subdomains IIA & IIIA. However, this has been found not to be the whole story since the 
diffraction patterns were determined from defatted albumin crystals when the importance 
of FA was not quite realised at that time. Although Carter and He recognised that albumin 
was a carrier of FA, more recent work has determined that albumin’s primary function is 
in the transport of FA, and it is these molecules that have been found to control the tertiary 
structure of albumin (Curry et al, 2001, Chuang et al, 2006, Muravskya et al, 2004, 
Bhattacharya et al, 2000, Kragh-Hansen et al, 2000 & Yang et al., 2007). It is for this 
reason that albumin is referred to as ‘flexible’ as it is the presence of FA that has been 
shown to alter the size and shape of the binding pockets and the molecule as a whole 
(Figure 5.16.). Bound FA means that for SA bind to subdomains IB & IIA, with 
subdomain IIA now being the dominant site, the X-ray crystal structure of bound SA is 
shown in Figure 5.17. 
 
 
Figure 5.16.  Conformational changes that are associated with site I 
in the presence of FA.  
(Curry et al, J.of Mol Biol, vol 353, Iss 1, 38-52, 2005) 
 
The superposition of binding site I in the absence of Myr is shown in light 
brown, and in the presence of Myr is shown in light blue which shows an 
expansion of the binding pocket. The red arrows indicate the direction of 
movement of the pocket. Also shown are the relevant residues associated with 




Another way in which FA can affect the tertiary structure of albumin is that its presence or 
absence will affect the specific binding sites of known marker ligands, in particular 
salicylic acids and its derivatives and warfarin (for a more detailed account on FA binding 
to HSA refer to Chapter 2). The number of FA molecules bound to albumin is also a 
determining factor, the presence of five Myr molecules will mean that domain II does not 
have any FA molecules bound in this region, whereas with seven Myr molecules bound to 
HSA reveals that FA7 binds to subdomain IIA (Zhu et al, 2008).  
 
 
Figure 5.17.  X-ray crystal structure of Myr:HSA:TIB. 
(Curry et al , Nature Structural Biology, 5, 827-835, 1998) 
 
5 Myr molecules bound to 1 HSA molecule with 2 TIB in situ bound to 
subdomains IIA & IB. The presence of bound Myr has changed the dominant 
binding site of TIB from subdomain IIIA to IIA and the secondary site from IIA to 
IB.  
 
Table 5.1. represents the points of contact of the ligands with albumin showing the 
residues within the binding cavity together with the protein side chain interaction.  
 
 
Table 5.1.  Ligand-binding residues in HSA. 
(Curry et al , Nature Structural Biology, 5, 827-835, 1998) 





The absence of FA as determined by Carter and He produce two specific binding sites for 
2,3,5-triiodobenzoic acid (TIB), a derivative of salicylic acids with the dominant and 
primary site located in subdomain IIIA, the second site was located in subdomain IIA 
(Carter et al, 1992). However, in the presence of FA, albumin experiences conformational 
changes that result in changes in the specific binding site for salicylic acid. The FA 
myrastate (Myr) binding to HSA has been shown to cause a rotation of domains I & III 
relative to domain II (Zhu et al, 2008). Now the dominant binding site is found in 
subdomain IIA with the second site located in IB that also binds Myr 1 with the two 
ligands in close contact (Curry et al, 1998), a site not renowned for its binding ability but 
has been shown to have increasing prominence as warfarin has also been shown to bind to 
this site (Zhu et al, 2008). The relocation of TIB to sundomain IB is thought to be due to 
the fact that Myr 3 & Myr 4 both bind to sbdomain IIIA and TIB is incapable of displacing 
the FA’s from their sites, therefore relocates to the low affinity site. This phenomena 
exhibited by TIB has been shown to exist in other drugs such as the binding of arsenic 
where two types of protein binding was shown, strong affinity binding to a small number 
of sites or weak affinity binding to a large number of sites, the site is dictated by the 
concentration of the ligand (Uddin et al, 2004). With seven Myr molecules bound, Myr 7 
is found to bind very weakly to IIA with the result that most drugs will displace it on 
binding, warfarin is found to cause displacement of this FA (Petitpas et al, 2001, Yang et 
al, 2007). However, some drugs such as AZT are not capable of displacing Myr 7 but 
coexist; displacement is governed by ligand affinity.  
 
Three derivatives were considered, salicylic acid (SA), 5-iodosalicylic acid (5ISA) and 
3,5-diiodosalicylic acid (DIS) for their binding properties to albumin and their relative 
stabilities. The derivatives increased in size by a controlled and known amount, this 




investigated. The effect of binding derivatives would highlight whether one or both on the 
binding pockets are affected, this together with changes in the environment such as pH and 
temperature, should aid to give a better understanding and characterisation of the binding  
pockets of HSA. 
 
5.4.  Multiple Ligand Binding 
 
Multi binding of ligands to albumin is dependent upon the affinity constant (Kf) of each 
ligand. The ligand with the greatest value of Kf will bind in preference to the others 
provided that they bind to the same site on the protein, the assumption being that both 
ligands will compete. However, if the ligands bind to different sites competitive binding is 
no longer a consideration, provided that one ligand does not alter or change the binding site 
of the other ligand; Table 5.2. gives some general information on the binding 
characteristics of some of the drugs studied. The use of ligands with known binding sites 
meant that it was possible to investigate and characterise drug and other ligands of 
unknown binding information based on the response and effect on known marker ligands. 
The presence of two or more strongly binding ligands produce competition at the binding 
site resulting in a higher concentration of free (unbound) drug, and a greater biological 
activity of both drugs then if the drugs were present individually (Perrin et al, 1973). 
Ligand Ka (in the absence 





Salicylic Acid 2.80 x 10-4 2.2 3.0 
Warfarin 21.0 x 10-4 1.2 5.1 
Diazepam 18.0 x 10-4 1.0 3.3 
Tryptophan 1.10 x 10-4 0.9 - 
Table 5.2.  The properties of some ligands investigated. 
 
With the relatively new X-ray crystallographic determination of the sub-chambers in site 
IIA, it has been found possible for each of the sub-chambers to bind independently making 








Figure 5.18.  The binding of three independent ligands in the  
sub-chambers of IIA. 
(Zue et al, J. of Structural Biol, Vol 162, Iss 1, 40-49, 2008) 
 
AZT is bound in one chamber and is represented in pale blue, indomethacin 
(Imn) is bound in another chamber and indicated as pale orange, and finally 
salicylic acid (Sal) is shown as pale red. 
 
5.4.i.  Diazepam : Warfarin Interaction with Albumin 
 
Warfarin binds to site IIA on HSA, while diazepam binds to site IIIA, therefore one would 
not expect these two ligands to compete but to coexist. Experiments such as equilibrium 
dialysis and fluorescence have shown that the binding of warfarin was not compromised in 
the presence of a constant amount of diazepam. What is surprising is that the binding of 
diazepam is somehow enhanced by the presence of warfarin (Kragh-Hansen, 1985); 
independent binding of the two ligands exists, but there appears to be some sort of 
coopertivity established when both drugs are present. 
 
5.4.ii.  Warfarin : Salicylate Interaction with Albumin 
 
Salicylate binds to domain IIA and IIIA on HSA in the absence of FA. It is therefore 
expected to see some sort of competitive interaction between salicylates and warfarin when 




also true for salicylate in the presence of warfarin. There is a mutual decrease in binding of 
one drug with respect to the other. From Table 5.2., it would be expected that because of 
the large difference in Ka between the two drugs with warfarin exhibiting a very much 
greater Ka than salicylates, warfarin would displace salicylates from its preferred site, that 
of site IIA if warfarin was added as the antagonist. Conversely, if the situation was 
reversed with salicylates now added as the antagonist, it would be expected for SA to bind 
to site IIIA only leaving site IIA occupied by warfarin, the stronger binding ligand. 
 
5.5  Experimental 
5.5.i.  Materials 
 
All the samples of albumin and the domain fractions were donated courtesy of Dr John 
Woodrow (Delta Biotechnology, Nottingham, UK). Purification was conducted by either 
dialysis using tubing with a molecular weight cut-off of 10,000 supplied by Delta 
Biotechnology, or by column chromatography. In the case of dialysis, the tubing was pre-
treated in a warm solution of 0.05% EDTA and 2% sodium bicarbonate (both at analytical 
grade supplied by BDH) and made up in distilled water, done to clean and degrease the 
tubing. The alternative method was to use column chromatography using Sephadex G 25m 
(PD-10) columns, (Code Number-17-0851-01, Lot Number SA 15390, supplied by 
Pharmacia). All samples of albumin were freeze-dried and stored in the refrigerator until 
use.  
 
The sample of warfarin used throughout this thesis was purchased from Sigma, UK, 
(Reference Number A-2250, Lot 16F0026). The diazepam (BN:811009, RO  5-2807) was 
a gift from Roche Products Ltd, Welwyn Garden City (Hertfordshire). SA, 5ISA and DIS 




Fluka Biochemika (UK), 99.99% purity. L-tryptophan and all the buffers used were bought 
from BDH (UK), analar grade to ensure the highest chemical and optical purity. 
 
5.5.ii.  Procedure 
 
Binding studies were conducted using a fixed concentration of the drug (concentration of 
1M equivalent) to varying concentrations of albumin, all made up in 10mM P/B. Samples 
of albumin was made up at 2x the required final concentration, with the drug concentration 
made up at 2 molar equivalent. These were referred to as the protein and drug stock 
solutions respectively. From the drug stock solution (2M≡), 500µl aliquot were measured 
using a calibrated Gilson pipettes and put into a series of containers. Into each container 
was placed a known aliquot from the albumin stock, and the remainder of the volume was 
made up with P/B so that the total volume added of the two components (P/D & albumin 
stock) was 500µl. This formed the titration series, each container containing 1M equivalent 
of the drug on final dilution but varying concentrations of albumin, all made up in P/B. 
Both CD and UV spectroscopy measurements were obtained of the titration series; for a 
few experiments the experimental conditions were reversed by now keeping the 
concentration of albumin fixed at 1M equivalent, the concentration of the drug was varied 
and compared with the other experimental data to see if there were any variations in the 
results of the titration curves; the final titration was conducted where a [1:1] molar 
equivalent of the drug and protein was titration with a 1M equivalent of drug, this ensured 
that the concentration of drug in the container remained fixed but the molar ratio 
equivalent varied as the addition of drug diluted the albumin concentration. 
 
pH measurements was conducted on a 3ml sample of the ligand:protein complex solution, 
diluted to the required P/D ratio in distilled water. The complex solution was divided into 




investigations. Using either 0.1M, 1M or 10M sodium hydroxide or hydrochloric acid (as 
pH adjusters), the pH was adjusted to the required value and the UV and CD were 
measured. The use of a range of pH adjusters meant that the volumes added would be 
small thus minimising dilution effects, the consequences of this meant that dilution factors 
did not have to be considered as they were within the realms of experimental error. At the 
end of the titration, both at low and high pH adjustments, the samples were readjusted to 
physiological conditions, and rechecked by UV and CD to determine if the adjustments at 
the extreme conditions were reversible. 
 
Finally temperature studies were conducted by three methods; the first method was to take 
a stock solution of albumin at 2x the required concentration and placed it into a water bath. 
The temperature of the water bath increased to a pre-determined temperature and the stock 
sample heated, once at equilibrium the temperature measured and a 500µl aliquot sample 
removed and cooled to RT. The water bath thermostat was then increased and the sample 
allowed equilibrate, once established a new 500µl sample was removed, cooled and stored 
for further investigation. This process was repeated until a series of preheated samples 
from RT to 90°C were obtained, each time 500µl aliquot was removed. Once all the 
samples were collected, to each was added 500µl of the 2 molar equivalent stock solution 
of the drug under investigation producing a [1:1] molar equivalent of protein:drug (P/D) 
sample. The samples were mixed and measured by UV and CD between the range of 
600nm – 240nm. 
 
A second method investigated the unfolding of a solution of the complex at known P/D 
ratio. The sample under investigation was put into a cuvette and placed into the 
thermostatically controlled holder in the CD spectrometer. A thermocouple was placed 
through the lid of the cuvette, immersed in the solution held in the neck of the cuvette.  




complex as a direct measurement was determined. The temperature of the water bath 
controlling the cell holder was adjusted to a required value, allowed to equilibrate, the 
temperature in the cuvette was recorded and the CD measured between 600nm – 240nm. 
The process of increasing the temperature by regular increments and recording the CD was 
repeated until the complete unfolding of the P/D complex was achieved and binding lost. 
 
The third method used to study heat denaturation was to investigate the systematic heating 
and quenching of a simple of the complex through temperatures cycling ranging from RT 
to 90°C. A sample of the complex was taken of known P/D ratio and placed into the 
thermostatically controlled CD spectrometer and the CD recorded. The temperature was 
increased, recorded, and the CD determined after a period of equilibration. The sample was 
allowed to cool down to RT and a further scan measured. The cooled sample was then 
reheated to a higher temperature, increased by a predetermined amount, allowed to 
equilibrate and once again recording its temperature and CD spectra. The sample was 
cooled to RT, its CD determined and the whole cycling process of heating and quenching 
repeated for temperatures up to 90°C, all data was compared. 
 
Some samples of the complex was studied after microcentrification. This involved the 
samples being filtered through a filter contained in an eppindorf tube while being 
centrifuged at a speed of 1500rpm for approximately 10 minutes, or until enough filtrate 
was collected that could be measured by UV. The amount of filtrate collected was only 
small, approximately 100µl, therefore a specially designed cell adapted by Dr A. F. Drake 






5.6.  Results of Warfarin Studies 
 
5.6.i.  Warfarin Binding 
 
The binding of warfarin was one of the first drugs to be considered as it binds to a single 
site on albumin (site IIA). The titration of a fixed concentration of the drug to varying 
concentrations of albumin was adopted and can be shown in Figure 5.19. It should be 
noted that the CD spectra of the racemic solution of warfarin was complicated by the 
apparent production of small but detectible CD signal produced by the racemic drug. It was 
expected that the racemic mix of the drug should produce a CD spectrum of zero through 
all wavelength regions in the absence of the protein. However, what was found was that 
the racemic mixture produced a CD maximum that corresponded to the absorbance 
maxima detected in the UV spectra. The binding of the racemic drug induced CD spectra 
that were characteristic of the association between the specific drug and the protein and can 
be used as a handle to monitor changes. The CD also reflected the environment of the drug 
while bound, and will produce a spectra characteristic to the product with distinct positive 
and/or negative maxima. Figure 5.19.a. highlights the apparent small positive CD detected 
found for the racemic warfarin in the absence of protein, shown to be a broad positive 
maximum expanding the wavelength range of 350 – 290nm; the consequence of the 
wasrfarin only CD was that it produced an offset when the fixed wavelength plot was 
plotted as shown in Figure 5.19.b. To normalise, the warfarin CD was subtracted from the 
data so that the results now pass through zero, this did not affect the overall trend observed 
merely the point of origin.  
 
The UV absorption of the warfarin titration is shown in Figure 5.19.c. and is found to have 
a maximum centred at 310nm with a shoulder around 290nm, further absorptions were 
detected at shorter wavelength but these overlapped with the very strong absorption 


































(HSA = 1.48X10-6M to 2.94x10-5M)
 Experimental Data at 310nm
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Figure 5.19.  Titration of a fixed concentration of Warfarin to rHSA, 5cm cell. 
 
a. The binding of Warfarin to rHSA for ratios between 1:0.1 to 1:2 in P/B, pH7.2, 5cm 
b. Fixed wavelength plot of warfarin binding to rHSA, P/B. 
c. UV Absorption Spectra of Warfarin:rHSA [1:0.1] to [1:2] equivalent, P/B, pH7.2, 5cm cell   
 
The CD of bound warfarin to albumin was found to contain a positive maximum at 310nm 
with a shoulder detected at 335nm, the samples were measured in a 5cm cell to compensate 
for its weak Cotton effects in the CD spectrum. The binding constant determined for this 





The conditions were altered to the warfarin binding titration such that a larger wavelength 
region was monitored with a view to monitor the large negative maximum detected at 
275nm, overlapping the backbone region and are shown in Figure 5.20. The fixed 
wavelength plots confirm a one to one drug to protein (D/P) relationship. 
 
 





































Figure 5.20.  Titration of a fixed concentration of Warfarin to rHSA, 
1cm cell. 
 
Under the conditions studied in the 1cm cell, the binding constants determined by the fixed 
wavelength plot revealed for wavelengths 335nm & 312nm values of Ka 5 x 10-6M-1 
(Figure 5.21.). It was reassuring to find that the titration in both the 1cm and 5cm cell gave 
identical Ka values. However, at the wavelength 275nm which lies directly under the 




wavelengths. There appeared to be two transitions evident with the second transition not 
quite obtaining completion for a P/D ratio of [1:1]. 





















Figure 5.21.  Fixed wavelength plot of the 
titration of a fixed concentration of 
Warfarin (7.46 x 10-5M) to rHSA, 
P/B, 1cm cell. 
 
 
5.6.ii.  Warfarin pH Studies. 
 
The P/D ratio of a [1:1] molar ratio equivalent solution of warfarin/rHSA was investigated 
with changing pH for the three wavelength regions highlighted previously (335nm, 312nm 
& 275nm). The pH transformations observed in rHSA revealed complex transitions in 
response to changing pH, with the result that rHSA, on binding to warfarin, produced 
transitions that overlapped the aromatic region of the protein alone (Figure 5.22.). 
Depending on the wavelength investigated, either two or three transitions were observed. 
At 255nm two transitions were seen, and at 287nm three transitions were observed, the 











































































Figure 5.22.  pH Titration of a [1:1] molar equivalent of warfarin:rHSA. 
 
A. CD Spectra of the pH titration of warfarin:rHSA, [1:1] in H2O, 1cm cell. 
B. UV Spectra of the pH titration. 








The pH titration revealed that the association of the drug to the protein only existed when 
the pH was not in the extreme regions of the range; otherwise binding was lost once the 
protein was in the extended form or in the aged form. 
 
pK at 255nm 
Aromatic for 
rHSA only 
pK at 287nm 
Aromatic for 
rHSA only 
pK at 312nm 
Warfarin:rHS
A 
pK at 335nm 
Warfarin:rHS
A 
pK at 275nm 
Warfarin 
1st 2nd 1st 2nd 3rd 1st 2nd 1st 2nd 1st 2nd 3rd 
4.0 11.5 3.5 6.1 11.7 5.2 10.6 5.2 11.2 4.3 9.7 12.1 
 
Table 5.3.  pK values of the transitions of Warf:rHSA complex of ratio [1:1]. 
 
Comparisons of the pK values between bound warfarin to albumin and albumin only 
revealed that although tree transitions were seen they were not necessarily in the same 
region. Once again it was the transitions at wavelength 275nm that highlight the multiple 
steps involving an intermediate transition with a pK 9.7, not seen in the aromatic residues 
of the protein nor in the secondary structure of the backbone (refer to Table 4.0 in Chapter 
4). The first transition observed at wavelengths 312nm & 335nm reflected the second 
transition detected in the backbone of the protein only, suggesting that it could be possible 
changes in the secondary structure of albumin that affected subdomain IIA at this pH.  At 
wavelength 275nm the changes monitored here possibly reflect the changes in the 
aromatics residues of the protein, occurring at a lower pK value, but not as low as the first 
transition in the backbone region of the protein that occurred around pK 3.0 and below. 
 
The final pH experiment conducted in this series was to microcentrifuge all the pH 
adjusted samples of the 1 molar equivalent Warf:rHSA complex to see if it was possible to 
determine the free unbound drug , the results are shown in Figure 5.23. The experiment 
highlighted four regions of transition with pK’s of 4.1, 5.4, 7.1 & 8.6. For a [1:1] molar 
ratio equivalent solution of the complex two pH regions were isolated where maximum 




the highest quantity of free warfarin was found at pH7 with approximately 75% of the drug 
bound and 25% free. Conversely, at pH 4,8 and at pH 8 were found the highest amounts of 
bound drug with only trace amounts being found unbound in solution.  
 























 Experimental Data at 322nm




Figure 5.23.  Microcentrifuged samples of the pH 
titration of a [1:1] molar ratio equivalent 
of Warf:rHSA, 1cm cell. 
 
The filtration through micro-eppingdorf filter tubes proved in this instance to be an 
effective way in determining the amount of free drug presents, highlighting the 
conformational stability of albumin in response to pH and in the presence of a drug.  
 
5.6.iii.  Warfarin Temperature Studies. 
 
The binding pocket of albumin to warfarin was investigated further with the response of 
the complex to temperature. On heating the warfarin complex revealed a continuous and 
increased dissociation of the drug with increasing temperature, with the loss of binding that 
appeared to occur in one transition as shown in Figure 5.24.a.. The dissociation of the drug 
was initiated by the onset of heating, occurring at temperatures where albumin in isolation 




movement and separation of domain I & II exposes IIA to such a degree that the pocket 
moves closer to the surface of the molecule, making it more accessible to local 
environmental changes. Heating causes further exposure and denaturation of the site 
producing greater deleterious effects. For temperatures exceeding 70°C the binding of 
warfarin was totally lost, supporting the theory that domain II becomes totally denatured at 
these temperatures. The transition temperature for the Warf:rHSA complex was found to 
be 46˚C, and showed the relative instability of the complex towards heating, but was 
higher than the first tm detected for rHSA which was found to be at 40˚C. The value of 
K=10 x 10-3 and was found to be lower than that for rHSA alone. 
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a.   Temperature Studies of Warfarin:rHSA, [1:1] Molar equivalent,













Warfarin, 2.16 x 10
-5
M, 312nm
b.    Spectroscopic Studies of the incubated samples of rHSA,
             added to Warfarin to make a [1:1] molar equivalent














Preheating the albumin samples prior to binding reflected the conformational changes that 
resulted within albumin and revealed that functionality of binding site IIA after heat was 
applied. As expected preheating albumin to 60°C revealed no instability of the binding site, 
the drug was still fully bound to the protein at this point. For temperatures between          
60 - 65°C revealed a slight loss of binding (Figure 5.24.b.). For the temperatures of       
65°C – 75°C binding of warfarin was dramatically affected with a cascade in the loss of 
the drug. The pre-incubated temperature studies highlighted the true loss in binding of 
warfarin occurring at temperatures exceeding 63°C that reflected the denaturation 
temperature of albumin only. Once albumin was denatured, binding was rapidly lost 
supporting that fact that site IIA was rapidly exposed on heating and de-shielded from 
domain I. The tm was determined to be 69.0˚C and the value for K = 28 x 10-3 determined 
for the binding pocket of IIA, lower than that determined for the second transition in rHSA 
only that was found to be K = 45 x 10-3. From the results it would appear that subdomain 
IIA denatures between the first and second transition of albumin, supporting the fact of the 
fragility of IIA.  
 
Cycling the temperature between heating and quenching, measuring at each temperature 
change the CD spectra of the heated and quenched samples reflected the culmination of the 
previous two heating methods studied and is shown in Figure 5.24. The sequential heating 
and subsequent quenching of a [1:1] molar ratio equivalent of the complex of warf: rHSA 
is represented in Figure 5.25., and reflected the intolerance to direct heating of the 
complex. However, quenching the sample highlighted some re-association of the drug, re-
establishing the complex but never to the same degree as that detected before heating (or 
that that was found for the pre-incubated samples heated to 60°C). The greatest loss in 




both heating and quenching. The results of the last temperature cycling experiment 
revealed the combination of the previous two experiments that detected the fragility of the 
binding of warfarin in the presence of heat (Figure 5.25.) with a transition observed at RT, 
this was supported in the results of the quenching curve that showed the loss of immediate 
binding once heated. Both the second transition of the heating curve and the first transition 
of the quenching curve gave very similar values for tm, and the same value for K. The 
second transition for the quenching curve showed the decomposition of IIA. 
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Figure 5.25.  Heating and quenching studies of warfarin:rHSA. 
 
The [1:1] warfarin:rHSA heated samples were spun in a microcentrifuge in special 
eppingdorfs containing micro-filters, this allowed only the free drug solution to pass 
through. Figure 5.26.a. shows the results of the filtrate obtained after spinning and revealed 




albeit very small. The fixed wavelength plot (Figure 5.26.b.) suggests a gradual loss in 
binding up to a temperature of 60oC. By 63oC an extensive loss in binding is seen with the 
continued loss reaching a maximum by 76oC. 
 


















a.   Microcentrifuged samples of the temperature investigation

































b.  Fixed wavelength plot of the heat denaturation of a [1:1] molar equivalent of 













Figure 5.26.  Microcentrifuged samples of the temperature study 
of Warfarin:rHSA 
 
5.6.iv.  Denaturation Studies of the Warfarin Complex 
 
Denaturation studies were carried out using urea and GuHCl, the results are shown in 
Figure 5.27. The addition of small quantities of GuHCl (0.2M) causes an inversion of the 




a mirror image (Figure 5.27.a.), and seems to be indicative of the S-enantiomer of warfarin 
binding. The negative maximum appears to be unchanged and suggests that binding for the 
other enantiomer may be preferred (note, the addition of any denaturants will have its own 
associated absorption in addition to those of the drug and protein, this makes it difficult to 
scan to shorter wavelengths). Subsequent additions of GuHCL resulted in the eventual 
reduction and then loss of the drug binding. The fixed wavelength plot in Figure 5.27.b. 
reflects the flip and subsequent loss in binding with total loss achieved by 4M; the use of 
GuHCL may be a way of enantiomeric selectivity, selecting one of the enatiomers from the 
racemic mixture of warfarin. GuHCL produced a two step deformation curve with the 
generation of an intermediate product that showed relative stability. 
 
The effect of urea, however, was not as dramatic for the initial additions as was seen for 
GuHCL. The addition of 1M urea produced an initial loss in binding of 22.2% at 
wavelength 312nm, that then appeared to stabilize for subsequent additions up to 2.8M 
ratio equivalent of urea. The main loss in binding occurred between 2.8-3M ratio 
equivalent as shown in Figure 5.27.c. & d. The loss in binding was quite specific with the 
initial loss then the subsequent stabilization of the complex between 1M and 2.8M 
equivalent. It appeared that urea exhibits a threshold producing an all or nothing binding 
situation,  
 
Microcentrifugation of the denatured samples showed the loss of drug binding. The results 
obtained in the GuHCL revealed the sequential loss in binding of warfarin that reflected 
the increase absorption detected due to the increased displacement of free drug found in the 
filtrate. The transition appears to be a two state process with an intermediate state observed 
between 2M – 4M (Figure 5.27.f.). What is evident is that although complete loss of 
binding appears to occur at 4M, the micro-centrifugated samples revealed that only 60% of 




the micro-centrifuged samples show complete displacement of the bound drug. A similar 
effect was also seen in the micro-centrifuged samples of the urea samples, where it was 
expected to see maximum displacement of the drug at 3M, but this was not complete until 
8M of urea was added (Figure 5.27.e). 
















































































Warfarin Concentration 7.46 x 10-5M
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Figure 5.27.   Denaturation of a [1:1] molar ratio equivalent of warf:rHSA. 
 
A   Titration of a [1:1] molar warfarin:rHSA in H2O with increasing GuHCl, 1cm cell 
B   Titration of GuHCl with a [1:1] molar ratio equivalent of Warfarin:rHSA in H2O, 1cm 
C   Titration of a [1:1] molar ratio of warfarin:rHSA in H2O with increasing urea concentration, 1cm 
D   Titration of urea with a [1:1] molar ratio of warfarin:rHSA in H2O, 1cm 
E   Micro-centtrifuged samples of a [1:1] molar ratio warfarin:rHSA in varying amounts of urea, 1cm  




5.7.  Result of Diazepam Studies 
5.7.i.  Diazepam Binding 
 
The binding of diazepam was the second drug to be considered, and as previously stated 
has its predominant binding site located within domain IIIA. To determine whether the 
relationship between diazepam and albumin was [1:1], a titration was conducted at fixed 
concentration of the drug to a molar equivalent excess of albumin. To ensure consistency 
throughout all the forms of albumin (nHSA, dHSA and rHSA), the titration was performed 
in all and was found to have no significant difference. Figure 5.28. shows the results of one 
such titration that contains a CD profile with a negative peak located at 320nm, and two 
positive maxima at 286nm and 260nm. A well-defined and established isosbestic point was 
located at 298nm indicative of a two state system state in equilibrium, as shown in Figure 
5.28.a. The absorption spectra of the complex was dominated by albumin absorption, thus 
limited the effective wavelength range that could be scanned (see Figure 5.28.b.). 
 













HSA = 2.11 x 10-6M  to 5.27 x 10-5M


























Figure 5.28.  CD and UV spectra of the titration of diazepam and HSA. 
 
A  Titration of a fixed concentration of diazepam to rHSA in 10mM P/B, pH7.2, 1cm cell 




Mathematically fitting the data derived from the titration (Mathcad software) produced a 
[1:1] relationship with a very strong binding constant, Ka = 8 x 107, this is shown in Figure 
5.28.c. 
  
Figure 5.28.c.  Mathcad fit of the titration of Diaz:rHSA  
Diaz = 5.27 x 10-5M 
 
Filtering the titrated samples of the Diaz:rHSA complex to determine the free drug 
revealed that the samples with the lowest D/P ratio gave the largest amount of detectable 
free drug as would be expected (Figure 5.29.). Even though complete binding was 
achieved by [1:1] molar ratio equivalent, the fixed wavelength plot highlighted a continued 
loss in free drug up to a ratio of [1:2]. The continued loss in absorption between the [1:1] 
and [1:2] was significant, highlighting the fact that binding continued.  
 



































HSA = 2.10 x 10-6 to 2.11 x 10-4M












Figure 5.29.  Determination of free diazepam by microfiltration of the Warf:rHSA complex. 
 
A   Micro-centifuged samples of the titration of Diaz:rHSA 




5.7.ii.  Diazepam pH Studies. 
 
The titration of the diazepam:rHSA complex (Diaz:rHSA) was investigated with changing 
pH, the results revealed that the pH perturbations mimicked those for HSA alone when 
monitored in the aromatic region where diazepam absorbs. Like rHSA alone, the 
Diaz:rHSA complex also showed three transitions throughout the whole range of the pH 
titration with a region of relative stability between pH8.5 10.5, Figure 5.30 highlights these 
findings. The CD spectra showed no spectral shifts or any compromising of its profile; the 
isosbestic point is maintained depicting the existence of two species in equilibrium. The 
dissociation of the drug was monitored as a collapse of the spectra indicating that both 
species were affected in the same way and by the same degree. What was also evident was 
that all the pK's were shifted by a significant amount, displaced to higher pH as shown in 
Table 5.4. It is possible that the presence of the bound diazepam stabilised the 
conformation of rHSA making it more resistant to pH perturbation. The pH titration 
revealed that the complex was more susceptible to low pH alterations than it was to high 
pH, losing binding by pH3 when the protein is in its extended form. Maximum binding 
was achieved when the protein was in the transition at pH5-6. 



































































Figure 5.30.  pH perturbations of Diaz:rHSA complex. 
 
A  The pH titration of a [1:1] molar ratio equivalent sample of Diaz:rHSA, 1cm cell 





λ (nm) pK1 pK2 pK3 λ (nm) pK1 pK2 pK3 
    320 4.2 8.0 12.1 
287 3.5 6.1 11.7 286 4.3 7.6 12.1 
255 4.0  11.5 260 4.6 7.4 11.8 
 
Table 5.4.  Comparison of the pK values for rHSA &Diaz:rHSA complex. 
 
Using the pH values isolated for the different forms of albumin conformations within the 
protein itself, diazepam binding was conducted at pH3.56, pH4.56, pH6.0 and pH 8.0 that 
represented the extended-form, the fast-form, the neutral-form and the aged form 
respectively. The results are drawn in Figure 5.31 with only the CD spectra shown for the 
pH titration at pH3.56 which could only be determined for the negative maxima. The fixed 
wavelength plots for the various pH’s investigated are shown in Table 5.5. 




























































































Figure 5.31.  Binding studies of Diaz:rHSA at different pH values. 
 
A  Fixed wavelength plot of the titration of Diaz:rHSA in 10mM B/R, pH4.56, 1cm 
B  Fixed wavelength plot of the titration of Diaz:rHSA in 10mM P/B, pH6.0, 1cm 
C  Fixed wavelength plot of the titration of Diaz:Rhsa, 10mM Tris buffer, pH8.0, 1cm 
D  Fixed wavelength plot of the titration of Diaz:rHSA in 10mM B/R, pH3.56, 1cm 





The CD profiles for the complexes of Daiz:rHSA studied at the various pH values were all similar except for the titration made at pH3.56 that 













λ (nm) K (M-1) λ (nm) K (M-1) λ (nm) K (M-1) λ (nm) K (M-1) 
320 1.8 X 105 320 0.8 X 106 320 1.8 X 108 320 1.8 X 105 λ (nm) K (M-1) 
286 1.8 X 105 286 0.8 X 106 286 1.8 X 108 286 1.8 X 105 320 2.0 X 105 
260 1.8 X 105 260 0.8 X 106 260 1.8 X 108 260 2.5 X 105 
Table 5.5.  Comparison of the values of the binding constants for Diaz:rHSA complex at different pH values. 
 
 
The binding titrations proved that although K at pH6.0 was high, the greatest binding constant was determined at pH7 when the protein was in its 





At all the pH values selected and studied, binding of diazepam occurred at varying 
amounts with albumin binding to the drug in the extended form of the protein being the 
most problematic. At pH3.56 albumin is in the extended form and produces binding with a 
ratio higher than the expected [D/P] ratio. Binding was not observed for a [D/P] molar ratio 
equivalent lower than 2M equivalent, with complete binding found at 5M equivalent 
(Figure 5.31.d.). In the extended form, it is thought that albumin offloads any bound 
ligands. However, it was found that in the extended form more diazepam ligands bind, 
suggesting more low affinity sites are created with a binding constant of 2.0 x 105M-1. For 
pH4.55, albumin is in the fast form and binds with a [1:1] molar ratio equivalent detected 
at wavelengths 320nm and 286nm, but for the wavelength 260nm, which also lies under 
the aromatic region of the protein, binding seemed incomplete. As previously stated the 
existence of two species is depicted by the isosbestic point, and perhaps the second species 
is to be found at the wavelength of 260nm. Binding constants at all wavelengths for this 
pH was determined at 1.8 X 105M-1, lower than that found at physiological conditions. 
 
For pH6.0, the same criteria that existed for pH4.56 also existed at this pH with a binding 
constant determined at 0.8 X 106M-1, this was found to be an order of magnitude greater 
than that found at the lower pH, and showed that by moving closer towards physiological 
conditions the maximum affinity of diazepam for albumin was achieved. Under 
physiological conditions, the binding constant was determined to be 1.8 X 108M-1, the 
highest determined for the binding of diazepam. However, changing the pH to pH8.0 
decreased the binding affinity producing a binding constant of 1.8 X 105 M-1, decreasing it 
by an order of magnitude. Unlike warfarin, diazepam is affected by the base form of 
albumin that shows reduced binding. What is evident is that the site for diazepam binding 
reflects the conformational state of albumin, by its binding affinity it may be able to 





5.7.iii.  Diazepam Temperature Studies. 
 
Temperature investigations was conducted on the [1:1] molar ratio equivalent of 
Diaz:rHSA in two ways, the first was the sequential heating and quenching of the samples, 
scanning between each temperature increment and cooling once equilibrium was attained. 
The results can be found in Figure 5.32. 
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 Experimental Data, Heated Samples
 Experimental Data, Quenched Samples
 
 
Figure 5.32.  Temperature studies of Diaz:rHSA by sequential heating and  
quenching studies. 
 
A  Melting studies of a [1:1] molar ratio equivalent of Diaz:rHSA in 10mM P/B, pH7.2, 1cm cell 
B  Quenching studies of the [1:1] molar ratio equivalent of Diaz:rHSA in 10mM P/B, pH7.2, 1cm cell 





The heating curve shows the stability of the complex for temperatures up to 40oC. 
Thereafter, there was a dramatic loss in binding spanning a 15oC range with almost 
complete dissociation attained by 60oC. The quenching curve almost mirrored the results 
seen in the melting curve; a small displacement was seen that suggested that a small but 
well defined recovery in structure of albumin was found that was sufficient to offer 
increased association of the drug towards the protein. Dissociation occurred at relatively 
low temperatures and was quite distinct from the dissociation seen for domain IIA in 
warfarin binding that covered a much broader temperature range (Figure 5.25.). Domain 
IIIA appears to be less resilient to temperature perturbations when compared to domain 
IIA, where domain IIIA seems to be affected by the onset of heating with re-association 
shown in the quenching curve to be minimal at low temperature. Initial observations show 
the dissociation of diazepam to site IIIA occurring between 50-60˚C, whereas in the case 
of warfarin binding to site IIA, dissociation occurred between 60-70˚C. 
 
There were two transitions seen in both the heating and quenching curves that seemed to 
follow reverse paths in terms of K. In the heating curve the first transition was observed at 
a tm=51.0˚C with K1=30 x 103 (Figure 5.32.c.). The second transition lies very close to the 
first and is found at tm 54.0˚C and a much higher value for K2=80 X 103. Conversely, in the 
quenching curve, although exhibiting two transitions, its first was detected at a tm 54.0˚C 
overlapping with that found for the second transition of the heating curve, and that may 
explain the high value for K. The second transition of the quenching curve was determined 
with a tm 60.5˚C with K2=35 X 103.  
 
The second temperature investigation was undertaken by using pre-heated samples of 
albumin creating partial intermediates binding was carried out at room temperature and the 




for similarities. At all the wavelengths studied, the results showed a relative stability of 
drug association to the protein for temperatures up to 48C. As with the heating and 
quenching studies, temperatures above 48˚C revealed a rapid loss in association of the drug 
towards the protein, with complete loss experienced by 60˚C. All wavelengths coalesce at 
60˚C with each wavelength showing two transitions. The first transition was observed with 
a tm = 50˚C that differed by 1˚C between the wavelengths, all values of K1=40 x 103. The 
second transition was equally as close with a tm = 55˚C, but this time only two of the three 
wavelengths studied produce identical values of K = 90 x 103, the third wavelength 
produced a value for K = 80 x 103, lower than for the other wavelengths. Here there is a 
difference between the negative CD maximum and the positive CD maxima at the point 
where the isosbestic point is found, this may be indicative of the relationship between the 
two species that are closely related but showing subtle differences.  
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Figure 5.33.  The binding of diazepam to pre-heated samples of rHSA. 
 
Fixed wavelength plot of the temperature studies of a [1:1]molar ratio of  Diaz:rHSA in 





5.7.iv.  Diazepam Denaturation Studies. 
 
The last determination to be considered in this series of investigation was the denaturing 
effects of urea and GuHCl on a D/P ratio equivalent of [1:1] for the Diaz:rHSA complex, 
the results are shown in Figure 5.34 & 5.35. The end results for the two denaturants were 
the same on the complex producing dissociation with the collapse of the CD signal, but the 
means to which the end points were obtained was different. Considering the urea titration 
first, for addition up to 3M equivalent produced a relatively small but gradual loss in 
binding of diazepam. Within the defined region of 3M – 4M equivalent produced the 
dramatic loss in binding experienced by the protein with only a small association of the 
drug at this molarity (Figure 5.34.b.). The microcentrifuged samples revealed an increase 
in association of diazepam towards albumin for small additions of urea. For molar ratio 
equivalent of urea greater than 1M, successive loss of association was seen with the 
increase of free diazepam detected (Figure 5.34.d.). In the absence of ligand albumin 
unfolds in one step in urea with the midpoint of the transition found around 5M equivalent. 
The presence of diazepam ensures that complete binding was lost by the time the midpoint 
of the conformational change for albumin occurs. 
 
The effect of GuHCl denaturation reflected a somewhat different picture than that shown 
for urea which produced a sigmoid relationship. The addition of GuHCl produced a steady 
loss in the association of the D/P complex with no real trend observed even though GuHCl 
in albumin only produces an intermediate conformational state. It is clear that this 
intermediate conformational state that was formed has no bearing on the activity of 



























































































Figure 5.34.  Denaturation studies of a [1:1] molar equivalent of Diaz:rHSA in urea. 
 
A  CD Titration of a [1:1] molar ratio equivalent of Diaz:rHSA in Urea, 1cm cell 
B  Fixed wavelength plot of Diaz:rHSA in Urea 
C  Microcentrifuged samples of a [1:1] molar ratio equivalent of Diaz:rHSA in the presence of Urea, 1cm  
















































































Figure 5.35.  Denaturation studies of a [1:1] molar equivalent of Diaz:rHSA in 
GuHCl 
 
A  GuHCl binding to a [1:1] molar ratio equivalent of Diaz:rHSA in H2O, 1cm cell 
B  Fixed wavelength plot of Diaz:rHSA in GuHCl 
C  Micro-centifuged samples of a [1:1] molar ratio equivalent of Diaz:rHSA in GuHCl, 1cm cell 





5.8.. Result of the Studies of Salicylic Acid and its Derivatives 
5.8.i.a.  Salicylic Acid Binding 
 
Salicylic acid (SA) and its derivatives were studied in much the same way as warfarin and 
diazepam, looking for variations in environmental changes to distinguish between binding 
sites. SA, known to bind to both domain IIA and IIIA would give a good indication of the 
kinds of conditions that may affect either or both of the sites. Salicylic acid was the last in 
this group of drugs to be studied, the simplest of the trio of salicylates and can be 
considered as the parent compound since the other two derive from its structure. The main 
absorption of this drug was found at 295nm also reflected in the CD spectra as shown in 
Figure 5.36. SA has a single positive CD maximum centred on its absorption maximum at 
295nm with the possibility of a second transition peak, a negative peak at 265nm which 
belongs to a secondary absorption that underlies the main absorption. The evidence of this 
was also confirmed in the absorption spectra where there seemed to be the resemblance of 
an isosbestic point located at around 325nm. There was also evidence of spectral shifts in 
the absorption maxima at the higher [D/P] ratios, with evidence of interference in the CD 
spectra also at high molar equivalent concentration. 
 
A D/P ratio equivalent for [SA:rHSA] was found to be [2:1]. The absorption spectra of the 
drug was found to have two main absorption bands (Figure 5.37.a.), one at 295nm and the 
other at 230nm that would be masked in the titration by the protein backbone. The fixed 
wavelength plot of the drug titration was found to produce consistent increases in CD 
maxima for every additional increase for ratios up to and including 1M equivalent. The 
increase however, for the additions of 1M – 2M equivalent only produced a small increase 

























rHSA= 2.31 X 10-5 to 4.62 x 10-4M








































Figure 5.36.  The binding of SA to rHSA. 
 
A  Titration of SA with rHSA in 10mM P/B, pH7.2, 1cm cell 
B  Absorption Spectra of the titration 
C  Fixed wavelength plot of SA with rHSA in 10mM P/B, pH7.2, 1cm  
 
All the samples measured in the binding studies were filtered and the UV spectra measured 
to determine the amount of free drug, if any was present. The filter removed all the 
albumin molecules in the sample and the results can be seen in Figure 5.37. The fixed 
wavelength plot reflected the results seen in the titration in that there was a consistent loss 
of free drug for molar ratio equivalent up to [1:1], for concentrations exceeding that ratio 




that binding continued up to 2M equivalent of the protein. 
 














































Figure 5.37.  Micro-centrifuged samples of the titration of SA:rHSA. 
 
A  Absorbtion spectra of the micro-centrifuged samples of SA with rHSA, 1cm cell 
B  Fixed wavelength plot of the micro-centrifuged samples of SA:rHSA in 10mM P/B, 
     pH7.2, 1cm cell 
 
5.8.i.b.  Salicylic Acid Temperature Studies 
 
Temperature studies were conducted on the [2:1] molar ratio equivalent of the complex of 
[SA:rHSA] in response to the pre-heating of albumin samples prior to drug binding at 
room temperature. The binding revealed as expected full binding of the drug to the pre-
heated samples of albumin for temperatures up to 52˚C, indicative of the temperature 
effects observed for diazepam. Once again there was a dramatic loss in binding between 
temperatures of 52oC - 60oC as demonstrated in Figure 5.38.a. Pre-heating the albumin 
samples brought about some structural changes within albumin that resulted in the negative 
peak at 265nm, not previously distinguished, now forming a prominent feature. At both the 
wavelengths studied two transitions were observed with tm temperatures that varied no 
more that 2˚C. The first transition revealed a tm = 52˚C & 54˚C for wavelengths 295nm & 




transition equally reflected similar results and proved that the conformational species 
detected at 265nm was much more unstable than that detected at 295nm. 
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Figure 5.38.  Temperature studies of SA:rHSA. 
 
A  Fixed wavelength plot of pre-heated rHSA samples added to SA, [2:1], 1cm 
B  Fixed wavelength plot of the microcentifuged samples of pre-heated rHSA bound to SA, 1cm  
 
 
Analysing the micro-centrifuged samples of the pre-heated samples revealed a similar 
response to that found when measuring by CD (Figure 5.38.b.). Minimal amounts of 
unbound drug was found for temperatures up to 45°C, thereafter an increase in displaced 
drug was detected as the protein became more denatured. Two transitional states were 
detected that were almost identical to that found by CD analysis proving that the two 
techniques were monitoring the same changes. 
 
5.8.i.c.   Salicylic Acid Denaturation Studies 
 
In keeping with the studies carried out on the other drugs the effects of denaturants were 
investigated with the [SA:rHSA] complex ([2:1]) and the results can be found in Figure 




in the gradual displacement of the bound drug with the greatest loss seen between 2M – 
3M equivalent. There was still a relatively high degree of association between the drug and 
the protein at these concentrations of urea. Additions between 3M – 3.2M equivalent 
revealed the greatest degree of dissociation where most of the drug was now in the free 
form (Figure 5.39.a.). When the samples were micro-centrifuged and the amount of free 
drug determined in the samples highlighted, the gradual loss in association over the entire 
range monitored was observed (Figure 5.39.b.). The dramatic loss seen by CD between the 
ratio of 3M – 3.2M equivalent was not evident in the filtered samples. 
 
The effects of GuHCl were more profound showing the general differences monitored at 
the two wavelengths. A 295nm the CD revealed that for a small amount of GuHCL of 
0.5M equivalent produced a stabilizing effect where no loss of binding was seem. For 
additions greater than that, a general loss in binding was detected up until 3M equivalent 
where total binding was lost. At 265nm up to 1M equivalent of GuHCL produced an 
inversion of the CD signal from negative to positive of almost equal magnitude. Further 
additions of GuHCL resulted in the gradual loss in CD back to the negative value of equal 
value to the value determined at the start (Figure 5.39.c.). The microcentrifuged samples of 






















































































Figure 5.39. The effect of denaturants on the SA:rHSA complex. 
 
A  Titration of a [2:1] molar equivalent of SA:rHSA in increasing concentrations of Urea, 1cm cell 
B  Fixed wavelength plot of the micro-centrifuged samples of SA:rHSA in Urea, 1cm cell 
C  Titration of a [2:1] molar equivalent of SA:rHSA in increasing concentrations of GuHCl, 1cm cell 










The titration of 5-iodosalicylic acid (5ISA) was conducted and compared with the results 
obtained from SA. Initially the pH titration of the 5ISA was conducted in water in the 
absence of protein and its spectral shifts observed. The absorption spectra was dominated 
by a single peak found at 300nm, shifted by 5nm to longer wavelength, with a second 
absorption found at lower wavelength too large to be investigated under these conditions 
(Figure 5.40.). 

































Figure 5.40.  pH titration of 5ISA in H2O. 
 
Absorbance spectra of the pH titration of 5ISA, 4.73 x 10-4M-1 in H2O, 1cm cell 
 
The titration of 5ISA with rHSA was conducted, determining the binding characteristics by 




parent drug with the existence of two positive CD maxima found at 300nm and 320nm, but 
in this case the two peaks were well defined and separated. The addition of the iodine atom 
to SA produces a shift of one of the CD maxima by 20nm to 320nm, with the other 
maximum remaining around 300nm. As with SA, 2M equivalent of 5ISA was titrated 
against varying concentrations of albumin until a [2:1] molar ratio equivalent was 
measured (Figure 5.41.a.). The fixed wavelength plot of the titration revealed complete 
binding by [2:1] molar ratio equivalent (Figure 5.41.b.). The UV spectra shows shifts in the 
maximum absorption at 300nm with the resemblance of an isosbestic point at 
approximately 290nm, indicative of several species in equilibrium. 




































































Figure 5.41.  Titration of 5ISA with rHSA in P/B. 
 
A  Titration of 5ISA:rHSA in 10mM P/B, pH7.2, 1cm cell 
B  Fixed wavelength plot of the titration of 5ISA:rHSA 
C  Difference absorbance spectra of the titration of 5ISA:rHSA in 10mM P/B, 1cm cell 





The micro-centrifuged sample analysis for the titration of 5ISA:rHSA in P/B is shown in 
Figure 5.42.a. The main absorption is located at 320nm and shows for low level of rHSA 
the highest absorption of 5ISA was detected. As the titration progressed, the amount of 
detectable free ligand decreased until a minimum value was measured. The fixed 
wavelength plot shown in Figure 5.42.b. indicates the rapid decrease in the free ligand. By 
the time the titration reached a D/P ratio equivalent of [1:0.5] complete binding was 
detected indicative of a [2:1] molar ratio equivalent. An anomaly was seen centred around 
a ratio of [1:0.25], this could be the point where the first ligand has completely bound and 
the second ligand starts to bind.  
 





































Figure 5.42.  Microcentrifuged samples of 5ISA with rHSA in P/B. 
 
A  Microcentrifuged samples of the titration of 5ISA:rHSA in 10mM P/B, pH7.2, 1cm cell 







5.8.ii.b.  5-Iodosalicylic acid Temperature Studies 
 
Temperature studies were conducted on a [2:1] molar ratio equivalent by the method of 
sequential heating and quenching, the results of the fixed wavelength plot are shown in 
Figure 5.43. The heating curves are characterised by two transitions with the different 
wavelengths reflecting different findings. Like the parent compound, 5ISA showed a 
certain amount of stability towards heating with complete association of the ligand found 
up to temperatures of 50˚C. At around 60˚C the first transition was seen for both 
wavelengths with the same values of K = 35 X 103. The second transition for both 
wavelengths gave identical values in terms of tm = 70˚C and K = 90 X 103. The quenching 
studies revealed that by heating its effects caused internal rearrangement of the protein that 
enhanced binding for temperatures exceeding 40˚C and up to 65˚C. Above 65˚C produces 
a cascade effect with the dramatic loss of binding giving a tm = 70-72˚C. However, what 
was evident was that even after the protein had been heated to temperatures above 70C 
binding of 5ISA was still very evident with still a high degree of association of the ligand 
to the partially denatured protein. This response is atypically as it was expected that at such 
high temperatures binding would be totally lost. 5ISA is a relatively smaller molecule, 
when rHSA is heated and cooled back down to room temperature the binding 
pocket/pockets are sufficiently conserved that binding was still achievable. Conformational 
changes in the protein coupled with the small size of the ligand have ensured binding even 
at such high temperatures. It has been demonstrated that heating albumin does not result in 
the complete collapse of its structure and that some secondary structural elements remain 
intact resulting in the binding of 5ISA, reinforces the fact that albumin still maintains 
sufficient structural integrity to maintain binding. This finding also confirms the theory 
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Figure 5.43.  Heat denaturation studies of 5ISA:rHSA complex. 
 
Fixed wavelength plot of the temperature cycling of a [2:1] molar ratio equivalent of 
5ISA:rHSAin 10mM P/B, pH7.2,1cm cell 
 
5.8.ii.c.  5-Iodosalicylic acid Denaturation Studies 
 
Denaturation studies were conducted on 5ISA:rHSA [2:1] using urea as the first 
denaturant, the results are shown in Figure 5.44. As has been previously observed the 
addition of a small amount of urea (1M) can cause conformational changes beneficial to 
the binding of the ligand, all wavelengths studied reveal this positive enhancement to 
varying degrees. A further addition of 1M causes an increased affinity in the D/L 
association, and the inversion of the 270nm maximum from negative to positive was also 
observed (Figure 5.44.b.). Further additions of urea produced reduced binding of 5ISA 

















































Figure 5.44.  The denaturation of 5ISA:rHSA using urea. 
 
A  Titration of a[2:1] molar equivalent of 5ISA:rHSA with Urea in H2O, 1cm  
B  Fixed wavelength plot of the urea titration of 5ISA:rHSA in H2O, 1cm cell 
 
The micro-centrifuged samples of the urea induced denaturation are shown in Figure 5.45. 
The initial addition of up to 2M of urea produces an increase association of ligand to 
protein and supports the findings in the titration data. There is a steady loss detected in 
association up to a concentration of 3.5M where complete dissociation is achieved.  













































Figure 5.45.  Absorption spectra of the microcentifuged samples of 5ISA:rHSA. 
 
A  Microcentrifuged samples of the [2:1] 5ISA:rHSA samples in urea, 1cm cell 









I I  
pKa ~ 7 
 
3,5 Diiodosalicylic acid (DIS) was extensively studied as the ligand that binds to two sites 
and used to represent the salicylate binding group as a whole. The substitution of iodine 
groups at positions 3 & 5 alters significantly the CD signal detected. The addition of iodine 
(one molecule in 5ISA and two molecules in DIS) produces two CD positive maxima at 
300nm and 320nm. The absorption spectra associated with DIS in an aqueous solution 
(Figure 5.46.a.) produced an absorption maximum at 320nm with further absorptions at 
shorter wavelengths produced as a response to high pH conditions. The pH titration of the 
free drug in water produced a uniform response to pH changes at wavelength 320nm with 
one transition found at a pK=2.1. There was a shift in the absorption maximum detected at 
the extreme pH regions to produce a second absorption peak at 345nm. At the wavelength 
of 345nm two constants were revealed, one at pK=1.7 and the other at pK=11.5 as shown 
in Figure 5.46.b. 















































Figure 5.46.  pH investigations of DIS only in water. 
 
A  Absorbance Spectra of the pH titration of free DIS in water, 3.26 X 10-4M-1, 1cm cell 




5.8.iii.a.  3,5 Diiodosalicylic Acid Binding Studies 
 
The CD spectra of the binding of DIS to rHSA showed similarities to the CD of warf:rHSA 
in that it possessed two overlapping positive peaks at 300nm and 330nm. However, the 
spectra in the case of DIS was more complex with two further maxima, a negative 
maximum located around 280nm and a positive maximum located below 240nm (Figure 
5.47.a.). The fixed wavelength plot confirmed a D/P ratio equivalent of [2:1] with the two 
positive maxima reaching completion at different ratios (Figure 5.47.d.), this may be a 
reflection of the different species in equilibrium. The CD spectra also reflected the 
complexity of the titration with the generation of potentially two isosbestic points, one at 
approximately 290nm and the other at approximately 265nm. The UV data also exhibited 
an isosbestic point dissecting that which was found above and below 350nm. 




















































Figure 5.47.  Binding studies of DIS:rHSA measured in a 5cm cell. 
 
A  CD Spectra of the titration of DIS with rHSA in P/B, pH7.2, 5cm cell 
B  Absorbance spectra of DIS:rHSA, (rHSA baseline subtracted), P/B, pH7.2, 5cm  




The data in Figure 5.47.c. showed the effect of concentration on the binding studies and 
revealed a perfectly symmetrical relationship that reflected no concentration dependencies. 
The binding relationship for DIS to rHSA remains the same as long as the D/P ratio 
remains the same regardless of the concentration used to attain that ratio. In optimising the 
conditions by increasing the D/P ratio equivalent to [1:25] and above revealed that there 
existed a higher complex than the [1:2] ratio previously thought to exist. Binding at the 
higher concentrations of rHSA meant that solubility became an issue. In order to 
compensate for that the concentration of DIS was reduced and ratios up to [1:70] were 
investigated and are shown in Figure 5.48. The loss of the positive maxima at 330nm  that 
seem to shift to lower wavelength that stabilised at 312nm and changed signs to become 
increasing negativity for ratios up to [1:50]. The maximum at 300nm became increasingly 
more positive. The experimental limit of this experiment was reached and it was 
impossible to push the boundaries further in view of the solubility problems of albumin 
and its optical transparency at such high concentrations. 
 













































Figure 5.48.  Titration of DIS with rHSA for high D/P ratios. 
 
A  Titration of a fixed concentration of DIS to rHSA in 10mM P/B, pH7.2, 1cm cell 





The binding of DIS to rHSA was compared to nHSA, the results showed great similarities 
(Figure 5.49). The characteristic features associated with DIS binding were evident. 
However, the appearance of a more defined isosbestic point at a relatively low D/P ratio 
indicated a difference not so prominently observed with the DIS:rHSA titration. A further 
difference was seen in the end point observed at the 300nm maximum that reached 
completion at 2M equivalent.  A [2:1] D/P ratio also existed under these conditions with a 
clear distinction between the behaviour of the two positive maxima that was more 
prominent in native albumin than in rHSA.  
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Figure 5.49.  The binding of DIS to nHSA 
 
A  DIS : nHSA titration, molar ratio equivalent [1:5.8] to [1:0.0165] in P/B, pH7.2, 1cm 
B  Fixed wavelength plots of DIS:nHSA titration in P/B, pH7.2, 1cm 
 
Elucidating the ultimate binding conditions for DIS:rHSA proved elusive, the extremely 
high concentration of albumin compared to that of the drug meant that monitoring the drug 
became increasingly difficult. The best possible data obtained for such a titration is shown 
in Figure 5.50. where the DIS concentration was increased and fixed at 3M equivalent, this 
provided a larger induced CD signal (i.e. 3x greater). As the D/P ratio increased the 




possible to monitor the CD spectral changes in the far UV CD region and revealed a 
further two CD maxima together with the negative maximum previously detected and 
centred at 260nm. The first new maximum was seen as a negative peak centred on 240nm 
as shown in Figure 5.50., this peak shifts to longer wavelength and changes in intensity 
until at high D/P ratios a positive maximum results. The last new maximum detected was 
positioned around 230nm and was seen as a large positive peak. Again, spectral shifts were 
also associates with this peak. The existence of several conformational binding complexes 
was evident at high D/P ratios, the use of 3M equivalent DIS highlighted this. The spectral 
changes observed could be due to the redistribution on DIS on albumin that could account 
for the dramatic changes observed in the spectra. 































 240nm, 0.2mm cell
 300nm,   1cm cell
 
 
Figure 5.50.  Ultimate titration of the binding of DIS to rHSA. 
 
A  Titration of DIS (fixed at 3 molar equivalent) with rHSA, 10mM P/B, pH7.2,1cm and 0.2cm 




5.8.iii.b.  3,5 Diiodosalicylic Acid Binding in the Presence of an Antagonist 
 
The binding at site IIIA of a ligand can be antagonised by some ions, fatty acids and amino 
acids such as tryptophan (Trp). Tryptophan was chosen to be the antagonist and was 
titrated with a [2:1] molar ratio equivalent of DIS:rHSA. The presence of a small amount 
of Trp (0.1M) slightly enhances the binding of the ligand. However, further additions of 
Trp resulted in the displacement of DIS, shown in Figure 5.51.a. The affinity of Trp was 
not strong enough to displace DIS from binding pocket IIIA. However, the presence of a 
small amount of Trp (0.1M equivalent) was sufficient to produce enhances binding of the 
ligand. The titration of DIS was now carried in the presence of 0.1M equivalent Trp bound 
to rHSA, and as expected Trp was shown to enhance binding. Figure 5.51.b. supports these 
findings. From this study it seems that Trp does not act as an antagonist in the case of DIS 
but rather as an enhancer.  
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Figure 5.51.  The binding of DIS to rHSA in the presence of Trp. 
 
A  Titration of tryptophan to fixed molar ratio equivalent of [2:1] DIS:rHSA, 10mM P/B, pH7.2, 5cm  





5.8.iii.c.  3,5 Diiodosalicylic Acid Binding to a Fixed Concentration of rHSA 
 
Binding studies can be conducted fixing either the concentration of the ligand or the 
protein. Whichever way the titration is performed the end result, in theory, should be the 
same. Carrying out the titration of DIS:rHSA to test this hypothesis, the concentration of 
rHSA was kept constant and fixed at 1.28 x 10-4M-1, Figure 5.52. shows the results of that 
titration. 
















































For D/P ratios above [1:5] 
the samples were diluted 













Figure 5.52.  The titration of a variable concentration of DIS to fixed rHSA. 
 
A  Fixed rHSA (1M equivalent) to increasing concentrations of DIS, P/B, pH7.2, 5cm 
B  Fixed wavelength plot of rHSA at fixed concentration with increasing amounts of DIS 





The CD profile of the titration was similar to the binding seen when the conditions are 
reversed (i.e. when the ligand concentration was constant). An isosbestic point was 
observed for ratios exceeding a D/P ratio equivalent of [4:1] suggesting the existence of 
two of more species in equilibrium. The end point of the titration was not reached with 
changes monitored up to a D/P ratio of [20:1], showing continuous changes for the main 
CD spectra at 320nm. An additional maximum at 344nm was now evident appearing as a 
shoulder on the main transition (Figure 5.52.a.). The binding of DIS to albumin seemed to 
occur in stages, the initial stage which reflected a D/P ratio of [2:1]. The initial stage was 
rapid as shown by the maxima at 300nm in Figure 5.52., and appeared to be stable resisting 
further perturbation until a point is reached where a second stage of binding dominates as 
demonstrated in Figures 5.48 & 5.52. Albumin triggered the binding of DIS at high D/P 
ratio, however, it was not possible to reach completion of the titration as the solubility of 
both DIS and albumin becomes a problem at such high concentrations.  
 
5.8.iii.d.  Variable Concentrations of both 3,5 Diiodosalicylic Acid and rHSA 
 
The final set of experiments conducted was to investigate the chemical properties of the 
binding of DIS was to vary both the ligand and protein concentrations, this was achieved 
by taking a [2:1] molar ratio equivalent sample of the complex and titrating in 2M 
equivalent sample of DIS. The method adopted serves to dilute the rHSA concentration 
and subsequently increase the DIS concentration. The results are shown in Figure 5.53. and 
reflects similar characteristics to the transitions shown when titrated with fixed DIS and 
varying rHSA. The continuous changing conditions of both the ligand and the protein 
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Figure 5.53.  The titration of DIS:rHSA varying both concentrations 
 
A  Variable concentrations of DIS with changing rHSA concentration in P/B, pH7.2, 1cm 
B  Fixed wavelength plot of variable DIS and rHSA concentrations 
 
5.8.iii.e.  3,5 Diiodosalicylic Acid pH Studies 
 
The environment of the binding pockets of DIS:rHSA for a [2:1] molar ratio equivalent 
was investigated with changing pH and was found to be quite robust for the wavelength 
maximum of 382nm, withstanding pH changes between pH3.5 and pH10. For the other 
wavelengths studied this was not the case, pH variation was reflected throughout, with 
these wavelengths showing three transitions with the exception of wavelength 280nm that 
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Figure 5.54.  pH perturbation of a [2:1] ratio of DIS:rHSA. 
 
A  pH Titration of a [2:1] molar ratio sample of DIS:rHSA in water, 1cm cell 
B  Fixed wavelength plot of the pH titration of a [2:1] molar ratio equivalent of DIS:rHSA in water 






 1st 2nd 3rd 4th 
280 4.1 5.3 6.5 11.1 
300 3.4 - 7.4 12.2 
320 3.9 - 8.2 12.4 
328 3.7 - - 12.3 
rHSA 
287nm 
3.5 - 6.1 11.7 
 




The wavelength in Dis:rHSA (300nm) closest to that of rHSA only wavelength maxima 
reflected similar transitions and values for pK, the other wavelengths were more 
distinctive. In order to ascertain whether the amount of bound DIS that gave different CD 
profiles over the same wavelength region investigated would respond differentially to pH 
perturbations, four different D/P ratio combinations were investigated. The ratios chosen 
were [0.2:1], [0.4:1], [0.6:1] and [0.8:1], and the results are shown in Figures 5.55. to 5.58. 
The data reflected spectral changes specific to the D/P ratios with good agreement reached 
the closer the D/P ratio moved towards the [2:1] molar ratio equivalent. 
 
The ratios were chosen such that the two lowest ratios would mean only one molecule of 
DIS was bound at any one time to the protein. The higher ratios were chosen to reflect the 
possibility of two molecules of DIS molecules bound to the protein. From the results there 
was a clear distinction between the first two titrations and the last two. The ratios that 
contained one DIS bound produced three transition at the wavelength maximum of 250nm, 
for the other two wavelengths monitored only two transitions were seen. There was also a  
certain amount of spectral shift of the maxima towards longer wavelength.  
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Figure 5.55.  pH titration of [0.2:1] molar ratio of DIS:rHSA. 
 
A  pH Titration of a [0.2:1] molar ratio equivalent of DIS:rHSA in water, 2cm cell 































































Figure 5.56.  pH titration of [0.4:1] molar ratio of DIS:rHSA 
 
A  Fixed wavelength plot of the pH titration of a [0.4:1] molar ratio of DIS:rHSA in water 
B  pH titration of a [0.4:1] molar ratio equivalent sample of DIS:rHSA in water, 2cm cell 
 
By the time the higher molar ratio equivalents were monitored the spectral shifts 
experienced at the lower ratios were not evident, but the maxima at 300nm and 320nm 
were firmly established.  




























































Figure 5.57.  pH titration of [0.6:1] molar ratio of DIS:rHSA 
 
A  pH titration of a [0.6:1] molar ratio equivalent of DIS:rHSA in water, 2cm cell 



























































Figure 5.58.  pH titration of [0.8:1] molar ratio of DIS:rHSA 
 
A  pH Titration of a [0.8:1] molar ratio sample of DIS:rHSA in water, 2cm cell 
B  Fixed wavelength plot of the pH titration of a [0.8:1] molar ratio sample of DIS:rHSA in water 
 
Now shifts in the number of transitions were observed at the wavelengths monitored. At 
250nm, previously three transitions were seen now reveals only two for the two higher 
ratios. However, at 300nm which showed two transitions now supported three transitions, a 
reversal in role between the two wavelengths. A table of all the transitions observed is 











 1st 2nd 3rd 4th 1st 2nd 3rd 4th 1st 2nd 3rd 4th 1st 2nd 3rd 4th 
250 4.5 5.1 8.1  2.1  8.4 10.4   7.8 10.7   8.2 10.6 
290 3.3  9.3              
300 3.1  9.3  3.6  8.3  2.8 6.0  11.5 3.6 6.7 10.1 11.9 
320     3.5   10.0 3.6   11.2 3.7   11.7 
 
Table 5.7.  Transitions in the different molar ratio equivalents with changing pH. 
 
Clear trends could be seen from the table of results. At all ratios studied the final 
wavelengths monitored revealed two transitions for all samples, one in the extended form 
and the other in the basic form. At 250nm, ratios [0.2:1] & [0.4:1] revealed three 




ratios, two transitions in the N-form & B-form were seen. The middle wavelength region 
was the area that revealed the greatest complexity with the higher ratios supporting three to 
four transitions, while at lower ratios only two transitions were observed in the E-form & 
B-form. It was clear that each conformational form experience by albumin had a direct 
effect on the binding of DIS and there was a dependency on the number of bound DIS 
present. In view of the pH susceptibility of DIS binding with respect to the conformation of 
albumin, the next experiment investigated the effects of binding at different pH values. The 
environment of HSA was altered, four pH regions were observed, pH3.56 with HSA in its 
extended form, pH4.57 where HSA was in the fast form, pH7 the neutral form of HSA, and 
lastly pH9.04 where HSA was in the basic form. At each specified pH, the titration of a 
fixed concentration of DIS was titrated to varying concentrations of albumin. The data is 
represented in Figure 5.59 – 5.62. In each case, the same concentration of DIS was used 
within a buffered environment to ensure continuity; the only parameter that varied was the 
pH. 
 
The binding of DIS was shown to be pH dependent; the profiles of the spectra appeared 
different in each titration. When rHSA was in its extended form (pH3.56) the positive 
maximum at 300nm was markedly affected even at low D/P ratios. The only titration that 
was comparable at these low ratios to pH3.56 was that conducted at pH9, which showed a 
depression of the maximum at 320nm and 300nm. For D/P ratios up to [1:0.5] there was a 
continued increase in the peak at 320nm with the protein in the extended form reaching a 
plateau, further increases had no effect on this maximum and the peak remains steadfast. 
The intensity of ∆A at the plateau has also been compromised, attaining a lower level than 
was expected (Figure 5.59.a.). The maximum at 300nm however, continues to increase, 
this suggests that the two maxima work independently and may be indicative of the two 
binding sites. When albumin was in the fast form (pH4.57) the binding of DIS brought 




the maximum at 320nm, suggesting that binding related to that peak has been 
compromised (Figure 5.59.b.). The spectra appeared noisy as the samples appeared to be 
quite affected when kept at that pH. Binding at 320nm had been slightly enhanced with an 
increased in ∆A by approximately a third to the expected value. Also noticeable was the 
loss of the negative maximum at 280nm, this suggests that perhaps the maxima at 300nm 
and 280nm were coupled and therefore the compromise at one will result in corresponding  
changes at the other peak. 







































































Figure 5.59.  pH effects on the binding titration of DIS to rHSA 
 
A  Titration of DIS:rHSA in 10mM B/R buffer, pH3.56, 1cm cell 
B  Titration of DIS:rHSA in 10mM B/R buffer, pH4.57, 1cm cell 
C  Titration of fixed DIS with rHSA in 10mM Tris buffer, pH7.01, 1cm cell 




Binding at physiological conditions (Figure 5.59.c.) produced the typical spectra that were 
expected but with one exception, there appears to be the generation of a new peak 
relatively small in intensity that was generated for low D/P ratios. The new peak was 
formed at 360nm and reduces to a minimum for ratios greater than [1:0.35]. The last pH 
condition to be studied was when albumin was in the aged transition (pH9). At this pH 
binding behaved similar to that at physiological conditions but with two exceptions. Firstly 
the maximum at 300nm had been compromised with a magnitude more typical for that 
found at 320nm, the distinction between both wavelengths were minimal. Secondly, the 
negative peak at 280nm was very much reduced, once again supporting the hypothesis that 
the peaks at 280nm and 300nm were coupled. The fixed wavelength plots of the CD data 
can be found in Figure 5.60. 
 













































































Figure 5.60.   Fixed wavelength plots of the pH effects on the binding titration. 
 
A  Titration of a fixed concentration of DIS to increasing rHSA in B/R buffer, pH3.56, 1cm cell 
B  Titration of a fixed concentration of DIS to increasing rHSA in B/R buffer, pH4.57, 1cm cell 
C  Titration of a fixed concentration of DIS to increasing rHSA in Tris buffer, pH7.01, 1cm cell 




The fixed wavelength plots reflected the trends seen in the CD spectra. Each pH titration 
reflected its unique set of binding data. 
 
5.8.iii.f.  3,5 Diiodosalicylic Acid Temperature Studies 
 
Like previously, temperatures studies were conducted in two ways. First the binding of 
DIS to preheated samples of rHSA was investigated; the results are shown in Figure 5.61. 
The CD spectra revealed the loss of both positive maxima with increasing heat 
denaturation. 






















































































Figure 5.61.  Binding studies of pre-heated rHSA with DIS. 
 
A  Temperature studies of a [2:1] molar ratio equivalent of DIS:rHSA in 10mM P/B, pH7.2, 1cm cell 
B  Fixed temperature plot of the pre-heated samples of rHSA bound to DIS in 10mM P/B, pH7.2, 1cm cell 




The fixed wavelength plots showed the existence of two transitions for both of the positive 
maxima studied, both occurring within a degree of each other showing that they were both 
responsive to the conformational perturbations (Figure 5.61.b.). The first transition was 
determined at a tm= 33.0˚C with a K = 25 x 103 for both maxima, this produces a reduction 
of approximately 50% of the CD signal. The second transition was more rapid and 
occurred at tm= 57-58.0˚C with a K = 55 x 103 that represented the total loss of binding of 
DIS. The micro-centrifuged samples measured by absorption also supported the findings in 
the CD spectra that revealed two transitions with very similar numerical values (Figure 
5.61.c.). The second temperature study was to measure the heating and quenching spectra 
for a [2:1] molar equivalent sample of DIS:rHSA. The observation of the heating curve 
revealed the gradual dissociation of the drug from albumin for temperatures up to 60oC. 
For temperatures exceeding this, the loss was more significant with complete dissociation 
achieved around 85oC (Figure 5.62). Three transitions were determined with the first tm 
detected at 42.0˚C that produced the highest value of K=28 X 103.  The other two 
transitions occur at 68.0oC & 74.0oC with lower values of K=10 X 103 & 20 X 103 
respectively. 
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Figure 5.62.  Temperature studies of a [2:1] molar ratio equivalent of DIS:rHSA. 
 





The quenching curve highlighted the relative stability of the DIS:rHSA association, and 
showed that temperatures up to 60oC did not affect the binding pockets of DIS. 
Dissociation was very rapid between 60oC and 70oC with virtually the complete loss in 
binding attained by the end point. Two transitions were seen at 66.5oC & 82.0oC with 
values of K=90 x 103 & K=18 x 103 respectively, revealing the difficulties of the first 
transition and the relative ease of the second.  
 
5.8.iii.g.  3,5 Diiodosalicylic Acid Denaturation Studies 
 
The denaturation studies of both urea and GuHCl are shown in Figure 5.63., and reveal the 
robustness of the DIS:rHSA binding site. Even at very high denaturation conditions 
substantial binding remained, with both positive maxima compromised the negative 
maximum was enhanced. The absorption spectra for the guarnadinium complex is shown 
in Figures 5.63.a. & b. and revealed no significant spectral changes in either the DIS 
absorption or the rHSA. The absorption spectra also reflected the same results as the CD, 
revealing little changes in absorption, with the fixed wavelength plot revealing consistency 
of binding (Figures 5.64.a. & b). 
 
Urea, like GuHCL, reflected similar changes with the endpoint of the titration still 
producing reduced binding of DIS to rHSA (Figures 5.63.c. & d.). Neither of the 
denaturants used was able to completely displace DIS from albumin. The response of 
albumin in the absence of ligand responded to either of the denaturants by completely 
unfolding, and indeed little structural integrity remains. However, in the presence of DIS, 





























































































Figure 5.63.  CD Spectra of DIS:rHSA, [2:1] molar ratio equivalent in denaturants. 
 
A  Titration of a [2:1] molar equivalent sample of DIS:rHSA with increasing GuHCl in water, 1cm cell 
B  Titration of a [2:1] molar ratio equivalent of DIS:rHSA with increasing concentrations of GuHCl, 1cm 
C  Titration of a [2:1] molar ratio equivalent of DIS:rHSA with increasing concentrations of Urea, 1cm 
D  Titration of a [2:1] molar equivalent sample of DIS:rHSA with increasing Urea in H\-(2)O, 1cm cell 
 
The measurements derived from the micro-centrifuged samples revealed a steady increase 
in absorbance with increase in concentration of GuHCl, however, there was still a 
substantial amount of bound drug shown. The micro-centrifuged samples measured for the 
urea complex reflected similar trends to its counterpart (Figure 5.64.e.), with urea 
producing a slightly greater displacement of DIS relative to GuHCL. Both produced 
unexpected binding since the denaturants were known to denature domains I & II. In view 































































































Figure 5.64.a, Absorbance spectra of the microcentrifuged samples of DIS:rHSA:GuHCL. 
 
A  UV Absorbtion of the tiration of a [2:1] molar ratio of DIS:rHSA in increasing concentrations of GuHCl 
B  Fixed wavelength plot of the UV absorption spectra of the titration of DIS:rHSA in GuHCl, 1cm 
C  Microcentrifuged samples of the titration of a [2:1] molar ratio equivalent of DIS:rHSA in GuHCl 
D  Fixed wavelength plot of the microenctrifuged samples of a [2:1] sample of DIS:rHSA in GuHCl, 1cm 
 
















Figure 5.64.b.  Fixed wavelength plot of microcentrifuged DIS:rHSA:Urea complex. 




5.8.iv.  DIS:Domain I+II Binding Studies 
 
The binding of DIS to one of the domain fractions of albumin was studied and compared to 
whole albumin, domain I+II was selected since it contained one of the binding sites of DIS 
and therefore its CD profile should be similar to that of the whole sample. The results of 
the titration are shown in Figure 5.65. and shows that for high D/P ratios the similarities 
between the binding to domain I+II and the whole were strikingly similar, revealing both 
the 300nm and 320nm positive maxima. The difference in peak heights between the two 
positive maxima were more pronounced in the fragment then they were in the whole, 
making it very difficult to measure the negative maximum at 280nm (Figure 5.65.a.). For 
ratios below [1:2], but greater than [1:0.5], the results highlighted the fluidity of the 
positive maxima that seem to be concentration dependant (Figure 5.65.b.). Firstly, the 
consolidation of the two positive maxima into a single peak detected at 320nm was 
observed. Secondly, an inversion of the consolidated peak resulting in a negative 
maximum was found that was also detected at 320nm, and was almost the mirror image of 
that which was seen for the positive maxima, the negative maximum at 275nm was 
unaffected. Ratios below [1:0.5] gave the characteristic single positive CD maximum at 
320nm, there was a noticeable lack of the 300nm peak. By all accounts, the CD profile of 
the fraction did not seem to be compromised in terms of binding ability by its preparation, 
its integrity seem to be intact at least where DIS binding was concerned.  
 
The fixed wavelength plot revealed that even at a molar ratio equivalent of [1:17] complete 
binding was not attained. Initial assessments revealed that there was a substantial increase 
of the number of binding sites on the domain fraction, higher than could be explained 








































































Figure 5.65.  CD Spectra of the binding of DIS to domain I+II. 
 
A  Titration of a fixed concentration of DIS to varying concentrations of Domain 1+2, P/B,pH7.2, 1cm 
B  Titration of a fixed concentration of DIS to varying concentrations of Domain 1+2, P/B,pH7.2, 1cm 









The micro-centrifuged samples of the titration of DIS:domain I+II revealed that for very 
low D/P ratios the amount of unbound drug was high, but as the concentration of the 
domain fraction increased so to did the degree of binding. For the D/P ratio of [1:15] there 
was only a minuscule amount of free drug detected as shown in Figure 5.66; the fixed 
wavelength plot showed complete binding at a D/P ratio of [1:8] (refer to Figure 5.66.b.), 
but as shown in Figure 5.65.a. this was not the complete picture. There was a shift to 
shorter wavelength of the CD maximum at 300nm that could not be taken into account in 
the fixed wavelength plot. 
 
 




























































Figure 5.66.  Absorbance spectra of the microcentrifuged samples of DIS:Domain 
I+II. 
 
A  Microcentrifuged samples of the titration of DIS:Domain I+II in 10mM P/B, pH7.2, 1cm cell 






5.9.  Multiple Binding of Ligands to rHSA 
 
Multiple binding studies to albumin was considered for three of the drugs/ligands 
previously studied with reference,  
(a). to monitor the binding of DIS:rHSA:Diaz complex. 
(b). War:rHSA:Diaz complexes.  
Both the CD of the multiple complex (drug:rHSA:drug/antagonist) and the CD of the 
bound drug/or the antagonist (drug/antagonist:rHSA) complex were determined and are 
represented in Figures 5.67. & 5.68. 
 
5.9.i.  DIS:rHSA:Diaz complex 
 
Considering the multiple complex first for DIS:rHSA complex and titrating with a 1M 
equivalent of diazepam, the CD of the combined drugs to rHSA gave a CD profile that was 
dominated by the DIS:rHSA signature. At high diazepam concentrations the peak at 
320nm belonging to the DIS:rHSA interaction diminished as the negative effects of the 
diazepam maximum also at 320nm became evident (Figure 5.67.a.). The fixed wavelength 
plot (Figure 5.67.b.) revealed the continual influence of increasing diazepam binding. 
When the [2:1] molar ratio equivalent of DIS:rHSA baseline was removed the binding of 
diazepam signal became much more apparent ( Figure 5.67.c.) albeit noisy compared to 
when diazepam binds to rHSA in the absence of any other perturbants. The fixed 
wavelength plot also supported the findings of a [1:1] molar ratio equivalent of diazepam 
binding to rHSA (Figure 5.67.d.). The CD for the corrected spectra revealed that 1M 
equivalent of diazepam had bound to rHSA in the presence of DIS. If 2M equivalent of 
DIS was also present at the same time that diazepam was present, then it was safe to 
assume that the binding site of DIS to IIIA had become displaced by diazepam and 
relocated to bind at IB. The presence of DIS to site IIA was unperturbed, thus supporting 




with the weaker site moving to IB as found by crystal structural analysis. 































1M  Equiv DIS = 3.21 x 10 -5M -1





































Figure 5.67.  The study of diazepam binding to DIS:rHSA, [2:1] complex. 
 
A  Titration of a [2:1] molar equivalent of DIS:rHSA with increasing Diaz, 10mM P/B, pH7.2, 1cm  
B  Fixed wavelength plot of [2:1] DIS:rHSA with increasing concentration of diazepam 
C  Induced binding of a[2:1] molar ratio equivalent of DIS:rHSA with Diaz, (DIS:rHSA CD spectra has 
been removed), 1cm 
D  Fixed wavelength plot of DIS:rHSA:Diaz - DIS:rHSA 
 
5.9.ii.  War:rHSA:Diaz complexes 
 
The other complex studied was the complex of War:rHSA binding to increasing 
concentrations of diazepam, monitored to investigate the possible coexistence of the two 
drugs to rHSA. The CD spectra reflected the combination of the two individual induced 
CD spectra; the results are shown in Figure 5.68. The results revealed the presence of a 




warf:rHSA complex became increasingly dominated by the profile of the diazepam signal 
as it bound to albumin with the generation of a negative maximum  located at 
298nm(Figure 5.68.a.). The fixed wavelength plot revealed an increase in binding for D/P 
molar ratio equivalent up to [1:1:0.5], thereafter followed by a dramatic reduction in 
binding at those specified wavelengths (Figure 5.68.b.). When the War:rHSA baseline was 
subtracted from the mixture the true induced diazepam CD spectra was revealed and 
showed the characteristic CD profile for the corrected Diaz:rHSA complex (Figure 
5.68.c.). The fixed wavelength plot obtained in Figure 5.67.d. mimicked the results found 
in the mixture (Figure 5.68.b.).  






























1M Equiv Diaz = 5.27 x10-5M -1
1M Equiv Warfarin = 7.01 x 10-5M -1
Isosbestic Point
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1M Equiv Warfarin = 7.01 x 10-5M -1

























Figure 5.68.  The multiple titration of Warf:rHSA [1:1] molar equivalent with diazepam. 
 
A  Titration of a [1:1] molar equivalent sample of War:rHSA with increasing Diaz, P/B, pH7.2, 1cm cell 
B  Fixed wavelength plot of the titration of [1:1] War:rHSA with increasing concentrations of Diaz 
C  Induced binding of a [1:1] molar ratio equivalent of War:rHSA with increasing Diaz, (War:rHSA 
spectra has been removed) 











































CHAPTER 6:  Large Ligand:HSA Interaction, The Chemistry of Dyes 
6.1.  Introduction 
 
The use of dyes in binding, structural and concentration studies of proteins is well 
established. Dyes are utilised because of their distinct colour and spectroscopic profiles. 
The absorption wavelength of a dye should be outside the spectroscopic range of the 
protein itself resulting in no spectral interference between the two; both the protein and the 
dye can be observed independently, a property utilised by UV and CD spectroscopy . HSA 
is no exception, the flexibility and adaptability of this protein is one of the main 
characteristics that allows it to bind numerous ligands with varying affinity. Locating 
binding sites however, has been problematic since HSA has the ability to present lower 
affinity binding sites as well as high. The specific binding of dyes can be used to provide 
excellent binding site markers, as they can be easily detected and monitored.  
 
Three dyes, with similar core molecular structures, were chosen in this study. All three 
dyes were believed to bind to the same region on HSA located within domain IIA, between 
positions 182 - 283 in the protein (Kragh-Hansen, 1990), referred to as Site I by (Sudlow et 
al., 1976), with an association constant of the order 104 - 105 M-1. Once Sudlow’s site I is 
fully occupied, HSA may bind the dyes at one of up to five other weaker sites that have 
with K~10-3M-1; subdomain IIA is one of the primary binding site on HSA, located near 
the surface of the molecule and is susceptible to environmental changes. Changes in pH 
causes changes in the protein conformation, which in turn potentially offsets the affinity of 
the weaker binding sites (Peter, 1996). It must be noted that subdomain IIIA is the 
strongest high affinity binding site of albumin, subdomain IIA has been found to be 
marginally weaker. There are four main forces that are responsible for the fixation of the 





i. Ionic forces- Occurring between the positive charges of the protein and the 
negative charge of the dye and visa versa in an aqueous or dilute acidic 
environment, this results in the protonation of the amino group of the protein. 
The dye is usually delivered in the sodium salt form. 
ii. Hydrogen Bonding- This is the involvement of 'lone pair' electrons from an 
electron donor atom. 
iii. Van der Waal's Forces- These forces are small in comparison to hydrogen 
bonding and ionic forces, involving the interaction of the π orbital of the dye 
with its host. This force is particularly prevalent in linear dye molecules (i.e. 
long and flat), where the dye can approach very close to the host and when both 
the dye and the host contain alkyl or aryl groups. 
iv. Covalent Bonds- Covalent bonds form as a result of chemical interaction 
between the dye with the host resulting in bond formation between the two. 
Covalent bonds are the strongest as they become an integral part of the product. 
This type of bonding is most commonly seen in reactive dyes. 
 
6.2.  Materials and Method 
 
Both nHSA (batch number ABC-0292B14611), supplied by Bio Products Laboratory, 
Hertfordshire, and rHSA (batch number GA 92014) supplied by Dr John Woodrow, Delta 
Biotechnology, (Nottingham, UK), were purified by either dialysing in distilled water, 
using dialysis tubing (MW cut-off of 10,000, supplied courtesy of Delta Biotechnology, 
Nottingham) or by column chromatography. The dialysis tubing was pre-treated in a 
heated solution of 0.05% of EDTA (analar grade supplied from BDH) and 2% of sodium 
bicarbonate (analar grade supplied from BDH) made up in distilled water. This was done 
to clean and degrease the tubing prier to use. The treated tubing was then washed several 




removing small contaminates such as salts but was ineffective for removing fatty acids, a 
component added to the preparation of both types of HSA (4%) as a stabiliser. The 
removal of fatty acids was achieved using Sephadex G 25m (PD-10) columns (Code 
Number-17-0851-01, Lot Number SA 15390, supplied from Pharmacia). All purified HSA 
solutions were freeze-dried and the purified product stored in the freezer. For consistency 
the same batch of HSA was used for experiments in the same series. 
 
Phenol red (PR) (Lot Number 00775-024) was supplied by Aldrich, UK and was made up 
to a concentration of 7.05 x 10-5M-1. Bromophenol blue (BPB) (Lot Number 14273G), 
concentration 1.49 x 10-5M-1 and bromocresol green (BCG) (4.30 x 10-5M-1) were obtained 
from BDH, UK. 8M equivalent stock solutions of the dye under investigation and 8M 
equivalent stock solution of the protein were made in either 10mM buffer solution adjusted 
to the required pH, or in distilled water. Two buffers were used, Britton Robinson (2.47g/L 
boric acid, 1.52ml/L acetic acid and 2.544ml/L o-phosphoric acid (Analar grade) supplied 
fby BDH) and phosphate buffer (Analar grade) also from BDH. Denaturation studies 
involved urea and GuHCl both supplied by BDH, UK. All other products used were of the 
highest analytical grade (Analar) to ensure the highest spectroscopic purity and 
transparency. Where necessary, the dye:protein solutions were spun in a microcentrifuge 
(Watman Microcentrifuge Force 14, model reference MOO 17279) using Millipore 
microcentrifuge tube filters with an ultrafiltration media (from Whatman, UK) having a 
nominal molecular weight limit of 10,000. 
 
6.3.  Experimental Procedure 
 
Using the stock solutions, a series of sequential dilutions were made, each containing 1M 
equivalent of dye solution (fixed concentration) with varying concentrations of protein 




the dye:protein complex with varying concentrations of protein (a stock solution of 8M 
equivalent was used) to a fixed concentration of dye (1M equivalent at final dilution), 
using two stock solutions. A total 1ml volume of each complex solution was made. A 
reference HSA baseline was also measured containing the equivalent concentration of 
protein as the complex solution but without dye, this was subtracted from the complex 
solution spectrum to obtain the effects of the dye only when bound to the protein. Any 
interference due to the protein was thus eliminated and only the induced spectra of the dye 
measured. 
 
When conducting denaturation studies with either GuHCl or urea, a 10M stock solution of 
each were made. Stock solutions of both 2M equivalent dye and 8M equivalent HSA were 
also prepared. Using the HSA and denaturant stock solutions a 2M equivalent solution of 
the protein in varying concentrations of the denaturant was prepared and stored overnight 
in the refrigerator so as to enable the denaturant to work and attain equilibrium (i.e. 2M 
equivalent of HSA in 1M equivalent denaturant, 2M equivalent HSA in 2M equivalent of 
denaturant etc. to produce the series was made). The following day, the protein : 
denaturant solutions were divided equally one to prepare the dye:HSA:denaturant complex, 
and the other to prepare the baseline (HSA:denaturant in water). Since the dye was not 
chiral, any surplus dye would be transparent when measured by CD, and therefore did not 
have to be considered in the data analysis. 
 
6.4.  UV Absorption Spectroscopy 
 
The absorption spectrum of all the samples were measured on a AVIV 17DS 
spectrophotometer with a spectral band width of 0.2nm and a scan speed of 0.2nm/sec in a 
1cm cell. Samples that had been spun in a microcentrifuge through microcentrifuge tube 
filters had low volumes (100 - 300µl); measurements were made with a 1cm pathlength 




manufactured by Helma, UK.  The total capacity of the cuvette was 300µl, the walls of the 
cell were black glass allowing a maximum light throughput through only the window of 
the cell. The cell holder of the spectrometer was modified such that the beam was 
concentrated only through the optical window of the cuvette. 
 
6.5.  Circular Dichroism Spectroscopy 
 
Two instruments were used to measure the CD, either a JASCO J600 spectropolarimeter or 
the JASCO J720 spectropolarimeter using a 1nm spectral bandwidth, a scan speed of 
10nm/min and a time constant of 4sec. Both instruments were calibrated against NH4-d-
Camphor-10-Sulphonate standard (supplied by Jasco, UK). All samples were measured in 
a 1cm cell between the wavelengths of 240 - 750nm and at room temperature, unless 
temperature studies were being conducted where a thermostatting water-bath was used to 
maintain the desired temperature. Quenched studies were conducted at room temperature 
















Results of Phenol Red : Human Serum Albumin Interaction Studies 
6.6.i.  Ultra-Violet / Visible Studies of Phenol Red 
 
Phenol red (PR) or Sulfonphthalein (C19H14O5S), MW 354.38, has two distinct pKa 
related colour changes, one under acidic conditions and the other in more neutral/basic 
conditions. A sample of 7.05 x 10-5M PR in distilled water was investigated, the pH 
equation is represented in Figure 6.1.a. and the UV spectral changes are shown in Figure 
6.1.b. Changing pH shifted the observed absorption wavelength maxima and the peak 
intensities. Plotting absorption against pH at fixed wavelengths of 557nm and 451nm 
highlighted a sigmoidal relationship depicted in Figure 6.1.c., with an inflection point 
located at pH 7.6. Literature states the pKa for PR to be 7.9, experimental data gave a 
calculated pKa at λ 431nm to be 7.7 and at λ 557nm as 8.0 showing close agreement with 











pKa = 1.5 pKa = 7.9
pH1.5 pH7.9
 
Figure 6.1.a.  Schematic representation of the dissociation of PR. 
 
 






Figure 6.1.c.  Fixed wavelength plot of PR pH titration in water, 1cm cell. 
 
6.6.ii.  Binding Studies of PR:HSA Interaction 
 
The characterisation of PR:HSA binding studies was carried out at pH7.2, a fixed 
concentration of 7.05 x 10-3M of dye solution was titrated with varying concentrations of 
HSA to determine the binding capacity of the dye to the protein. The absorption spectra of 
PR exhibits a single maximum at 450nm when dissolved in water at physiological 
conditions. However, when bound to albumin an additional peak was observed at 550nm 
that decreased in magnitude with increasing albumin concentration (Figure 6.2.a. &6.2.b.). 
The resulting CD spectra of the complex revealed three maxima, the largest, a positive 
maxima at 450nm matches the main absorbance band of the dye, followed by two features 
approximately equal in intensity but opposite in sign with maxima at 380nm and 330nm 
respectively, shown in Figure 6.2.c. & 6.2.d.. Two isosbestic points at 350nm and 400nm 
were observed indicative of two states in equilibrium. The binding of PR to rHSA revealed 
a [1:1] relationship indicative of only one ligand binding to a single protein molecule in 










































































Figure 6.2.  The CD of PR:rHSA titration at pH 7.19, 1cm cell. 
 
A  Absorption spectra of the titration of PR to rHSA in 10mM P/B, pH7.2,1 cm cell 
B  Absorption spectra of the titration of PR to rHSA in 10mM P/B, pH7.2,1 cm cell 
C  CD spectra of the titration of PR to rHSA in 10mM P/B, pH7.2, 1cm cell 











6.6.iii.  pH Studies of Phenol Red to Albumin 
 
To elucidate the binding characteristics of subdomain IIA, the [1:1] complex of PR:rHSA 
was investigated against changing pH. Previous studies on the protein alone highlighted 
three main structural transition associated with changing pH (refer to Chapter 1 on 
Structure and Properties of HSA), the N-form at pH7.2, the F-form at pH4.3 and the E-
form at <pH3 were highlighted as the areas of interest (Peters et al, 1996). The objective 
was to ascertain whether the observed changes seen in HSA only with changing pH were 
due to specific regional changes in the protein denaturing (reversibly), thus knocking out 
the specific binding site for that ligand or whether the observed changes in HSA were more 
global and non-specific. The UV of the pH titration in essence remained unchanged, 
similar in appearance to the pH titration of the dye in the absence of protein (Figure 6.1.b.). 
However, the CD reflects many changes especially at low pH values, at pH3.55 there was 
an inversion of the CD spectra found at pH7.14 and is shown in Figure 6.3. with the 
creation of a further isosbestic point at shorter wavelength totalling three in all. At high pH 
values the CD of the complex collapsed.  The pH titration highlighted several areas of 
interest, that at pH7.9, pH4.44 and pH3.55 indicative of the areas of known structural 
changes within the protein. Therefore, the molar titrations, binding studies and temperature 
studies were investigated at these designated pH values. The fixed wavelength plots of the 
pH titration revealed three different species existing when the three distinct regions of 
concerns were monitored, each wavelength studied showed different transitions. It was 
clear that each wavelength studied reflected the structural changes that occurred in the 





















































Figure 6.3.  pH Titration of a [1:1] Molar Ratio of PR:rHSA 
 
A  CD spectra of the titration of a [1:1] molar ratio equivalent sample of 
PR:rHSA in water, 1cm 
B  Fixed wavelength plot of the titration of a [1:1] molar ratio equivalent of 
PR:rHSA 
 
Associated with the main absorption maximum, three pH transitions were seen, one in the 
E-form, one in the F-form and the final one in the B-form (Figure 6.3.).  In the E-form, the 
CD spectra of the 450nm maximum became inverted and of the same intensity, further 
reduction in pH produced CD spectra in the inverted position but very much reduced with 




akin to what was expected, revealing two transitions observed in the E-form and B-form, 
between those regions consistent changes were observed (Table 6.0.). At the final 
wavelength studied at 330nm, once again three transitions were observed two in different 
regions from that detected at the other wavelengths, the first lower than the E-form at very 
much reduced pH. The second transition was found surprisingly near the physiological 
conditions giving a pKa=6.4, also not seen at the other wavelength. The final transition was 
observed in the recognised B-form bordering on the aged-form. The pH titration reflected 
the complexity of the binding processes between the dye and the protein.  
 
rHSA PR:rHSA 
λ (nm) pK1 pK2 pK3 λ (nm) pK1 pK2 pK3 
255 4.0  11.5 330 2.4 6.4 8.9 
287 3.5 6.1 11.7 380 3.3  9.2 
    450 3.1 4.3 8.4 
Table 6.0.  Comparison of the pK values for rHSA &PR:rHSA complex 
 
Lowering the pH to 4.40 and conducting a binding titration produced a CD profile similar 
to that found at pH7 but with the maximum at 450nm very much reduced, this reduction 
makes the other two maxima found at shorter wavelength appear much larger and more 
pronounced with a more apparent symmetry between them. At this pH increased binding 
was observed for a molar ratio equivalent of [3:1] for PR:rHSA, the structure perturbation 
of HSA was sufficient to induce increased binding of the dye (Figure 6.4.). At low molar 
ratio equivalents ([0.4:1] and below) little to no binding was observed in contrast to that 
found at pH7. The UV spectra of the binding at this pH revealed a decrease in absorption 
for ratios up to [1:1] molar equivalent. Thereafter, an increase was observed up to a ratio of 
[2:1] molar equivalent that stabilized (Figure 6.4.a. & b.). The UV fixed wavelength plot 
contradicted that found in the CD fixed wavelength plot, in that increasing CD was 
determined after the molar ratio equivalent of [2:1], with increase binding detected at [3:1] 

























































































Figure 6.4.  Molar titration of PR:rHSA at pH 4.40. 
 
A  Absorption spectra of the titration of PR:rHSA at pH4.40, 1cm cell 
B  Fixed wavelength plot of the absorption of PR:rHSA 
C  CD spectra of the titration of PR:rHSA in B/R buffer, pH4.4, 1cm cell 
D  Fixed wavelength plot of the titration of PR:rHSA in B/R buffer, 
pH4.40, 1cm cell 
 
Lowering the pH further to pH3.56 produced changeable CD spectra that were dependent 
on the molar ratio equivalent of its components. The UV however, produced spectra that 
behaved as expected with increase absorption detected for increase D/P ratios, a plateau 
was observed for ratios greater than 1M equivalent of the protein. In contrast the CD 




420nm with a further positive peak observed at shorter wavelength, outside the measuring 
range of this experiment. The positive maximum previously located at 460nm had either 
been lost or had shifted to the newly determined maximum found at 420nm. At a ratio of 
[1:0.5], to ratio equivalents up to [1:0.9], the 460nm maximum became split forming a 
positive and negative doublet that appeared to be linked. As the D/P ratio increased, so to 
did the intensities of the doublet, changing from a relatively intense positive and weaker 
negative maxima to a relatively weak positive and stronger negative maxima (Figure 
6.5.c.) until the [1:1] molar ratio equivalent was reached where only the negative 
maximum was found and the positive peak had disappeared. For the molar ratio equivalent 
of [1:2] the doublet peak returned but this time two negative peaks were determined of 
almost equal intensities. The binding of PR at pH3.56 proved to be concentration 
dependent more so than at any of the other pH values studied, with changing spectra that 
reflected the changes seen in concentration. 
 
Plotting the CD against molar ratio at fixed wavelength for the titration at pH3.56 revealed 
variations within the binding site and in the protein as a whole, not consistent with that 
found at pH7. At this pH the protein is in the extended form, more of the protein is exposed 
to the solvent and therefore to environmental changes. From the profile of the CD binding 
spectra there appears to be mainly two types of profile present, one with a predominantly 
positive maxima at 420nm and a weak negative at 460nm, the other a predominant 
negative maxima at 460nm and another negative located at 380nm. It was possible that the 
dye’s preferred binding site had become compromised or modified in such a way that an 
alternative location was used that may account for the changes in the CD profile, with the 
use of a non-specific site that may account for the changing CD profile as the titration 
























































































Figure 6.5.  Molar titration of PR:rHSA at pH 3.56, 1cm. 
 
A  Absorption spectra for the titration of PR:rHSA in B/R buffer, pH3.56, 1cm 
B  Fixed wavelength plot of absorbance for of the titration of PR:rHSA IN B/R, 
pH3.56 
C  CD spectra of the titration of PR:rHSA in 10mM B/R buffer, pH3.56, 1cm cell 
D  Fixed wavelength plot of the CD measurements of PR:rHSA in 10mM B/B, 
pH3.56 
 
The titration of PR to albumin at varying pH values revealed the changing CD profile that 
exists with the deterioration and changing signs of the maxima. The largest CD profile was 
determined at physiological conditions and revealed a [1:1] molar ratio equivalent. As the 
pH reduced so to did the magnitude of the spectra, with pH4.40 producing spectra that 
were approximately two thirds that found under physiological conditions with the profile in 
essence essentially the same. A further reduction in pH produced the spectra that revealed 
the most spectral changes and the greatest reduction in magnitude, reducing the spectra by 
approximately one third of that found at physiological conditions. Modification in the CD 




6.6.iv.  Temperature Studies of  Phenol Red:Human Serum Albumin 
 
Temperature investigations were undertaken by heating and quenching studies. A [1:1] 
molar ratio equivalent of PR:rHSA was heated at various pH values predetermined by 
previous studies. pH7.2 was the first sample to be investigated and highlighted spectral 
changes in the CD that were associated with reduced binding with the onset of heating. 
Approximately two thirds of the binding of the dye was lost by the time the temperatures 
reaches 50°C, a characteristic previously observed with other ligands . Continued heating 
produced further decreases in the loss of binding resulting in total loss by 63°C (Figure 
6.6.). Two transitions were observed for each wavelength studied with the first transition 
occurring easier than the second. At the main absorption band (450nm) K1=23x103, and 
was the lowest determined at 42°C. At 330nm, tm1 determined was similar to that found at 
450nm but the value of K had considerably increased. The results at 380nm found both 
high values for K and an especially high tm for the first transition. The second transition at 
all three wavelengths studied gave consistently similar results. 
 















































































































Figure 6.6.  Temperature studies of a 1:1 molar ratio of PR:rHSA at pH 7.20. 
 
A  CD spectra of the temperature studies of a [1:1] molar ratio equivalent of PR:rHSA, 
P/B, pH7.2, 1cm 





The quenched samples highlighted the stability of the protein for temperatures not 
exceeding 55°C as was expected, since HSA in isolation shows no denaturation when 
heated to temperatures up to 60oC. The onset of denaturation was evident by 60°C and by 
67°C a dramatic decrease in binding of the dye was experienced with no binding evident 
by 73°C. As previously detected for site IIA binding, a rapid loss of binding was 
experienced between 58 - 67°C. The structural integrity of the protein had been 
compromised resulting in an inability of the dye to bind at 67° C, even though there was a 
considerable amount of structure in albumin retained at that temperature (Figure 6.7.). 
Only one transition was seen for each of the wavelengths monitored. 






















































Figure 6.7.  Quenched studies on a [1:1] molar ratio of PR:rHSA at pH 7.20. 
 
A  CD spectra of the quenched samples of a [1:1] molar ratio equivalent of 
PR:rHSA, 1cm cell 
B  Fixed wavelength plot of the quenched samples of a [1:1] molar ratio 




Temperature studies were now conducted on a [1:1] molar ratio equivalent sample of 
PR:rHSA at pH4.40.  Increasing the temperature of the complex from room temp to 48.2°C 
produced a decrease in the positive maxima at 450nm that initially stabilised between 48 - 
66.3°C. At this pH, modifications in the protein were such that the binding pocket was 
conserved or protected from its environment to some degree, allowing a residual amount of 
binding to occur at higher temperatures than would normally be expected. Higher 
temperatures result in the collapse of the binding pocket as demonstrated in Figure 6.8. 
Binding was still evident at 75°C with the CD at all maxima reversed. Wavelength 330nm 
revealed the first transition to be relatively easy, K=13x103 at a tm=44.5°C, the second 
transition was considerably higher with K = 50x103 and a tm=71.0°C. 






































































Figure 6.8.  Temperature studies of a [1:1] molar ratio of PR:rHSA at pH4.40. 
 
A  Temperature studies of a [1:1] molar ratio equivalent of PR:rHSA, 10mM B/R, pH4.56, 1cm 
B  Fixed wavelength plot of the temperature studies of [1:1] molar ratio equivalent of PR:rHSA in 




The quenching studies revealed no loss in structural integrity of the binding site for 
temperatures below 50°C. Heating the samples above 50°C produced a steady decrease in 
the binding of the dye with an inversion of the CD maxima observed for all the peaks, 
almost equal but opposite for temperatures up to 75.3°C with a similarity in the CD profile 
to that observed at pH3.56. Heating had allowed the protein to adopt a structure similar to 
that induced by adjusting the pH to 3.56. Binding was still evident even after heating rHSA 
to 75.3°C (Figure 6.9.), but the binding observed was not the same as that found at room 
temperature for that pH. The results reflected that either the same binding pocket had been 
modified to accommodate the changing conditions or that another site had been used, 
bearing in mind that subdomain IIA has three chambers that the dye can be located in. 





























































Figure 6.9.  Quenching studies of a [1:1] molar ratio of PR:rHSA at pH4.40. 
 
A  Quenching studies of a [1:1] molar ratio equivalent of PR:Rhsa, 10mM B/R, pH4.35, 1cm  
B  Fixed wavelength plot of the quenched temperature studies of a [1:1] molar ratio equivalent 





Once the pH of the [1:1] molar ratio equivalent complex of PR:rHSA was lowered to 3.56, 
as may be expected the complex offers no resistance to heating as demonstrated in Figure 
6.10a & b. The CD spectra collapses in the region of 450nm as soon as heating was 
initiated revealing the exposure of the binding pocket under these conditions. The CD was 
measured for samples heated up to 88.4°C, and even though the profile of the spectra had 
changed, reverting back to that found at high temperatures at pH7.2, increased binding was 
observed suggesting modification of the site (Figure 6.10.) or the possibilities of a lower 
affinity binding site being used. Heating HSA to such high temperatures at pH3.56 
revealed that PR was still able to induce binding even though the protein had become 
denatured. It should be noted that the heated samples of HSA in isolation never produced 
the complete collapse of the protein, there was always a residual amount of structure that 
was retained estimated to be greater than 35% structured. The possibility existed that one 
of the lower affinity sites existed within that region and was utilised by PR. What was 
evident was that the appearance of the CD profiled had significantly altered such that the 
main maximum at 450nm collapsed, however, binding was still evident at 330nm and at 
380nm. 
 
The quenched samples of albumin offered a bit more insight into the binding ability of 
albumin showing the resilience of the association of PR to albumin. The binding remained 
steadfast for temperatures up to 60°C. For temperatures greater than 60°C the complex 
deteriorated and altered but PR retained bound to the altered state for temperatures up to 
80°C (Figures 6.10.c. & d.). Once again the CD profiles at high temperatures were 
different to that seen at pH7, however, pH4.56 and pH3.56 both showed the reverse CD 
spectra at 450nm as the samples were heated to higher temperatures. Both the heated and 
quenched samples at pH3.56 revealed two transitions at all the wavelengths monitored, this 




samples. Also evident was the existence of a new transition that occurred at longer 
wavelength with the resemblance of a maximum starting at 650nm, this was also observed 
at pH4.56. Table 6.1. compares all the transitions that occurred for the complex at the three 
pH values studied and reveals the complexity of the melting process.  
 
Studying the transitions for the samples at pH3.56 highlighted the instability of the protein 
and revealed the ease of the first transition. With the exception of the first transition at 
330nm the other two occurred at very low tm temperatures in the heating cycle, the 
transition at the main absorption maximum occurs at a temperature little higher than RT.  








































































































































Figure 6.10.  Temperature studies and quenched samples of a [1:1] molar ratio 
equivalent of PR:rHSA at pH3.56, 1cm cell. 
 
A  Temperature studies of a [1:1] molar ratio equivalent of PR:rHSA in 10mM B/R, pH3.56, 1cm 
B  Fixed wavelength plot of the temperature studies of [1:1] molar ratio equivalent of PR:rHSA, 10mM 
B/R, pH3.56 
C  Temperature studies of the quenched samples of PR:rHSA, [1:1], in 10mM B/R, pH3.56, 1cm cell 






























K tm (°C) K tm (°C) K  tm (°C) K  tm (°C) K tm 
(°C) 
K 
450 1st  42.0 23 X 103 62.9 40 X 103 35.0 50 X 103 61.4 30 X 103 27.5 14 X 103 61.0 25 X 103 
2nd  62.8 50 X 103   72.0 50 X 103   72.0 30 X 103 63.0 50 X 103 
380 1st  60.0 43 X 103 61.5 50 X 103 72.9 40 X 103 65.9 30 X 103 35.0 10 X 103 60.0 45 X 103 
2nd  62.0 50 X 103       67.0 50 X 103 69.5 60 X 103 
330 1st  44.0 37 X 103 66.5 35 X 103 44.5 13 X 103 68.9 40 X 103 50.0 10 X 103 61.0 25 X 103 
2nd  67.0 50 X 103   71.0 50 X 103   72.0 30 X 103 63.0 50 X 103 
 




6.6.v.  Denaturation Studies of Phenol Red:Human Serum Albumin 
 
Both urea and guanadiniun chloride were used as denaturants in protein assays, unfolding 
the protein by varying degrees depending on the amount of denaturant added. Considering 
urea binding to a [1:1] molar ratio equivalent of the complex of PR:rHSA, small additions 
in the region of up to 0.2M of urea produces an immediate decreased in the observed CD 
spectra with approximately a half reduction in magnitude in the presence of 0.4M of urea. 
Spectral shifts in the CD maxima were observed especially for the maximum at 380nm 
where an inversion of the peak was witnessed, this was also seen for the peak at 330nm. 
The main absorption at 450nm was now represented by a couplet comprising of a positive 
and negative peak (except for the first addition of urea that produced the single positive 
maximum at 450nm). Between 1M - 3M of urea the CD produced by the complex showed 
a region of stability. The greatest loss in binding was detected between 3 – 3.5M with 
greater than 90% of binding lost. One significant feature detected at longer wavelengths 
greater than 600nm was the appearance of a new maximum that increased in magnitude 
with increasing urea concentration shown in Figure 6.11. Although the main absorption at 
450nm was lost, the absorption at longer wavelength continued to grow. The definition in 
the spectra of the other two maxima (380nm & 330nm) were also lost at high 
concentrations of urea. For 5M urea a positive CD was observed at 330nm with no 
characterising features. The fixed wavelength plot revealed a two transition step process 
that did not reflect the transitions seen in albumin alone that exhibited only one in the 
presence of urea.  
 
Beyond this point no further measurements in CD was conducted as it was impossible to 
determine a region of zero CD in which to normalize the data on. What was evident was 
that binding still existed at high concentrations of urea even if it was not necessary at the 




albumin with urea, it was unclear which regions were affected and at which point in the 
titration that they occurred. What was certain was that PR still remained bound to albumin 
even if the characteristic features of the spectra were unrecognisable. 





















Note: The apparent spectral dispersion observed
          at 700nm is probably an artefact due to the 














Figure 6.11.  Urea titration of PR:rHSA in water, 1cm cell. 
 
A  Titration of a [1:1] molar ratio equivalent of PR:rHSA with increasing urea, 1cm 
B  Fixed wavelength plot of the titration of PR:rHSA in increasing concentrations of urea  
 
The addition of GuHCl as the denaturant agent to the PR:rHSA complex affected the 
folding of HSA with relatively small additions, causing adverse effects as shown in Figure 
6.12. The integrity of the CD profile remained intact with conservation of all the maxima 




an 80% reduction in the binding of the dye with the loss shown by the maximum at 450nm, 
and by 2M GuHCl all the binding at this maximum was lost. The other wavelengths also 
reflected similar trends with the collapse of their peaks. However, also seen with 
increasing concentration of denaturant was an additional maximum at longer wavelength, 
greater than 700nm (Figure 6.12.). Similar to the urea denaturation studies, the presence of 
GuHCl induces changes in the protein that could allow weaker affinity sites to become 
active. At wavelengths greater than 700nm increased binding was observed, this occurred 
to the detriment of the other absorptions. 


































Figure 6.12.  GuHCl titration of PR:rHSA, [1:1], in water, 1cm. 
 
A  Titration of a [1:1] molar ratio equivalent sample of PR:rHSA with GuHCl,  




6.6.vi.  Microcentrefuged Samples 
 
Considering the PR:rHSA titration in P/B at pH7.20, for low molar ratios equivalent of the 
complex the largest quantity of free dye was detected (Figure 6.13.). At low concentrations 
of protein, the availability of dye will be high since there will only be a small quantity of 
protein to interact with the dye. Therefore, at that concentration it would be expected to 
have a high detection level of dye. As the concentration of the protein increases so will the 
rate of formation of the complex, therefore there will be less dye detected in the mixture 
that will be proportional to the rate of formation of the complex and limited by the dye 
concentration since it is that quantity that has been fixed, a fact found in the results shown 
in Figure 6.13. The detection of free dye was not a smooth transition but peaks were 
determined at [1:0.2] & [1:0.6] molar ratio equivalent of the complex, a fact mimicked at 
both wavelengths studied. 













































Figure 6.13  Microcentrifuged samples of PR:rHSA titration at pH7.19, 1cm. 
 
A  Absorbance spectra of the microcentrifuged samples of PR:rHSA titration, P/B, pH7.2, 1cm  
B  Fixed wavelength plot of the microcentrifuged samples of PR:rHSA in 10mM P/B, pH7.2, 1cm 
 
Next studied was the microcentrifuged samples of the pre-heated complex of PR:rHSA 




albumin samples in isolation. Samples heated to temperatures up to 55°C produced small 
UV absorption spectra, confirming that most of the dye was bound to the protein at these 
temperatures. Raising the temperatures resulted in more of the free dye being detected as 
more of the protein becomes denatured displacing the dye; thus larger absorption maxima 
observed for the free dye was detected until a point where all the dye had been displaced 
from the protein. Displacement was rapid, occurring within a specific and well defined 
temperature region with a tm=55.6°C and K=70 x 103. From these results that look at the 
binding from the prospective of the dye only, it can be seen that only in the first thermal 
transition in the protein (tm=57.0°C with K=18 x 103) is the dye dissociation detected. 
Since PR only binds to site IIA on albumin, it is reasonable to infer that it is site IIA that is 
first affected by heating in the protein, the other two thermal transitions were not detected 
in terms of this dye binding. The CD data of the quenched samples reflected different 
results with tm=62.9°C and K=40 x 103 for the main absorption, there will be re-association 
of the dye that will influence the CD detected and this may explain the higher values 
obtained. 
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Figure 6.14.  Microcentrifuged samples of pre-heated PR:rHSA, pH7.19, 1cm. 
 
A  Absorbance spectra of the microcentrifuged samples of quenched rHSA samples and PR in P/B, 1cm  




The microcentrifuged samples containing urea was investigated (Figure 6.15.). For low 
molar ratios of urea the UV of the free dye was shown to be small, showing that most of 
the dye was bound. A steady loss in binding was detected between 1M - 3M of urea, with 
the greatest loss in binding detected between 3.0M – 3.5M where approximately 80% of 
binding was lost. For ratios higher than that the residual dye remaining was lost resulting in 
the total loss of binding supporting the results measured by CD.  





















Figure 6.15. Absorbance spectra of the microcentrifuged 
samples of PR:rHSA in urea, water, 1cm 
 
Conversely, for samples containing GuHCl the absorption measured remained relatively 
constant (Figure 6.16.) even though the main absorption of the complex detected by CD 
collapsed. It was evident that small additions of GuHCl caused substantial displacement of 





Figure 6.16.  Microcentrifuged samples of PR:rHSA in 




6.7.  Bromophenol Blue : Human Serum Albumin Interaction 
 
The second in the series of dyes to be considered with increased complexity was 
Bromophenol Blue (BPB) chemically known as 3'3''5'5''Tetrabromophenolsufonphthalein 
(C19H10BR4O5S), MW 669.99, and has a pH working range of between pH3.8 to pH5.4, 
(Figure 6.17.). BPB’s pH titration curve is represented in Figure 6.18. with the titration 
producing four isosbestic points indicating several species in existence at the same time. 
The isosbestic points produced by BPB were well defined in contrast to PR whose points 













Figure 6.17.  Structure of BPB. 
 
 
























































Figure 6.18.  pH titration of BPB in water, 1cm cell. 
 
A  UV Spectra of the pH Titration of BPB in water, 1cm 





BPB differs from PR in the addition of two bromides to each of the two phenolic rings 
(compare with Figure 6.1.a.). Although BPB is a bulkier molecule its binding site on HSA 
is still reported as being located within subdomain IIA. 
 
6.7.i.  Binding Studies of Bromophenol Blue : Human Serum Albumin 
 
The presence of rHSA on binding with BPB revealed distinct changes in the UV spectral 
profile with absorption maxima distinct from that of PR, the main difference was in the 
main absorption maxima. PR absorbs at the wavelength 435nm at pH7 with a shoulder at 
560nm, whereas with BPB the absorption experienced a bathochromic shift to 610nm with 
a shoulder situated at 560nm in the same position as the minor absorption as the shoulder 
in PR (Figure 6.19.a.). The fixed wavelength plot of the UV absorption of the titration of 
BPB:rHSA expressed complete binding at a ratio of [0.5:1] of dye:protein respectively, 
showing a 2:1 binding ratio as shown in Figure 6.19.b. The CD reflected the same changes 
observed for the UV absorption. Four maxima were seen, two positive that were smaller in 
comparison to the other two peaks that were negative and larger, with the main CD 
absorption found at 610nm. Literature quotes a 1:1 relationship with the possibilities of 
other sites being available if the primary affinity site had been blocked or occupied, but at 































































































Figure 6.19.  UV and CD spectra of the molar titration of BPB:rHSA at pH 7.20, 1cm 
 
A  Absorbance spectra of the titration of BPB:rHSA, 1cm 
B  Fixed wavelength plot of the titration of BPB:rHSA 
C  CD spectra of the titration of BPB:rHSA in 10mM P/B, pH7.2, 1cm cell 
D  Fixed wavelength plot of the CD spectra of the titration of BPB:rHSA in 10mM P/B 
 
A pH titration was conducted of the [2:1] complex of BPB:rHSA that revealed a general 
increase in absorption for all the major absorptions maxima considered with increasing pH. 
The profile of the UV spectra did not change in quite the same way as BPB in isolation that 
exhibited a greater range of spectral shifts. Two transitions were found at each wavelength 
studied, the first under acidic conditions and the other in the alkaline region. The UV was 
detecting only the effects of the dye at the wavelengths studied. The CD spectra revealed 




profile of the complex specifically detected at pH 3.56 as shown in Figure 6.20. These 
findings were consistent with PR that also showed the biggest change at this pH and like 
PR, BPB revealed a reversal in some of its CD maxima at this pH. The CD like the UV 
highlighted a general increase in magnitude for pH values up to pH11, by pH 12 the CD 
collapses.  








































 pH 1.67           pH 7.92
 pH 2.70           pH 8.90
 pH 3.56           pH 10.57
 pH 5.55           pH 11.26



















































































Figure 6.20.  pH titration of BPB:rHSA complex [1:1] in water, 1cm cell. 
 
A  Absorption Spectra of the pH Titration of BPB:rHSA, [2:1] in water, 1cm 
B  Fixed wavelength plot of the absorbance spectra of the complex 
C  CD Spectra of the pH titration of the complex, 1cm cell 
D  Fixed wavelength plot of the CD spectra of the complex 
 
As with all the other ligands monitored, the titration of the BPB:rHSA complex was 
investigated at pH4.56. When titrated under these conditions the BPB:rHSA complex  




pH7.19, and in contravene to that expected (Figure 6.21.). Both the UV and CD spectra 
was markedly changed from that determined at physiological conditions with the UV 
spectra showing a pronounced shoulder at 565nm in addition to the other two peaks found 
at shorter wavelength. In response to the formation of the shoulder seen in the absorption 
spectra the CD spectra reflected this change with the generation of positive and negative 
couplet, the negative peak being larger than the positive.  












































































































Figure 6.21.  Molar titration of BPB:rHSA at pH 4.56, 1cm. 
 
A  Absorption spectra of the titration ot BPB to rHSA in 10mM B/R, pH4.56, 1cm 
B  Fixed wavelength plot of the absorption spectra of the titration 
C  CD spectra of the titration of BPB:rHSA at pH4.56, 1cm 





Reducing the pH further to pH3.57 and conducting the binding titrations under these 
conditions revealed a [2:1] binding relationship as shown in Figure 6.22. The reduction in 
pH exposed more of the binding sites that the dye made use of. 
























Figure 6.22.  Molar titration of BPB:rHSA at pH 3.56, 1cm cell. 
 
6.7.ii. Temperature Studies of Bromophenol blue: Recombinant Human Serum 
Albumin 
 
Like PR, BPB at pH7.2 offers little resistance to increasing temperatures above 40oC, the 
dye becomes displaced and the CD signal lost (Figure 6.23.). Only a small quantity of dye 
is lost up to temperatures of 55oC. However, between the temperatures of 55oC and 65oC 
most of the binding was lost, but complete dissociation was never achieved. At 610nm 
binding was still evident at 70oC as a strong negative CD signal was still seen. At 67oC the 
CD spectra obtained showed close similarities to the CD measured at pH3.56, it was 
evident that the structural changes induced by heating albumin to high temperature also 




was not clear was if at high temperatures the BPB molecules were bound to the same site 
on albumin or if they had found alternative positions. 
 








































































































Figure 6.23.  Temperature studies of a [2:1] molar ratio complex of BPB:rHSA in P/B, 1cm. 
 
A  CD spectra of complex in P/B, pH 7.19, 1cm 
B  Fixed wavelength plot of the CD spectra of the temperature studies of BPB:rHSA, 1cm 
 
Conducting temperature studies at reduced pH for the [2:1] molar ratio equivalent complex 
of BPB:rHSA, reducing to pH3.56 revealed the reverse situation from that found at the 
other two pH values studied, thus highlighting the special conditions that pH3.56 produces 
in albumin. At the other pH values the heating curve produced at least two transition for 
each wavelength studied, and a single transition for the quenched curves. At pH3.56, only 
a singe transition was produced for the heating curve, however, surprisingly two transitions 
were produced for all the wavelengths investigated. Considering the heating curve first, of 
the three maxima studied the absorption peak at 315nm behaved distinctly different from 
the other two, requiring a higher K and tm. The peaks at 550nm and 620nm appeared 




both curves coalescing to the same point, confirming the instability of the complex (Figure 
6.24.a.). The peak at 620nm also experienced a reversal in sign changing from negative to 
positive as soon as the complex was heated. Once again residual binding was also detected 
with the incomplete collapse in binding as detected with other ligands. 
 
































































Figure 6.24.a.  Temperature studies of a [2:1] complex of BPB:rHSA at pH 3.56, 1cm. 
 
A  CD spectra of the temperature study at pH3.56, 1cm 
B  Fixed wavelength plot of the CD Spectra of the titration 
 
The quenched samples reinforced that which was seen in the heating studies with the peaks 
at 620nm and 550nm behaving similarly and almost coalescing. However, unlike the 
heating curve the first transition for wavelengths 315nm and 620nm now behaved very 
similarly with K1=20 X 103 for both and tm’s of 61.5oC and 58.5oC respectively. The 
transition at 550nm occurred at a much higher value of K that increased by 10 x 103 at a  
tm1 = 47oC. The second transition reverts back to that which was expected with the values 
at 550nm and 620nm behave very similarly with identical values of  K2=45 X 103  and tm’s 
of 69.0oC and 67.0oC respectively. At 315nm, again a 10 x 103 increase was experienced in 
K2 with a tm2 = 66.2oC. Once again at wavelength 620nm a change in sign of the CD signal 




Binding was still evident in spite of the albumin samples being heated to temperature that 
caused irreversible damage, although greatly reduced at the main absorption, it was still 
significant to be prominent at all the wavelengths studied. Albumin when heated retains 
approximately one third of its original structure when cooked, and it must be that part that 
the BPB molecules/molecule binds to. Again it is difficult to say whether one or two 
binding sites are in use and their apparent location/s within the albumin molecule. 




































































































Figure 6.24.b.  Temperature studies of the quenched samples of BPB:rHSA at pH 3.56, 1cm. 
 
A  CD spectra of the quenched samples of a [2:1] complex sample at pH3.56, 1cm 
B  Fixed wavelength plot of the CD spectra of the quenched samples at pH3.56, 1cm 
 
6.7.iii. Denaturation Studies on Bromophenol Blue:Recombinant Human Serum 
Albumin 
 
The addition of urea to the [2:1] molar equivalent complex samples revealed by UV 
spectroscopy that binding was maintained throughout the entire titration for the main 
absorption maximum at 600nm, the other wavelengths showed only 36% binding at 380nm 
and 46% at 310nm (Figure 6.25.a.).  Indeed, for the peak at 600nm, enhanced absorption 
was detected for additions of between 2M – 4M of urea. CD spectroscopy highlighted a 
different trends, at 600nm, for urea concentrations up to 6M equivalent an increase in the 




7M – 8M equivalent (Figure 6.25.b.). The peak at 390nm remained fairly steadfast with a 
slight loss in its negative CD observed. Like that seen at 600nm, the peak at 390nm 
between   4M – 6M equivalent proved significant with the biggest loss in CD detected at 
those concentrations, a slight recovery was detected for concentrations of urea between 7M 
– 8M equivalent. The spectral changes that occurred at 390nm was mirrored at 315nm but 
to a greater extent. Once again it was the spectral changes at 600nm that proved atypical.  
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Figure 6.25.  Denaturation studies of BPB:rHSA complex in urea, 1cm. 
 
A  Fixed wavelength plot of the absorption spectra of the urea titration of the complex 
B  Fixed wavelength plot of the CD spectra in the presence of Urea, water, 1cm 
 
Denaturation studies involving GuHCl produced similar results as that experienced with 
the urea titrations, with the results confirming that it was the maximum at 600nm proving 
atypical. The UV spectra revealed the enhanced binding experienced at 600nm with a 
gradual sequential increase in the magnitude of the absorption (Figure 6.26.a.). However, 
there were spectral changes that occurred for the peaks at lower wavelengths with the peak 
detected previously at 380nm now shifted to shorter wavelength located at 350nm, and the 




1M – 3M equivalent produced decreases in association of the dye to the protein that was 
detected at wavelengths 350nm and 320nm, that then became stable with no further losses 
experienced at either wavelength.  Likewise, the CD also observed shifts in the absorption 
maxima obtained with the main absorption still detected at 600nm, but additional peaks 
shifted from 390nm to 350nm, and from 315nm to 320nm (Figure 6.26.b.). The CD spectra 
revealed that for increasing concentrations of GuHCl up to 8M equivalent, generally a 
decrease in CD absorption was detected. However, binding was not totally lost as a 
significant amount of association of the dye was still detected, this suggested that binding 
was observed in regions of the protein that remained unaffected by the additions of GuHCl. 
The findings differed from that of PR that produced a complete collapse in the complex by 
1.8M equivalent of GuHCl. 
 


















































Figure 6.26.  Denaturation studies of BPB:rHSA complex in GuHCl, 1cm. 
 
A  Fixed wavelength plot of the absorption spectra in GuHCl 











6.7.iv. Microcentrefuged Samples of Bromophenol Blue:Recombinant Human Serum 
Albumin 
 
Considering the titration conducted at the three pH values chosen expressed that for low 
molar ratios equivalents of BPB:rHSA and up to [2:1] the microcentrifuged samples 
showed the presence of decreasing amounts of free dye in solution. For molar ratio 
equivalents above a value of [2:1], all the dye was in the bound state and no free dye could 
be detected (Figure 6.27.). 


































































Figure 6.27.  Microcentrifuged samples of the titrations of BPB:rHSA 
conducted at different pH values. 
 
A  Microcentrifuged samples of the BPB:rHSA titration in P/B, pH7.19, 1cm cell 
B  Microcentrifuged samples of BPB:rHSA in B/R buffer, pH4.56, 1cm cell 





Temperature studies on the pre-heated samples of the complex indicated no free dye 
present for samples heated to 50°C; above that temperature increasing amounts of free dye 
was visible, supporting the theory that as the protein becomes denatured its ability to bind 
ligands was increasingly debilitated. It also suggests that one of the binding sites may be 
exposed or close to the surface of the protein and had lost its ability to bind.  The fixed 
wavelength plot in Figure 6.28. shows that there was greater than 50% of the dye still 
bound at temperatures exceeding 70°C, suggesting more than one binding site existed 
(Figure 6.28.a.). Two transitions were observed at each wavelength that supported the 
previous finding of the relationship between wavelengths 380nm and 310nm, and revealed 
that the first transition was much easier to achieve then the second. This was the reverse of 
that found at the main absorption peak that found both the first and second transitions were 
equally as difficult All three wavelengths gave identical values for both K and tm at all 
wavelengths, supporting that one of the binding sites previously determined was 
incapacitates at a tm = 65.2°C. The second site was unperturbed at these temperatures.  
 
The micro-centrifuged samples of BPB:rHSA in urea were measured and shown that for 
small additions of urea up to 3M equivalent produced small amounts of free dye that was 
detected (Figure 6.28.b.). Additions greater than 3M equivalent produced more of the dye 
being displaced from the protein resulting in larger absorptions detected at the main 
absorption band, that never attained maximum levels, indicating incomplete displacement 
of the dye. The greatest amount of unbound dye was detected for the complex in 5M 
equivalent of urea, this supported the findings in the CD where the greatest change was 
seen at this concentration. Additions of urea greater than 5M equivalent produced 
decreasing amounts of free dye at the main absorption band, suggesting increased 
association of the dye:protein complex. This contradicted the findings at the other two 




became increasingly displaced for amounts higher that that. For the GuHCl samples, only 
the main absorption band was monitored and showed that only at 4M equivalent was the 
concentration of GuHCl sufficiently high enough to produce any appreciable levels of dye 
that could be detected.  For concentrations above 4M equivalent, negligible amounts of 
free dye was found (see Figure 6.28.c.) reinforcing previous finding that full dye binding is 
maintained in the GuHCl samples. 
 











































































































Figure 6.28.  Denaturation studies on BPB:rHSA complex, 1:2, 1cm cell. 
 
A  Microcentrifuged samples of the pre-heated samples of BPB:rHSA in P/B, pH7.19, 1cm 
B  Microcentrifuged samples of the complex in urea, 1cm 





6.8.  Bromocresol Green : Human Serum Albumin Interaction 
 
The last in the series of dyes to be considered with increasing complexity was Bromocresol 
Green (BCG) or 3'3''5'5''Tetrabromo-m-cresolsufonphthalein (C21H14BR4O5S), MW 
698.04, this has a working pH range of 3.8 - 5.4. BCG differs from BPB in the addition of 















Figure 6.29.  Schematic representation 
of BCG. 
 
6.8.i.  Binding Studies of Bromocresol Green to Recombinant Human Serum Albumin 
 
Binding studies at physiological conditions (pH 7.19) were conducted and revealed that the 
binding of BCR was not straight forward in that the CD underwent several spectroscopic 
changes depending on the molar ratio equivalent present (Figure 6.30.). For low molar 
ratio equivalents, at the main absorption a positive CD maximum was seen. As the ratio 
increased, so the positive peak transformed to a positive and negative couplet, then through 
to a negative peak of increasing magnitude. The other peaks present behaved more 
typically increasing in magnitude as the molar ratio equivalent increased. An increase in 
CD magnitude was observed at all the wavelengths studied for molar ratio equivalents up 
to [1:0.5], after that, a decrease was experienced at all wavelengths up to a ratios of [1:1] 
molar equivalent. A small loss was observed after that for molar ratio equivalents up to 




relationship exists in the BCG:rHSA, the same as for BPB which was not unexpected since 
they both share similar complexities of structure.  























 [1:3]        [1:0.6]
 [1:2]        [1:0.5]
 [1:1]        [1:0.4]
 [1:0.9]     [1:0.3]
 [1:0.8]     [1:0.2]












Figure 6.30.   Titration of BCG:rHSA in P/B, pH 7.2, 1cm. 
 
C  CD spectra of the titration of the complex in P/B, 1cm 
D  Fixed wavelength plot of the CD spectra of the titration in P/B, pH 7.45, 1cm cell 
 
6.8.ii.  pH Studies of Bromocresol Green to Albumin 
 
Considering the pH titration and comparing the effects of native protein with the 
recombinant, the titration was conducted under identical conditions for both. The CD 
profile of BCG:nHSA complex for a [2:1] molar ratio equivalent bears similarities with its 
counterpart the BPB:rHSA complex, with the CD maxima located in similar positions and 
with the same sign, however, the detection wavelengths were not the same (Figure 6.31. & 
6.32.). Although the UV showed a general increase in the main absorption band at 630nm 
with increasing pH as detected with BPB:rHSA complex, the fixed wavelength plots for 
the CD spectra revealed spectral changes that were complex. Between pH5 & pH10 the  
CD maximum at wavelength 420nm for the BCG:rHSA complex seemed relatively 




comparing the changes between the complexes of nHSA and rHSA bound to BCG 
diversities were observed with the two complexes producing CD maxima at different 
wavelengths. The use of this dye was the first ligand to show such diversities between the 
two proteins (Figure 6.31. & 6.32.). For both proteins, the UV spectra revealed the fluidity 
of the absorptions and also their complexities that gave rise to such complex CD spectra. 
The CD showed the existence of coupling of two of the main absorptions, and the 
existence of independent absorption that responded to changing pH in isolation to the other 
absorptions. It was evident that the increase in complexity of the dye molecule had 
profound effects that changed its binding abilities to albumin. 

























































































































































Figure 6.31.  pH titration of BCG:rHSA in a 1cm cell. 
 
A  Absorbance spectra of the pH titration of the complex, 1cm cell 
B  Fixed wavelength plot of the absorbance of the pH titration of [2:1] complex 
C  CD spectra of the pH titration of the complex in H\-(2)O, 1cm 


























































































Figure 6.32.  pH titration of BCG:nHSA in a 1cm cell. 
 
A  CD spectra of the pH titration of the [2:1] complex, 1cm 
B  Fixed wavelength plot of the pH titration of BCG:nHSA in water 
 
Comparisons of the pKa values for each protein has been tabulated in Table 6.1. and 
highlighted subtle differences that exists together with minor spectral shifts. Overall the 
two proteins behave similarly. In keeping with all the other experiments, work was 
conducted on the recombinant protein. 
rHSA nHSA [2:1] BRG:nHSA Complex [2:1] BRG:rHSA Complex 
λ (nm) λ (nm) pK1 pK2 pK3 pK4 pK1 pK2 pK3 pK4 
650 650 2.9 5.2 8.0 10.2 3.0 5.0 9.2 11.9 
540 530 3.0 5.1 7.8 10.8 2.6 4.0 7.8 10.5 
420 405 4.7 10.4   2.9 4.0   
360 320 2.8 5.2 8.0 10.2 3.7 5.5 7.8 10.6 
Table 6.2. Comparison of rHSA and nHSA in response to pH changes 
 
Further binding titration were conducted at pH4.40 and pH3.56. Dropping the pH to 
pH4.40 the titration of BCG:rHSA revealed a [2:1] relationship similar to that found for 
BPB:rHSA (Figure 6.33.). At pH4.40, the titration was conducted within the working pH 
range of the dye and gave the best fixed wavelength plot results. However, when the pH 
was decreased further to pH3.56, outside the range of the dye, CD spectral changes were 




was not attained. rHSA at pH3.56 was able to bind more than 3M equivalent of dye when 
the protein was in the E-form as shown in Figure 6.34. 





















































Figure 6.33.  Molar titration of BCG:rHSA at pH4.4, 1cm. 
 
a  CD spectra of the titration in B/R buffer, pH 4.40, 1cm 
b  Fixed wavelength plot of the CD titration at pH4.41 
 

















































Figure 6.34.  Molar titration of BCG:rHSA at pH3.56, 1cm. 
 
a  CD spectra of the titration in B/R buffer, pH3.56, 1cm 




6.8.iii.  Temperature Studies of Bromocresol Green:Human Serum Albumin 
 
When a [2:1] complex of BCG:rHSA at pH7.19 was heated, the complex revealed stability 
to temperatures up to 50°C (Figure 6.35.). Between the temperatures of 50 - 60°C a steady 
decrease in binding was detected that partially stabilised between 60 - 68°C. For 
temperatures exceeding 68°C highlighted the greatest loss in binding resulting in almost 
complete loss by 78°C. Once again there were several spectral changes observed that 
included a change in the sign of some of the peaks determined. Two transitions were 
observed at every wavelength monitored, and the data revealed that there was increasing 
difficulty as the value for K1 increased as you moved from 530nm, 405nm and 320nm 
respectively, with the transition at 650nm being the hardest to achieve and occurred at the 
highest tm. The second transitions all gave identical values for  K2=80x10-3 with the 
exception of wavelength 650nm that was extremely low (K2=20x10-3). Binding at the main 
absorption was always detected even though most of the other absorptions were lost. 
















































































































































Figure 6.35.  Melting of a [2:1] Complex of BCG:rHSA at pH7.19, 1cm cell. 
 
a  Temperature studies in P/B, pH7.19, 1cm 




The quenched samples of the [2:1] complex of BCG:rHSA at pH7.19 revealed the stability 
to temperatures not exceeding 55°C, for higher temperature the results revealed a loss of 
binding with negligible amounts bound at 92.3°C (Figure 6.36.). The fixed wavelength plot 
of the quenched curve at pH7.19 revealed stepwise sequential unfolding transitions similar 
to those observed in the melting studies, with two transitions observed except for that 
found at wavelength 650nm that only produced one. Three of the wavelengths studied 
produced similar results for values of K1 and tm1,  with the second transition being that 
much harder to achieve as would be expected. Once again the main absorption found at 
650nm proved atypical producing a K1 and tm1 much higher than that found at the other 
wavelengths. At wavelength 530nm there was a change in sign of the peak from negative 
to positive that then reversed again to form the negative CD peak. As seen before, binding 
of the dye was maintained with at least 50% of the dye remaining in situate, this suggests 
that one of the possible two dye molecules have become displaced and reinforces the 
theory of there being two dye molecules bound to the protein. 

















































































































Figure 6.36.  Temperature studies of quenched BCG:rHSA at pH7.19, 1cm cell. 
 
a  CD spectra of the quenched samples of the complex, in P/B, pH7.19, 1cm 




In order to perturb the stability of the [2:1] binding complex of BCG:rHSA the temperature 
study of the complex was conducted under reduced pH conditions (Figure 6.37.). Lowing 
the pH values  to pH4.40 revealed the fragility of the complex with the loss of binding 
experienced at the main absorption band of 650nm once the sample was heated. At the 
three other wavelengths studied, there was an increase in binding detected for temperatures 
up to 55°C, the location of the first of two transitions that occurred with relative ease at 
low temperature, suggesting some sort of reorganisation of the protein . For temperatures 
above 55°C, all wavelengths monitored followed very similar paths with the loss of 
binding detected. Again spectral shifts were observed, the  biggest was the creation of a 
positive CD band at shorter wavelength at the temperature of 72.8°C.  
 
The second transition also occurred with relative ease with all the values of K2 found to be 
identical and the tm2 occurring between 62°C – 68°C, a sharp decrease in binding was 
determined. Once again most of the binding was seen at the main absorption band of 
650nm with only approximately a 25% loss in binding.  


































































































Figure 6.37.a. & b.  Temperature studies of BCG:rHSA at pH4.40, 1cm cell. 
 
a  CD spectra of the temperature studies of BCE:rHSA in B/R, pH4.42, 1cm 




The quenching curve reflected similar trends as that seen in the heating curve at the same 
pH, but its changes were not as pronounced.  There was a variation in the relative ease of 
the two transitions found at each wavelength, and like the heating curve a high proportion 
of binding was still maintained even after cooking the protein. 
 
































































































Figure 6.37.c. & d. Temperature studies of the quenched samples of BCG:rHSA at 
pH4.40, 1cm cell. 
 
c  CD spectra of the quenched samples of the BCG:rHSA complex in B/R buffer, pH4.42, 1cm 
d  Fixed wavelength plot of the quenched samples of the complex 
 
Decreasing the pH further to pH3.56 resulted in the initial reorganisation in binding for 
temperatures up to 57°C, but also revealed were many spectral changes in the CD, 
indicative of what would be expected for the protein once in the extended form. For 
temperatures above 57°C an increase in binding was observed with binding at 80°C greater 
than that detected for the unheated samples. rHSA in the E-form once heated to high 
temperatures seem to facilitate binding of the comparably large dye molecule. 
Denaturation of the protein did not affect this binding site at very low pH values, 
suggesting that this site was shielded in some way thus preserving its integrity. Both the 















































































































































































































Figure 6.38  Temperature studies of BCG:rHSA at pH 3.56, 1cm cell. 
 
 
a  CD spectra of the temperature study of the complex in B/R buffer, pH3.56, 1cm 
b  Fixed wavelength plot of the CD spectra of the temperature study at pH3.56 
c  CD spectra of the quenched temperature samples of the complex in B/R buffer, pH3.56, 1cm 




6.8.iv.  Denaturation Studies of Bromocresol Green:Human Serum Albumin 
 
The addition of small amounts of urea (up to 3M equivalent) to samples of the [2:1] molar 
ratio equivalent of BCG:rHSA resulted in little to no effect. There was however, loss in 
binding for samples containing between 4M - 5M equivalent addition of urea. For molar 
ratios in excess of 5M of urea, an increase in binding of the dye was observed with 
maximum effect detected at 7M. The value of ∆A at 7M was greater than that found in the 
absence of urea suggesting facilitated binding and enhancement, and is represented in 
Figure 6.39. 
 












































Figure 6.39.  Molar titration of BCG:rHSA in Urea, 1cm cell. 
 
a  CD spectra of the complex of BCG:rHSA with increasing concentrations of urea 
in water, 1cm 
b  Fixed wavelength plot of the CD spectra of the urea titration 
 
 
6.8.v  Microcentrifuged Samples of Bromocresol green:Recombinant Human Serum 
Albumin  
 
Considering the temperature studies conducted at physiological conditions, the 




of the dye was bound to the protein (Figure 6.40.). For temperatures above 52°C, 
increasing amounts of free dye were found as the protein became denatured.  Between 68 - 
76°C a plateau was obtained for wavelength 610nm at the main absorption band. At the 
other wavelengths, fluctuations where observed with wavelength 590nm producing the 
greatest absorption of 0.4 at 65°C, after that a small amount of re-association was 
observed. At wavelength 385nm, low levels of free dye was detected. The micro-
centrifuged samples revealed that more than 50% of BCG remained bound to albumin at 
the end of the experiment, the equivalent of potentially one of the two dye molecules 
bound.  







Microcentrifuged samples of the temperature studies 













Figure 6.40.  Temperature studies of BCG:rHSA at pH7.19, 1cm cell. 
 
Microcentrifuged samples of the temperature studies of BCG:rHSA, [2:1], P/B, 1cm 
 
Considering BCG:rHSA in the denaturant urea, at low molar ratio equivalents, there was 
little to no detection of the free dye, all the dye was found to be bound to albumin. A 5M 
equivalent concentration of urea seemed to be the pivotal point where the most significant 
displacement of dye was observed at all the wavelengths monitored, and specifically at 
598nm the absorption detected was 0.7, this equates to 70% displacement of the dye. 




denaturation conditions, this fact was further supported by the CD measurements that 
revealed the magnitude and sign of the CD spectra.  
 





























































CHAPTER 7:  Conclusion and Further Discussion 
7.1.  Final Conclusion 
 
Albumin has lived up to it reputation of being a multi-faceted, resilient protein, willing to 
participate in any biological activities, facilitating the fast, but effective transport of ligands 
that bind with high affinity. Albumin’s resilience to heat denaturation was demonstrated 
when heating the protein to temperatures exceeding 85oC (Figure 4.7. – 4.11.). The 
anticipated collapse in structure was not achieved, there was still a noticeable amount of 
secondary structure detected with estimations of between 15 - 20% of α-helix and the same 
amount in β–sheet found. The loss in secondary structure was found to come from the 
conversion of α-helix that was converted mainly into irregular structure with a minimal 
gain in β-sheet. There was a mirrored effect observed between changes in irregular 
structure and β-sheet, a trend what was reflected in all of the albumin samples studied 
including the glycosylated sample (L27). The only exception was found in the domain I 
fraction that contained an unusually high amount of irregular structure (Figure 4.10.c.). 
The high irregularity may be an artefact of the method of preparation of the fraction, or 
more likely to be caused by the incomplete folding of the remaining protein in the absence 
of the other domains. Whatever the reason, domain I’s predominant structure was found to 
be irregular structure that was in contrast to that found in the other samples. 
 
Considering the glycoylated sample, the modifications seen in the secondary structure did 
not influence the performance of this protein towards heat; the structural changes seen in 
the other forms were evident here. Heating all the whole albumin samples through a 
second temperature cycle did not evoke much spectral changes. Most of the denaturation 
was caused in the first temperature cycle, and further changes in the protein were shielded, 
and suggested that there was a core of residual structure that could not be penetrated. This 
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core was thought to exist in domain III, with domain II seeming to be the most susceptible 
to heat denaturation. 
 
Albumin unfolded occurred in a series of transitions or steps that appeared to reflect 
subdomain denaturation (Figure 4.12.b.), suggested the hypothesis that heat could be used 
as a means of partially unfolding the protein, thus selectively interfering with possible 
binding sited. The hypothesis was further supported by the fact that albumin retained the 
structure to which it was heated (Figure4.14) with little to no recovery on cooling. The 
resultant protein acted like a template for partial denaturation. The effects on the binding of 
albumin in the presence of a drug with increasing temperature revealed that for domain IIA 
binding ligands (e.g. warfarin), the dissociation was almost instant (Figure 5.25.). 
However, re-association of the drug occurred once the temperature dropped, provided that 
the protein was not heated to temperatures above 60 oC. The loss in binding was evoked on 
initiation of heating. For domain IIIA binding (e.g. diazepam), a state of equilibrium 
existed for temperature up to 45oC, above this temperature displacement was seen with the 
rapid loss in binding (Figure 5.32.). By comparison, the two melting and quenching 
profiles of the association between albumin and warfarin and diazepam were completely 
different, possible being a reflection of the different sites that the two drugs bind to. DIS, 
being an example of a ligand that binds to both sites, reflected a combination of both sites 
(Figure 5.61. & 62.). 
 
Dye binding was also investigated with temperature, with the use of different pH values 
coupled to the reaction. Dyes, also bind to domain IIA, like other site-specific markers 
displayed dissociation on heated (Figure 6.6.). Lowering the pH to pH4.4 and pH 3.56 
evoked greater stability in both cases (Figure 6.8. & 6.10.) in the region where loss was 
previously detected, although the amount of dye that bound was greatly reduced, a trend 
that was exhibited for all the dyes studied. 
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pH effects were shown to play a pivotal role on structural conformations of albumin, 
promoting elongation of the molecule with decreasing pH. The robustness of albumin in 
isolation, with changing pH, demonstrated the relative stability that exists between the pH 
values of pH4 to pH10. Several ions while bound to albumin were chosen for further 
investigations on their pH effects, and were found not to be drastically affected by the 
physical changes in albumin within the range of pH3 to pH10. The dyes proved to be the 
ligands that showed significant change with changing pH. In PR there was a complete CD 
spectral reversal at pH3.55 and pH2.65. The effect of pH in conjunction with temperature 
with the dyes highlighted the relative stability of the binding site to temperatures 
approaching 50oC. 
 
The effects of multiple binding to albumin proved promising when studied by CD. It was 
possible to see the effect of both drugs binding to albumin for non-competitive ligands 
binding to different sites, and it was possible to subtract the effects of one drug to reveal 
the effect of the other. Monitoring was possible in the cocktail for ligands that absorb at 
different wavelengths of the absorption, sufficiently removed to distinguish their 
absorption maxima. The results postulated the possibility of taking a ligand whose binding 
properties to albumin was unknown, and by the use of ligands of known binding sites on 











7.2.  Further Discussion 
 
The results in this thesis are exciting, revealing possibilities for further work that can be 
done in order to further characterise the albumin molecule. pH studies are known to induce 
different conformational structure, however, the use of temperature was not appreciated. 
Temperature studies in the thesis has highlighted the conformational rigidity of albumin 
and the ability to isolate different conformational forms, perturbing the different domains 
in albumin depending on what temperature the protein is heated to. More work is needed to 
isolate and fully characterise the conformations formed with a view to elucidate the 
binding sites present. Further work is also needed to look at the unfamiliar subdomains 
such as subdomain IB, suggested to play a pivotal role in the binding activity of some 
ligands binding to subdomain IIA. The possibility of the temperature studies may well 
offer a possible route of clarification. 
 
rHSA offered a possible therapeutic alternative to natural human albumin. The results 
obtained in this thesis showed that it was equally as good as its human counterpart without 
the obvious health risk. It was also possible to produce is in sufficiently large quantities 
relative cheaply. More work is needed on a more diverse range of drugs and ligands to 
validate better the initial finding. If proven correct over an adequate range of ligands then 
its findings will be significant.  
 
Finally, the Mathcad fits of single site binding proved to be an essential asset for 
determining binding constants of a simple one to one binding relationship. However, when 
two or more ligands were involved involving more than one site, it became 
disproportionately difficult to fit with no obvious or simple solution. More work is needed 
to properly formalise this with a view to making the determination of multiple binding and 
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